Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Настанова з дитячого діалізу (2011).doc
Скачиваний:
12
Добавлен:
20.03.2015
Размер:
2.05 Mб
Скачать

Літературні джерела

  1. Алексеев Г. И., Бидерман Ф.М. Организационно-тактические и лечебные аспекты неотложной помощи при острых отравлениях//Неотложные состояния в клинике внутренних болезней/Докл. VI Всероссийского съезда терапевтов. — Горький. - 1990. - С. 257-258.

  2. Амберт Э. Избирательная токсичность. Пер. с англ. — М,: Мир, 1971. —227 с.

  3. Ананченко В.Г., Лушников Е.А., Мамонов А. В. и др. Гемосорбция и ультрафиолетовое облучение крови при отравлениях//Клинич. медицина. — 1988. — Т. 66, №2. - С. 122-126.

  4. Афанасьев В. В. Отравления противоэпилептическими средствам /Клиническая токсикология детей и подростков/Под ред. И.В. Марковой и др. — СПб: Интермедика, 1998. — С. 229-235.

  5. Бидерман Ф.М., Сосюкин А.Е. Концентрационные критерии рациональной инфузионной терапии тяжелых форм острых пероральных отравлений//Инфузионная терапия неотложных состояний. — Л.: Медицина, 1990. — С. 23—27.

  6. Болдина И.Г., Миловский В.Г. Способ лекарственной профилактики повреждения эритроцитов при гемосорбции//Эндогенные интоксикации. — СПб: 1994. - С. 209-210.

  7. Виллерт О.Х., Баботина И.К., Андреев A.M., Белокуров А.Ю. Инфузия 37 л жидкости в сутки при остром отравлении//Анестезиология и реаниматология - 1983. - №6. - С. 60-61.

  8. Глозман О.С, Касаткина А.П. Детоксикационная терапия при острых отравлениях и аутоинтоксикациях. — Ташкент: Медицина, 1970. — 320 с.

  9. Голиков С.Н., Саноцкий И.В., Тиунов Л.А. Общие механизмы токсического действия. — Л.: Медицина, 1986. — 280 с.

  10. Горчаков В.Д., Сергиенко В. И., Владимиров В. Г. Селективные гемосорбенты. — М.: Медицина, 1989. — 223 с.

  11. Гудивок И.И., Волошинский А.В., Харенко Т.Р., Палийчук Ю.Р. Клинические аспекты лимфогенной экстракорпоральной детоксикации при острых эндотоксикозах //Экстракорпоральная детоксикация и гемокоррекция в клинической практике/Тр. Воен.-мед. акад. — Т. 223, СПб: ВМедА, 1993. — С. 81-84.

  12. Гуревич А.К. с соавт. Перитонеальный диализ в схемах и таблицах (пособие для врачей). СПб, 2003

  13. Гуревич К.Я. с соавт. Перитонеальный диализ (пособие для врачей). Издание второе, переработанное и дополненное. СПб, 2003

  14. Ливанов Г.А. Острые отравлениях//Энтеросорбция/Под ред. НА. Беляко­ва. — Л.: Центр сорбционных технологий, 1991. — С. 258—265.

  15. Ливанов Г.А., Батоцыренов Б.В., Калмансон М.Л. и др. Лечение эндотоксикоза при острых отравлениях нейротоксическими ядами как основа лечебной тактики //Тез. докл. 1-го съезда токсикологов России — М.: 1998. — С. 179.

  16. Лопаткин Н.Д., Лопухин Ю.М. Эфферентные методы в медицине. — М.: Медицина, 1989. — С. 350.

  17. Лопухин Ю.М., Молоденков М.Н. Гемосорбция. 2-е изд. — М.: Медицина, 1985. - С. 287.

  18. Лужников Е.А., Гольдфарб Ю. С. Актуальные проблемы диагностики и лечения острых экзогенных отравлений//Терапевт, арх. — 1996. — Т. 68, №10. — С. 74-79.

  19. Лужников Е.А., Гольдфарб Ю.С, Мусселиус С./".//Анестезиология и реани­матология. — 1993. — №1. — С. 55-66.

  20. Лужников Е.А., Гольдфарб Ю.С, Поцхверия М.М. и др. Ультрафиолетовое облучение крови в интенсивной терапии острых отравлений//Анестезиология и реаниматология — 1989. — №4. — С. 31—35.

  21. Лужников Е.А., Гольдфарб Ю.С, Широкова М.Н. и др. Реаниматологиче­ские аспекты сорбционной детоксикации в практике лечения острых экзогенных отравлений //Анестезиология и реаниматология. — 1987. — №5. — С. 35—37.

  22. Лужников Е.А., Гольдфарб Ю.С. Коррекция нарушений химического гомеостаза при острых экзогенных отравлениях//Эфферентная терапия. — 1995. — Т. 1, №3. - С. 3-12.

  23. Лужников Е.А., Гольдфарб Ю.С. Физиогемотерапия при острых экзо-и эндотоксикозах. — М.: 1991. — С. 5—14.

  24. Лужников Е.А., Костомарова Л.Г. Острые отравления. — М.: Медицина, 1989. - С. 432.

  25. Лужников Е.А., Фирсов Н.Н., Ярославский А.А. Опыт применения осмоти­ческого диуреза в клинической токсикологии//Терапевт. арх. — 1976. — Т. 48, №10. - С. 122-127.

  26. Лужников Е.А., Ярославский А.А., Мусселиус С.Г., Барсуков АЭ.Р.//Применение перитонеального диализа при лечении тяжелых форм отравлений, осложненных экзотоксическим шоком //Анестезиология и реаниматология — 1977. — №1. — С. 82—85.

  27. Лужников Е.А.,Дагаев В.Н., Горин Э. С. Критические состояния при острых отравлениях и их лечение//Терапевт. арх. — 1982. — Т.54, №9. — С. 3—8.

  28. Максудов А. С, Багирова И.Р. Раннее применение плазмафереза в лечении острых отравлений ядом гюрзы//Тез. докл. 1-го съезда токсикологов России — М.: 1998. -С. 186.

  29. Маркова И.В., Афанасьев В.В., Цыбулькин Э.К., Неженцев М.В. Клиническая токсикология детей о подростков. СПб.: Интермедика, 1998. — С. 302.

  30. Нефрология. Учебное пособие для послевузовского образования. Под ред. Шилова Е.М. М, 2007.

  31. Новиковская Т.В. Клиника и лечение острых отравлений дихлорэтаном: Автореф. дис... канд. мед. наук. — М., 1972. — С. 16.

  32. Пилотович В.С., Калачик О.В. Хроническая болезнь почек. Методы заместительной почечной терапии. М, 2009.

  33. Расулов АР., Бердымурадов Д.Б. Интенсивная терапия при укусах ядовитых змей //Анестезиология и реаниматология — 1994. — №3. — С. 59—60.

  34. Семенюк Я.П. Применение форсированного диуреза при острых отравлениях //Воен.-мед. журн. — 1977. — №12. — С. 60-62.

  35. Соколов А.А., Костюченко А.Л. 85 лет первому плазмаферезу в России/Эф­ферентная терапия. — 1998. — Т. 4, №2. — С. 51—67.

  36. Сосюкин А.Е. Сорбционно-диализная терапия при острых пероральных отравлениях фосфорорганическими инсектицидами//Экстракорпоральная детоксикация и гемокоррекция в клинической практике/Тр. Воен.-мед. акад. — Т. 223. - СПб: ВМедА, 1993. - С. 37-42.

  37. Сосюкин А.Е., Вельских А. Н., Зуев В.В. Соотношение экзо- и эндотоксикоза при острых отравлениях карбофосом//Актуальные вопросы военно-полевой те­рапии: Тез. докл. науч.-практ. конференции. — СПб, 1997. — С. 163.

  38. Цыбулькин Э.К. Активная детоксикационная терапия//Клиническая токсикология детей и подростков/Под ред. И.В. Марковой и др. — СПб: Интерме­дика, 1998. - С. 105-110.

  39. Челмакина В.П., Шель Ф.Г. Гемосорбция как основа детоксикационной терапии при острых отравлениях//Анестезиология и реаниматология. — 1987. — №4. - С. 72-74.

  40. Челмакина В.П., Шель Ф.Г., Рябцева СВ. Мионевральный синдром и его лечение' у больных некоторыми острыми отравлениями//3дравоохр. Казахста­на. - 1980. - №10. - С. 70-72.

  41. Шиманко И.И., Савина А.С., Обуховский И.А. Об особенностях миоренального синдрома при острых отравлениях//Сов. медицина. — 1976. — №3. — С. 107-112.

  42. Янчур Ф.М. Перитонеальный диализ: Автореф. дис... канд. мед. наук. — М., 1967. - С. 16.

  43. A controlled comparison of four regimens of streptomycin plus pyrazinamide in the retreatment of pulmonary tuberculosis. Tubercle 1969; 50: 81–114 (B)

  44. Abraham S, Johnson CL, Najjar F: Weight and height of adults 18-74 years of age. DHEW Pub. No (PHS) 79-1659(211). Washington, DC, US Government Publications Office, Vital and Health Statistics, Series 11, 1979

  45. Abramson D, Butler LD, Chrai S. Depyrogenation of a parenteral solution by ultrafiltration. J Parenter Sci Technol 1981; 35: 3–7 (B)

  46. Abramson F, Gibson S, Barlee V, Bosch JP. Urea kinetic modeling at high urea clearances: implications for clinical practice. Adv Renal Replace Ther 1994; 1:5–14 (B)

  47. Abreo K, Brown ST, Sella M. Correction of microcytosis following elimination of an occult source of aluminum contamination of dialysate. Am J Kidney Dis 1989; 13: 465–468 (B).

  48. Abuelo JG, Chang BS. Is prostacyclin better than nothing for anticoagulation in haemodialysis? Lancet 1981; 2: 470– 471 (B)

  49. Acchiardo SR, Hatten KW, Ruvinsky MJ et al. Inadequate dialysis increases gross mortality rate. ASAIO J 1992; 38: M282–M285 (B) SECTION II. Haemodialysis adequacy 27

  50. Acchiardo SR, Moore LW, Burk L: Morbidity and mortality in hemodialysis patients. ASAIO Trans 36:M148-M151, 1990

  51. Acchiardo SR, Moore LW, Latour PA: Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. Kidney Int Suppl 16:S199-S203, 1983

  52. Adami S, Viapiana O, Gatti D et al. Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake. Bone 2008; 42: 267–270.

  53. Agarwal R, Cronin RE. Heterogeneity in gentamicin clearance between high-efficiency hemodialyzers. Am J Kidney Dis 1994; 23: 47–51 (A)

  54. Agency for Toxic Substances and Disease Registry: Methanol toxicity . Am Fam Physician 1993; 47(1): 163-7.

  55. AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18–23.

  56. Agresti J, Conroy JD, Olshan A et al. Heparin-free hemodialysis with Cuprophan hollow fiber dialyzers by a frequent saline flush, high blood flow technique. ASAIO Trans 1985; 31: 590–594 (B)

  57. Ahmad S, Pagel M, Vizzo J, Scribner BH: Effect of the normalization of acid-base balance on postdialysis plasma bicarbonate. ASAIO Trans 26:318-322, 1980

  58. Ahmed FE: Seafood safety . Committee on Evaluation of the Safety of Fishery Products 1991; Food & Nutrition Board, Institute of Medicine: National Academy Press.

  59. Ahrenholz P, Winkler RE, Ramlow W, Tiess M, Mueller W.On-line haemodiafiltration with pre- and postdilution: acomparison of efficacy. Int J Artif Organs 1997; 20: 81–90 (B)

  60. Akiba T, Tachibana K, Ozawa K et al. Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis. ASAIO J 1992; 38: M326–M330 (B)

  61. Akizawa T, Kinugasa E, Koshikawa S. Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysis. ASAIO Trans 1991; 37: M384–M385 (B)

  62. Akkina SK, Connaire JJ, Snyder JJ, et al. Earlier is not necessarily better in preemptive kidney transplantation. Am J Transplant 2008;8:2071-6

  63. Akmal M, Sawelson S, Karubian F, Gadallah M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42:198-202, 1994

  64. Akrum R, Frohlich M, Gerritsen AF, Daha MR, Chang PC. Ultrapure water for dialysate contributes to a lower activation state of peripheral blood mononuclear cells. Kidney Int 1999; 55: 1158–1171 (C)

  65. Al Saady NM, Leatham EW, Gupta S et al. Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 1999; 81: 134–140 (B)

  66. Alexander S, Honda M. Continuous peritoneal diaysis for children: a decade of worldwide growth and development. Kidney Int 1993;43:S65-S74.

  67. Alexander S. Pediatric uses of recombinant human erythropoietin: the outlook in 1991. Am J Kidney Dis 1991;18:42-53.

  68. Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG. Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 1991; 11: 102–111 (B)

  69. Alfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9–19 (B)

  70. Allegra V, Vasile A, Maschio M, Mengozzi G. Immune response after vaccination with recombinant hepatitis surface antigen in maintenance hemodialysis patients and healthy controls. Nephron 1992; 61: 339–340 (B)

  71. Allon M, Lockhart ME, Lilly RZ. Effect of preoperative sonographic mapping on vascular access outcomes in hemodialysis patients. Kidney Int 2001; 60: 2013–2020

  72. Allon M, Ornt DB, Schwab SJ et al. Factors associated with the prevalence of arteriovenous fistulas in hemodialysis patients in the HEMO study. Hemodialysis (HEMO) Study Group. Kidney Int 2000; 58: 2178–2185

  73. Almond, Clark: Nonsteroidal anti-inflammatory agents . Emergency Medicine A Comprehensive Guide 1995; 4th ed.: 792-795.

  74. Amaral S, Hwang W, Fivush B, et al. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. J Am Soc Nephrol 2006;17:2878-2885.

  75. Ambrosch A, Domroese U, Westphal S et al. Compositional and functional changes of low-density lipoprotein during hemodialysis in patients with ESRD. Kidney Int 1998; 54: 608–617 (B)

  76. American Academy of Pediatrics: Naloxone dosage and route of administration for infants and children . Pediatrics 1990; 86(3): 484-485.

  77. American Psychiatric Association: Diagnostic and statisical manual of mental disorders. 1994; 4th ed:.

  78. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol Dial Transplant 2002;17:340-345.

  79. Amiral J, Bridey F, Dreyfus M et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95–96 (B)

  80. Amitai Y, Yoram M, et al: Scorpion stings in children . Clinical Pediatrics 1885; 24: 136-40.

  81. Amore A, Gyarnieri G, Atti M, Schena FP, Coppo R. Use of alkaline rinsing solution to prevent heypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. J Nephrol 1999; 12: 383–389 (B)

  82. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin (‘fragmin’) for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol 1989; 32: 290–296 (A)

  83. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996; 124: 261–271 (B)

  84. Anderson JE, Chang ASY, Anstadt MP. Polytetrafluoroethylene hemoaccess site infections. ASAIO J 2000; 46: S18–S21 (B)

  85. Anderson R, Hart G, Crumpler C: Clonidine overdose: Report of six cases and review of the literature . Annals of Emergency Medicine 1981; 10(2): 107-112.

  86. Anderstam B, Katzarski K, Bergstrom J Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997; 8: 1437–1442 (B)

  87. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999; 10: 2177–2184 (B)

  88. Andrassy K. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride. Blood Coagul Fibrinolysis 1993; 4 [Suppl 1]: S39–S43 (B)

  89. Andress D. Intravenous versus oral vitamin D therapy in dialysis patients: what is the question? Am J Kidney Dis 2001;38:S41-S44.

  90. Andrew EB, Swift BS, Swift TR: Ciguatera (Review) . J Toxicol Clin Toxicol 1993; 31(1): 1-29.

  91. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B)

  92. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B) 149. Andrew OT, Schoenfeld PY, Hopewell PC, Humphreys MH. Tuberculosis in patients with end-stage renal disease. Am JMed 1980; 68: 59–65 (B)

  93. Annibale B, Lahner E, Chistolini A, et al: Endoscopic evaluation of the upper gastrointestinal tract is worthwhile in premenopausal women with iron-deficiency anaemia irrespective of menstrual flow. Scand J Gastroenterol 38:239-245, 2003

  94. Anochie I, Eke F. Acute renal failure in Nigerian children: Port Harcourt experience. Pediatr Nephrol 2005;20:1610-1614.

  95. Anon: Self-treatment with herbal and other plant-derived remedies-rural Mississippi, 1993 . Morbidity and Mortality Weekly Report 1995; 44 (11): 204-7.

  96. Ansell D, O’Neill JO, Johnson R, et al. Transplantation of older patients does not improve survival compared with those wait listed. Analysis of 9,700 wait listed patients in the UK. Transplantation 2008;86(2S):314

  97. Anthon T, Jastremski M, Elliot W: Charcoal hemoperfusion for the treatment of a combined diltiazem and metoprolol overdose . Ann Emerg Med 1986; 15: 1344-1347.

  98. Anthropometric data and prevalence of overweight for Hispanics:1982-84. Data from the National Health Survey, 1989. Hyattsville, MD, DHHS, US Government Publications Office, Vital and Health Statistics, Series 11, Nr 239, 1989

  99. Antonen JA, Hannula PM, Pyhala R et al. Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 2000; 86: 56–61 (B)

  100. Apfelbaum JD, Caravati EM, Kerns WP: Cardiovascular Effects of Carbamazepine Toxicity . Ann Emer Med 1995; 25: 631-635.

  101. Applebaum-Bowden D, Goldberg AP, Hazzard WR et al. Postheparin plasma triglyceride lipases in chronic hemodialysis: evidence for a role for hepatic lipase in lipoprotein metabolism. Metabolism 1979; 28: 917–924 (B)

  102. Araki Y, Hataya H, Tanaka Y, et al. Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis for children. Perit Dial Int 2000;20:445-451.

  103. Arduino MJ, Bland LA, McAllister SK, Favero MS. The effects of endotoxin-contaminated dialysate and polysulfone or cellulosic membranes on the release of TNF alpha during simulated dialysis. Artif Organs 1995; 19: 880–806 (B)

  104. Arduino MJ. Proper mechanisms for assuring disinfectant concentrations for use in haemodialysis. Nephrol News Issues 1999; 13: 18, 23, 27 (B)

  105. Arena J: Plants That Poison . Emergency Medicine June 15, 1989; pp. 20-64.

  106. Arenas J, Sanchez-Paya J, Gonzales C et al. Audit on the degree of application of universal precautions in a haemodialysis unit. Nephrol Dial Transplant 1999; 14: 1001–1003 (B)

  107. Argile´s A, Garcia-Garcia M, Derancourt J, Mourad G, Demaille JG. Beta 2 microglobulin isoforms in healthy individuals and in amyloid deposits. Kidney Int 1995; 48: 1397–1405 (B)

  108. Argiles A, Ficheux A, Thomas M et al. Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. Kidney Int 1997; 52: 530–537 (B)

  109. Arnadottir M, Berg AL, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int 1997; 52: 1651–1655 (B)

  110. Arnadottir M, Berg AL, Hegbrant J, Hultberg B. Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 1999; 14: 142–146 (B)

  111. Arnadottir M, Berg AL, Kronenberg F et al. Corticotropininduced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: relation to apolipoprotein(a) size polymorphism. Metabolism 1999; 48:342–346 (B)

  112. Arnadottir M, Brattstrom L, Simonsen O et al. The effect of high-dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 1993; 40: 236– 240 (B)

  113. Arnadottir M, Kurkus J, Nilsson-Ehle P. Different types of heparin in haemodialysis: long-term effects on post-heparin lipases. Scand J Clin Lab Invest 1994; 54: 515–521 (B)

  114. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 1995; 48: 779–784 (B)

  115. Arnaout MA, Hakim RM, Todd RF, Dana N, Colten HR. Increased expression of an adhesion-promoting surface glycoproteinin the granulocytopenia of hemodialysis. N Engl J Med 1985; 312: 457–462 (B)

  116. Arnesen E, Refsum H, Bonaa KH et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704–709 (B)

  117. Arnow PM, Bland LA, Garcia-Houchins S, Fridkin S,Fellner SK. An outbreak of fatal fluoride intoxication in along-term haemodialysis unit. Ann Intern Med 1994; 121:339–344 (B)

  118. Arnow PM, Garcia-Houchins S, Neagle MB et al. An outbreak of bloodstream infections arising from hemodialysis equipment. J Infect Dis 1998; 178: 783– 791 (B)

  119. Arvanitidou M, Spaia S, Katsinas C et al. Microbiological quality of water and dialysate in all haemodialysis centres of Greece. Nephrol Dial Transplant 1998; 13: 949–954 (B)

  120. Asaka M, Iida H, Izumino K, Sasayama S. Depressed natural killer cell activity in uraemia. Evidence for immunosuppressive factor in uraemic sera. Nephron 1988; 49: 291–295 (B)

  121. Asayama K, Ito H, Nakahara C, et al. Lipid profiles and lipase activities in children and adolescents with chronic renal failure treated conservativelly or with hemodialysis or transplantation. Pediatr Res 1984;18:783-788.

  122. Ascher E, Gade P, Hingorani A et al. Changes in the practice of angioaccess surgery: impact of dialysis outcome and quality initiative recommendations. J Vasc Surg 2000 (Jan); 31 (1 pt 1): 84–92

  123. Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17 [Suppl 7]: 7–15

  124. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). US Renal Data System: USRDS 2004 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004

  125. Aterini S, Ippolito E, Salvadori M et al. Second messenger formation altered by different dialysis membranes in human leukocytes. Kidney Int 1994; 46: 461–466 (B)

  126. Atger V, Duval F, Frommherz K, Drueke T, Lacour B. Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I. Atherosclerosis 1988; 74: 75–83 (B)

  127. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.

  128. Atkins D, Briss PA, Eccles M et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005; 5: 25.

  129. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia—relation to renal function and dialysis. Nephron 1991; 57: 401–410 (B)

  130. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573–592 (C)

  131. Attman PO, Samuelsson OG, Moberly J et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999; 55: 1536–1542 (B)

  132. Attman PO. Hyperlipoproteinaemia in renal failure: pathogenesis and perspectives for intervention. Nephrol Dial Transplant 1993; 8: 294–295 (C)

  133. Auerbach P: Marine envenomations . N Engl J Med 1991; 325: 486-493.

  134. Auerbach P: Wilderness Medicine - Management of Wilderness and Environmental Emergencies . 1995; 780-81.

  135. Auerbach PS: Marine envenomations. In Auerbach PS (Ed.) Wilderness Medicine: Management of Wilderness and Environmental Emergencies, 3rd ed . 1995; 1327-74.

  136. Auerbach PS: Seafood toxidromes . Wilderness Medicine: Management of Wilderness and Environmental Emergencies 1995; 3rd ed: 1379-1384.

  137. Auerbach PS: Wilderness medicine, management of wilderness and environmental emergencies . 1995;.

  138. Aufderheide TP, White SM, et al: Inhalational and percutaneous methanol toxicity in two firefighters . Ann Emerg Med 1993; 22(12): 1916-8.

  139. Auguet T, Senti M, Rubies PJ et al. Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 1993; 8:1099–1103 (B)

  140. Aull L, Chao H, Coy K. Heparin-induced hyperkalemia. DICP: Ann Pharmacotherap 1990; 24: 244–246 (B)

  141. Auron A, Simon S, Andrews W, et al. Prevention of peritonitis in children receiving peritoneal dialysis. Pediatr Nephrol 2007;22:578-585.

  142. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495–506 (C)

  143. Austin MA, Mykkanen L, Kuusisto J et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92: 1770–1778 (B)

  144. Avram MM, Fein PA, Antignani A et al. Cholesterol and lipid disturbances in renal disease: the natural history of uremic dyslipidemia and the impact of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Med 1989; 87: 55N–60N (B)

  145. Babb AL, Farrell PC, Uvelli DA, Scribner BH. Hemodialyzer evaluation by examination of solute molecular spectra. ASAIO Trans 1972; 18: 98–105, 122 (B)

  146. Bacchini G, Cappello A, La Milia V, Andrulli S, Locatelli F. Color doppler ultrasonography imaging to guide transluminal angioplasty of venous stenosis. Kidney Int 2000; 58: 1810–1813

  147. Bachmann J, Tepel M, Raidt H et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6: 121–125 (B)

  148. Bacon NC. Heparin-induced disturbance of potassium homeostasis. Q JMed 1997; 90: 725 (B)

  149. Bagnis R, Kuberski T, Laugier S: Clinical observations on 3009 cases of ciguatera (fish poisoning) in the South Pacific . Am J Trop Med Hyg 1979; 28: 1067-1073.

  150. Bagnis R: Problems of toxicants in marine food products . Bull WHO 1970; 42: 69.

  151. Bahlmann J, Schoter KH, Scigalla P, et al: Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol 88:90-106, 1991

  152. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147–152 (C)

  153. Baigent C, Wheeler DC. Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? Nephrol Dial Transplant 2000; 15: 1118–1119 (C)

  154. Bain RJI: Accidental digitalis poisoning due to drinking herbal tea . Br Med J 1985; 290: 1624.

  155. Baker ME: Licorice and enzymes other than 11-beta-hydroxysteroid dehydrogenase: an evolutionary perspective . Steroids 1994; 59: 136-141.

  156. Balfe J, Hanning R, Vigneux A. A comparison of peritoneal water and solute movement in younger and older children on CAPD. In: Fine R, Schaefer F, Mehls O, eds. CAPD in children. New York: Springer-Verlag New York, 1985:14-19.

  157. Balfe J, Irwin M. Continuous ambulatory peritoneal dialysis in children. In: Legrain M, ed. Continuous ambulatory peritoneal dialysis. Amsterdam: Excerpta Medica, 1980:131-136.

  158. Balfe J, Secker D, Coulter P, et al. Tube feeding in children on chronic peritoneal dialysis. Adv Perit Dial 1990;6:257-261.

  159. Balfe J, Vigneux A, Willumsen J, et al. The use of CAPD in the treatment of children with end-stage renal disease. Perit Dial Bull 1981;1:35-38.

  160. Balfe J. Intraperitoneal amino acids in children receiving chronic peritoneal dialysis. Perit Dial Int 1996;16:S515-S516.

  161. Baluarte HJ, Grossman MS, Polinsky MD, et al. Experience with intermittent home peritoneal dialysis (IHPD) in children. Pediatr Res 1980;14:994.

  162. Bambauer R, Meyer S, Jung H, Goehl H, Nystrand R. Sterile versus non-sterile dialysis fluid in chronic haemodialysis treatment. ASAIO Trans 1990; 36: M317–M320 (A)

  163. Bambauer R, Rucker S, Weber U, Kohler M. Comparison of low molecular weight heparin and standard heparin in hemodialysis. ASAIO Trans 1990; 36: M646–M649 (B)

  164. Bambauer R, Schauer M, Jung WK, Daum V, Vienken J. Contamination of dialysis water and dialysate. A survey of 30 centers. ASAIO J 1994; 40: 1012–1016 (B)119. Laurence RA, Lapierre ST. Quality of haemodialysis water: a 7-year multicenter study. Am J Kidney Dis 1995; 25:738–750 (B)

  165. Bambauer R, Walther J, Jung WK. Ultrafiltration of dialysis fluid to obtain a sterile solution during haemodialysis. Blood Purif 1990; 8: 309–317 (C)

  166. Bambauer R, Walther J, Meyer S et al. Bacteria- and endotoxin-free dialysis fluid for use in chronic haemodialysis.Artif Organs 1994; 18: 188–192 (C)

  167. Bankhead MM, Toto RD, Star RA. Accuracy of urea removal estimated by kinetic models. Kidney Int 1995; 48: 785–793 (B)

  168. Bansal R, Agarwal SK, Tiwari SC, Dash SC. A prospective randomized study to compare ultrasound-guided with nonultrasound-guided double lumen internal jugular catheter insertion as a temporary hemodialysis access. Ren Fail 2005; 27: 561–564

  169. Barceloux DG, et al. American Academy of Clinical Toxicology practice guide­lines on the treatment of ethylene glycol poisoning. Ad Hoc Committee. J Toxi-col Clin Toxicol 1999;37:537-560.

  170. Bardin T, Zingraff J, Shirahama T et al. Hemodialysisassociated amyloidosis and beta-2 microglobulin. Clinical and immunohistochemical study. Am J Med 1987; 83: 419–424 (B)

  171. Bargman J, Nordfors L, Silverman E. The effect of in vivo erythropoietin on cytokine mRNA in CAPD patients. Adv Perit Dial 1994;10:129-134.

  172. Barrera P, Janssen EM, Demacker PN, Wetzels JF, van der Meer JW. Removal of interleukin-1 beta and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes. Lymphokine Cytokine Res 1992; 11: 99–104 (B)

  173. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, Handa SP, Jindal KK, Kjellstrand CM, Levin A, Mandin H, Muirhead N, Richardson RM: Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 29:214-222, 1997

  174. Basile C, Casino F, Lopez T. Percent reduction in blood urea concentration during dialysis estimates KtV in a simple and accurate way. Am J Kidney Dis 1990; 15: 40–45 (B)

  175. Bass J: Effects of Enteral Tube Feeding on Absorption and Pharmacokinetic Profile of Carbamazepine . Epilepsia 1989; 30: 364-69.

  176. Bastani B. McNeely M, Schmitz PG: Serum bicarbonate is an independent determinant of protein catabolic rate in chronic hemodialysis. Am J Nephrol 16:382-285, 1996

  177. Bateman J, Chapman RD, Simpson D: Possible toxicity of herbal remedies . Scot Med J 1998; 43: 7-15.

  178. Baud FJ, Barriot P, Toffis V: Elevated blood cyanide concentrations in victims of smoke inhalation . N Engl J Med 1991; 325: 1761-1766.

  179. Baudouin-Legros M, Asdram L, Tondelier D, Paulais M, Anagnostopoulos T. Extracellular urea concentration modulates cAMP production in the mouse MTAL. Kidney Int 1996;50: 26–33 (B)

  180. Baum M, Powell D, Calvin S, et al. Continuous ambulatory peritoneal dialysis in children: comparison with hemodialysis. N Engl J Med 1982;307:1537-1542.

  181. Baumelou A, Singlas E, Petitclerc T et al. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients. Nephron 1994; 68: 202–206 (B)

  182. Baurmeister U, Travers M, Vienken J et al. Dialysate contamination and back filtration may limit the use of high-flux dialysis membranes. ASAIO Trans 1989; 35: 519–522 (C)

  183. Baxter EH, Gallichio HA: Cross-neutralization by Tiger Snake (Notechis scutatus) Antivene and Sea Snake (Enhydrina schistosa) Antivene Against Several Sea Snake Venoms . Toxicon 1974; 12: 273-78.

  184. Bay WH, Van Cleef S, Owens M. The hemodialysis access: preferences and concerns of patients, dialysis nurses and technicians, and physicians. Am J Nephrol 1998; 18: 379–383

  185. Baz M, Durand C, Ragon A et al. Using ultrapure water in haemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681–685 (B)

  186. Beall CM, Goldstein MC: Hemoglobin concentration of pastoral nomads permanently resident at 4,850-5,450 meters in Tibet. Am J Phys Anthropol 73:433-438, 1987

  187. Beathard GA, Arnold P, Jackson J, Litchfield T. Aggressive treatment of early fistula failure. Kidney Int 2003; 64: 1487–1494

  188. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic haemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475–486 (C)

  189. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475–486 (C)

  190. Beck-Sague CM, Jarvis WR, Bland LA et al. Outbreak of Gram-negative bacteremia and pyrogenic reactions in a hemodialysis center. Am J Nephrol 1990; 10: 397–403 (B)

  191. Belay B, Esteban-Cruciani N, Walsh C, et al. The use of levo-carnitine in children with renal disease: a review and a call for future studies. Pediatr Nephrol 2006;21:308-317.

  192. Belcon MC, Smith EK, Kahana LM, Shimizu AG. Tuberculosis in dialysis patients. Clin Nephrol 1982; 17: 14–18 (B)

  193. Bellizzi V, Minutolo R, Terracciano V, et al: Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. Am J Kidney Dis 40:549-555, 2002

  194. Bello VA, Gitelman HJ. High fluoride exposure in haemodialysis patients. Am J Kidney Dis 1990; 15: 320–324 (C)Wathen RL, Burcham CW Jr. Understanding the dangers of fluoride during dialysis. Nephrol News Issues 1993; 7: 32–36 (C).

  195. Ben-Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000; 95: 3579–3383 (B)

  196. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003–4008.

  197. Benhamou E, Courouce AM, Jungers P et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143–147 (A)

  198. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983; 3: 155–193 (B)

  199. Benowitz N: Beta-Adrenergic receptor blocker overdose . Haddad and Winchester, W.B. Saunders Co 1990; Second Edition: 1315-1326.

  200. Bereket G, Fine R. Pediatric renal transplantation. Pediatr Clin North Am 1995;42:1603-1628.

  201. Bergstrom J, Furst P. Uraemic toxins. In: Drukker W,Parsons FM, Maher J, eds. Replacement of Renal Function by Dialysis. Martinus Nijhoff, Dordrecht: 1983; 354–390 (C)

  202. Bergstrom J, Heimburger O, Lindholm B: Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? Perit Dial Int 18:467-473, 1998

  203. Bergstrom J, Lindholm B, Lacson E Jr et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000; 13: 163–175 (C)

  204. Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis [letter]. Lancet 1987; 1: 628–629 (C)

  205. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995; 6: 1329–1341 (C)

  206. Berk W, Henderson W: Alcohols . Emergency Medicine: A Comprehensive Study Guide 1996; 765-72.

  207. Berkahn L, Keating A: Hematopoiesis in the elderly. Hematology 9:159-163, 2004

  208. Berkley SF: Dermatitis in grocery workers associated with high natural concentrations of furanocoumarins in celery . Ann Int Med 1986; 105: 351-355.

  209. Berland Y, Brunet P, Ragon A, Frenkian G, Crevat A. Dialysate biocompatibility: evaluation and expectations. Contrib Nephrol 1993; 103: 76–88 (C)

  210. Berland Y, Brunet P, Ragon A, Reynier JP. Dialysis fluid and water: their roles in biocompatibility. Nephrol Dial Transplant 1995; 10 [Suppl 10]: 45–47 (C)

  211. Berman SJ, Hess JR, Sugihara JG, Wong ECC, Wong I, Siemens AW. Morbidity of infection in chronic hemodialysis. Dial Transplant 1979; 8: 324–328 (B)

  212. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64:1514-1521, 2003

  213. Berthoux F, Abramowicz D, Bradlet B, et al. European best practice guidelines for renal transplantation (Part 1). Nephrol Dial Transpl 2000;15:Suppl 7

  214. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998

  215. Besarab A, Caro J, Jarrell B, et al: Effect of cyclosporine and delayed graft function on posttransplantation erythropoiesis. Transplantation 40:624-631, 1985

  216. Besarab A, DeLucia T, Picarello N, Jungkind D. Formaldehyde, sodium hypochlorite, and metabisulphite are equally effective as sterilants for central delivery systems. ASAIO J 1993; 39: M590–M595 (B)

  217. Besarab A, Levin A: Defining a renal anemia management period. Chandra M, Miller ME, Garcia JF, Mossey RT, McVicar M: Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients.

  218. Besarab A. Preventing vascular access dysfunction: which policy to follow. Blood Purif 2002; 20: 26–35

  219. Bessen HA: Therapeutic and toxic effects of digitalis: William Withering, 1785. J Emerg Med 1986; 4: 243-282.

  220. Besso L, Rovere A, Peano G et al. Prevalence of HCV antibodies in a uraemic population undergoing maintenance dialysis therapy and in the staff members of the dialysis unit. Nephron 1992; 61: 304–306 (B)

  221. Besunder JB, Super DM, Anderson RL: Comparison of dimercaptosuccininc acid and calcium disodium ethylenediaminetetraacetic acid versus dimercaptopropanol and ethylenediaminetetraacetic acid in children with lead poisoning . J Pediatr 1997; 130: 966-71.

  222. Beto JA, Bansal VK, Ing TS, Daugirdas JT. Variation in blood sample collection for determination of haemodialysis adequacy. Council on Renal Nutrition National Research Question Collaborative Study Group. Am J Kidney Dis 1998; 31: 135–141 (B)

  223. Beto JA, Bansal VK: Interventions for other risk factors: Tobacco use, physical inactivity, menopause, and homocysteine. Am J Kidney Dis 32:S112-S119, 1998 (suppl 3)

  224. Bhat DJ, Tellis VA, Kohlberg WI, Driscoll B, Veith FJ. Management of sepsis involving expanded polytetrafluoroethylene grafts for hemodialysis access. Surgery 1980; 87: 445–450 (B)

  225. Bhatia DS, Money SR, Ochsner JL et al. Comparison of surgical bypass and percutaneous balloon dilatation with primary stent placement in the dialysis patient: one-year follow-up. Ann Vasc Surg 1996; 10: 452–455

  226. Biasioli S, Schiavon R, Petrosino L et al. Role of cellulosic and noncellulosic membranes in hyperhomocysteinemia and oxidative stress. ASAIO J 2000; 46: 625–634 (B)

  227. Bick RL, Frenkel EP. Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost 1999; 5 [Suppl 1]: S7–S15 (B)

  228. Bielak LF, Klee GG, Sheedy PF et al. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography. Arterioscler Thromb Vasc Biol 2000; 20: 2167–2171 (B)

  229. Biesenbach G, Zazgornik J. Influence of smoking on the survival rate of diabetic patients requiring hemodialysis. Diabetes Care 1996; 19: 625–628 (B)

  230. Bigazzi R, Atti M, Baldari G. High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination. Blood Purif 1990; 8: 190–198 (B)

  231. Biglieri EG: Spectrum of mineralocorticoid hypertension . Hypertension 1991; 17(2): 251-261.

  232. Bijsterveld NR, Hettiarachchi R, Peters R et al. Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999; 82 [Suppl 1]: 139–147 (B)

  233. Bilo HJ, Homan van der Heide JJ, Gans RO, Donker AJ. Omega-3 polyunsaturated fatty acids in chronic renal insufficiency. Nephron 1991; 57: 385–393 (B)

  234. Bingel M, Lonnemann G, Koch KM, Dinarello CA, Shaldon S.Plasma interleukin-1 activity during hemodialysis: the influence of dialysis membranes. Nephron 1988; 50: 273–276 (B)

  235. Binzer M, Andersen P, Kullgren G: Clinical characteristics of patients with motor disability due to conversion disorder: A prospective control group study. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 63: 83-88.

  236. Birk HW, Kistner A, Wizemann V, Schu¨ tterle G. Protein adsorption by artificial membrane materials under filtration conditions. Artif Organs 1995; 19: 411–415 (B)

  237. Birmbaumer D, Besson H: Alcohols and glycols . Emergency Medicine Concepts and Clinical Practice 1992; 3rd ed: 2520-32.

  238. Bishai WR, Chaisson RE. Short-course chemoprophylaxis for tuberculosis. Clin Chest Med 1997; 18: 115–122 (B)

  239. Biswal N, Mathai B, Bhataia BD: Scorpion sting envenomation: complications and management . Indian Pediatrics 1993; 30: 1055-9.

  240. Blacher J, Demuth K, Guerin AP et al. Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 1998; 18: 535–541 (B)

  241. Blaikie A, Ellis J, Sanders R: Eye disease associated with handling pet tarantulas: three case reports . BMJ 1997; 314: 1524-25.

  242. Blair SN, Applegate WB, Dunn AL, Ettinger WH, Haskell WL, King AC, Morgan TM, Shih JA, Simons-Morton DG: Activity Counseling Trial (ACT): Rationale, design, and methods. Activity Counseling Trial Research Group. Med Sci Sports Exercise 30:1097-1106, 1998

  243. Blake J, Burkart J, Churchill D. Recommended clinical practices for maximizing peritoneal dialysis clearances. Perit Dial Int 1996;16:448-456.

  244. Bland LA, Arnow PM, Arduino MJ, Bova J, McAllister SK. Potential hazards of deionization systems used for water purification in haemodialysis. Artif Organs 1996; 20: 2–7 (B)

  245. Bland LA, Favero MS, Oxborrow GS, Aguero SM, Searcy BP, Danielson JW. Effect of chemical germicides on the integrity of hemodialyzer membranes. ASAIO Trans 1988; 34:172–175 (B)

  246. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic haemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)

  247. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)

  248. Blankestijn PJ, Vos PF, Rabelink TJ et al. High-flux dialysis membranes improve lipid profile in chronic hemodialysis patients. J Am Soc Nephrol 1995; 5: 1703–1708 (B)

  249. Blaufox MD, Hampers CL, Merrill JP. Rebound anticoagulation occurring after regional heparinization for hemodialysis. ASAIO Trans 1966; 12: 207–209 (B)

  250. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655–63.

  251. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium3phosphate product with mortality risk in chronic hemodialysis patients:a national study. Am J Kidney Dis 1998; 31: 607–617 (B)

  252. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226–1237 (C)

  253. Bloembergen WE, Hakim RM, Stannard DC et al. Relationship of dialysis membrane and cause-specific mortality. Am J Kidney Dis 1999; 33: 1–10 (B)

  254. Bloembergen WE, Port FK. Epidemiological perspective on infections in chronic dialysis patients. Adv Ren Replace Ther 1996; 3: 201–207 (C)

  255. Bloembergen WE, Stannard DC, Port FK et al. Relationship of dose of haemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557–565 (B)

  256. Bloembergen WE, Stannard DC, Port FK et al. Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 1996; 50: 557–565 (B)

  257. Blomquist S, Malmros C, Martensson L, Tho¨ rne J. Absence of lung reactions after complement depletion during dialysis: an experimental study in pigs. Artif Organs 1991; 15: 397–401 (B)

  258. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27: 687–694 (B)

  259. Blumenkrantz MJ, Gahl GM, Kopple JD, Kamdar AV, Jones MR, Kessel M, Coburn JW: Protein losses during peritoneal dialysis. Kidney Int 19:593-602, 1981

  260. Blumenthal M: The Complete Medicinal Herb . DK Publishing 1993;.

  261. Blythe DG, DeSylva DP, Fleming LE: Clinical experience with IV mannitol in the treatment of ciguatera . Bull Soc Pathol Exot 1992; 85: 425.

  262. Boaz M, Matas Z, Biro A et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438–444 (B)

  263. Boaz M, Matas Z, Biro A et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 1999; 56: 1078–1083 (B)

  264. Boaz M, Smetana S, Weinstein T et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356: 1213–1218 (A)

  265. Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000; 86: 19L–22L (B)

  266. Boelaert JR, Cantinieaux BF, Hariga CF, Fondu PG. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. Nephrol Dial Transplant 1990; 5: 504–517 (B) SECTION VI. Haemodialysis-associated infection 83

  267. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130–134 (B)

  268. Boelaert JR, De Baere YA, Geernaert MA, Godard CA, Van Landuyt HW. The use of nasal mupirocin ointment to prevent Staphylococcus aureus bacteraemias in haemodialysis patients: an analysis of cost-effectiveness. J Hosp Infect 1991; 19 [Suppl B]: 41–46 (B)

  269. Boelaert JR, de Locht M, Van Cutsem J et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91: 1979–1986 (B)

  270. Boelaert JR, De Smedt RA, De Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278–281 (A)

  271. Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991; 18: 660–667 (B)

  272. Boelaert JR, Van Landuyt HW, De Baere YA et al. Staphylococcus aureus infections in haemodialysis patients: pathophysiology and use of nasal mupirocin for prevention. J Chemother 1995; 7 [Suppl 3]: 49–53 (C)

  273. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235–239 (B)

  274. Boelaert JR, Van Landuyt HW, Valcke YJ et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis 1987; 156: 384–387 (B)

  275. Boelaert JR, van Roost GF, Vergauwe PL et al. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature. Clin Nephrol 1988; 29: 261–266 (B)

  276. Boelaert JR. Staphylococcus aureus infection in haemodialysis patients. Mupirocin as a topical strategy against nasal carriage: a review. J Chemother 1994; 6 [Suppl 2]: 19–24 (B)

  277. Boen S, Mion C, Curtis F, et al. Periodic peritoneal dialysis using the repeated puncture technique and an automated cycling machine. Trans Am Soc Artif Intern Organs 1964;10:409-414.

  278. Bogdan GM, Dart RC: Prolonged and recurrent coagulopathy after North American pit viper envenomation (abstract) . Ann Emerg Med 1996; 27: 820.

  279. Bologa RM, Levine DM, Parker TS et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107–114 (B)

  280. Bommer C, Werle E, Walter-Sack I et al. D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients. J Am Soc Nephrol 1998; 9: 90–96 (B)

  281. Bommer J, Gemsa D, Waldherr R, Kessler J, Ritz E. Plastic filing from dialysis tubing induces prostanoid release from macrophages. Kidney Int 1984; 26: 331–337 (B)

  282. Bommer J, Pernicka E, Kessler J, Ritz E. Reduction of silicone particle release during haemodialysis. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 287–290 (B)

  283. Bommer J, Ritz E, Andrassy K et al. Effect of vaccination schedule and dialysis on hepatitis B vaccination response in uraemic patients. Proc Eur Dial Transplant Assoc 1983; 20: 161–168 (B)

  284. Bommer J, Ritz E, Waldherr R. Silicone-induced splenomegaly. Treatment of pancytopenia by splenectomy in a patient on hemodialysis. N Engl J Med 1981; 305: 1077–1079 (B)

  285. Bommer J, Vergetis W, Andrassy K et al. Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J 1995; 41: 127–131 (A)

  286. Bommer J, Weinreich T, Lovett DH et al. Particles from dialysis tubing stimulate interleukin-1 secretion by macrophages. Nephrol Dial Transplant 1990; 5: 208–213 (B)

  287. Bommer J, Wilhelms OH, Barth HP, Schindele H, Ritz E. Anaphylactoid reactions in dialysis patients: role of ethylene oxide. Lancet 1985; 2: 1382–1385 (B)

  288. Bond GR, Burkhart KK: Thrombocytopenia following timber rattlesnake envenomation . Ann Emerg Med 1997; 30: 40-4.

  289. Bond GR: Antivenin administration for Centruroides scorpion sting: risks and benefits . Annals of Emergency Medicine 1992; 21: 788-91.

  290. Bonomini V, Coli L, Scolari MP, Stefoni S. Structure of dialysis membranes and long-term clinical outcome. Am J Nephrol 1995; 15: 455–462 (B)

  291. Bonomini V, Coli L, Scolari MP, Stefoni S. Structures of dialysis membranes and long term clinical outcomes. Am J Nephol 1995; 15: 455–462 (B)

  292. Boogaerts MA, Yamada O, Jacob HS, Moldow CF. Enhancement of granulocyte-endothelial cell adherence and granulocyte-induced cytotoxicity by platelet release products. Proc Natl Acad Sci USA 1982; 79: 7019–7023 (B)

  293. Borah M, Schoenfeld P, Gotch F, et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978;14:491-500.

  294. Borah M, Shoenfeld P, Gotch FA et al. Nitrogen balance during intermittent dialysis therapy for uraemia. Kidney Int 1978; 14: 491–500 (B)

  295. Borah MF, Schoenfeld PY, Gotch FA et al. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 1978; 14: 491–500 (B)

  296. Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfsen M, Humphreys MH: Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int 14:491-500, 1978

  297. Bories PC, Subbaiah PV, Bagdade JD. Lecithin: cholesterol acyltransferase activity in dialyzed and undialyzed chronic uremic patients. Nephron 1982; 32: 22–27 (B)

  298. Borm JJ, Krediet R, Sturk A, ten Cate J. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986; 16 [Suppl 2]: 59–68 (A)

  299. Borovnicar DJ, Wong KC, Kerr PG, Stroud DB, Xiong DW, Strauss BJ, Atkins RC: Total body protein status assessed by different estimates of fat-free mass in adult peritoneal dialysis patients. Eur J Clin Nutr 50:607-616, 1996

  300. Borron SW, Baud FJ: Acute cyanide poisoning: Clinical spectrum, diagnosis, and treatment . Arch Toxicol Indust Hygiene 1996; 47: 307-322.

  301. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24:495-499, 2001

  302. Bosse GM, Arnold TC: Overdose with sustained-release lithium preparations . J Emerg Med 1992; 10: 719-700.

  303. Bosticardo GM, Avalle U, Giacchino F, Alloatti S. Comparison of a modified urea kinetic model direct dialysis quantification and classic urea kinetic modeling. ASAIO J 1995;41: M798–M800 (B)

  304. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10–20 (C)

  305. Bostom AG, Shemin D, Lapane KL et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147–152 (B)

  306. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93–103 (B)

  307. Bostom AG, Shemin D, Lapane KL et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 1996; 125: 91–101 (B)

  308. Bostom AG, Shemin D, Nadeau MR et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 1995; 113: 129–132 (B)

  309. Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554– 2558 (B)

  310. Bostom AG, Shemin D, Yoburn D et al. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996; 120: 241–244 (B)

  311. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and postdilution haemofiltration in four different membranes. Blood Purif 1998; 16: 261–268 (B)

  312. Bouman CS, van Olden RW, Stoutenbeek CP. Cytokine filtration and adsorption during pre- and post-dilution hemofiltration in four different membranes. Blood Purif 1998; 16: 261–268 (B)

  313. Bourquelot P, Cussenot O, Cordy P, et al. Microsurgical creation and follow-up of arteriovenous fistulae for chronic haemodialysis in children. Pediatr Nephrol 1990;4:156-159.

  314. Bourquelot P, Raynaud F, Pirozzi N. Microsurgery in children for creation of arteriovenous fistulas in renal and non-renal diseases. Ther Apher Dial 2003;7:498-503.

  315. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. Aquantitative assessment of plasma omocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995; 274: 1049–1057 (B)

  316. Bousquet J, Maurice F, Rivory JP et al. Allergy in long-term hemodialysis. II. Allergic and atopic patterns of a population of patients undergoing long-term hemodialysis. J Allergy Clin Immunol 1988; 81: 605–610 (B)

  317. Bouts A, et al. Standard peritoneal permeability analysis in children. J Am Soc Nephrol 2000;11:943-950.

  318. Bown B: Encyclopedia of hebs and their uses . Dorling Kindersley 1995;.

  319. Boyer D: The American Zoo and Aquarium Association and the American Association of Poison Control Centers Antivenin Index . 1994; 16-7.

  320. Brady JP, Hasbargen JA: Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 31:35-40, 1998

  321. Braitberg G, et. al: Toxic Plant Ingestions . Wilderness Medicine 1995; pp. 862-889.

  322. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998; 98: 2520–2526 (B)

  323. Braun DK, Janssen DA, Marcus JR, Kauffman CA. Cryptococcal infection of a prosthetic dialysis fistula. Am J Kidney Dis 1994; 24: 864–867 (B)

  324. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394–401 (B)

  325. Bray SH, Tung RL, Jones ER: The magnitude of metabolic acidosis is dependent on differences in bicarbonate assays. Am J Kidney Dis 28:700-703, 1996

  326. Brem A, Lambert C, Hill C, et al. Clinical morbidity in pediatric dialysis patients: data from the Network 1 Clinical Indicator Project. Pediatr Nephrol 2001;16:854-857.

  327. Brent J, Kulig K: Mushrooms . In, Haddad's Clinical Management of Poisoning and Drug Overdose, 3rd ed. 1998; 365-374.

  328. Bressler R: The Unripe Akee-Forbidden Fruit. . NEJM 1976; 295: 500-501.

  329. Brewer E. Growth of small children managed with chronic peritoneal dialysis and nasogastric tube feedings: 203 months experience in 14 patients. Adv Perit Dial 1990;6:269-272.

  330. Brimacombe J: Use of calcium chloride for propranolol overdose. . Anaethesia 1992; 47: 907-908.

  331. Brimble KS, Rabbat ChG, Treleaven DJ, Ingram AJ.Utility of ultrasonographic venous assessment prior to forearm arteriovenous fistula creation. Clin Nephrol 2002; 58: 122–127

  332. Brittin GM, Brecher G, Johnson CA, Elashoff RM: Stability of blood in commonly used anticoagulants. Use of refrigerated blood for quality control of the Coulter Counter Model S. Am J Clin Pathol 52:690-694, 1969

  333. Brod J, Hornych A: Effect of correction of anemia on the glomerular filtration rate in chronic renal failure. Isr J Med Sci 3:53-59, 1967

  334. Brooks PM, Day RO: Nonsteroidal Antiinflammaroty drugs: Differences and similarities . N Engl J Med 1991; 324: 1716-1725.

  335. Brouhard B, Berger M, Cunningham R, et al. Home peritoneal dialysis in children. Trans Am Soc Artif Intern Organs 1979;25:90-94.

  336. Brouillard M, Reade R, Boulanger E et al. Erythrocyte sedimentation rate, an underestimated tool in chronic renal failure. Nephrol Dial Transplant 1996; 11: 2244–2247 (B)

  337. Brown C, Shepherd S: Marine trauma, evenomations and intoxications . Emerg Med Clin North Am 1992; 10: 385-408.

  338. Brown CH, Leverett LB, Lewis CW, Alfrey CP, Hellums JD. Morphological, biochemical, and functional changes in human platelets subjected to shear stress. J Lab Clin Med 1975; 86: 462–471 (B)

  339. Brownbridge G, Fielding D. Psychosocial adjustment and adherence to dialysis treatment regimes. Pediatr Nephrol 1994;8:744-749.

  340. Brownbridge G, Fielding D. Psychosocial adjustment to end-stage renal failure: comparing haemodialysis, continuous ambulatory peritoneal dialysis and transplantation. Pediatr Nephrol 1991;5:612-662.

  341. Browning RG, et al.: Cinical toxicity of ethylene glycol monoalkyl ethers . Hum Exp Toxicol 1994; 13(5): 325-335.

  342. Broyer M, Le Bihan C, Charbit M, et al. Long-term social outcome of children after kidney transplantation. Transplantation 2004;77:1033-1037.

  343. Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990; 8 [Suppl]: S47–S49 (B)

  344. Brunet P, Berland Y. Water quality and complications of haemodialysis. Nephrol Dial Transplant 2000; 15: 578–580 (C)

  345. Brunett J, Calton G: Jellyfish evenomations syndromes updated . Ann Emerg Med 1987; 16: 1000-1005.

  346. Brunzell JD, Albers JJ, Haas LB et al. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903–910 (B)

  347. Bryson P: Nonsteroidal Antiinflammatory Agents . Comprehensive Review in Toxicology 2nd ed: 445-454.

  348. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432–438 (B)

  349. Bucher HC, Guyatt GH, Cook DJ et al. Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771–778.

  350. Buckley NA, Whyte IM, Dawson AH: Pheniramine: A much abused drug . Med J Aust 1994; 160: 188-92.

  351. Bunchman T, Donckerwolcke R. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol 1994;8:96-102.

  352. Bunchman T, McBryde K, Mottes T, et al. Pediatric acute renal failure: outcome by modality and disease. Pediatr Nephrol 2001;16: 1067-1071.

  353. Buoncristiani U, Quintaliani G, Cozzari M, Giombini L, Ragaiolo M. Daily dialysis: long-term clinical metabolic results. Kidney Int Suppl 1988; 24: S137–S140 (B)

  354. Buoncristiani U. Fifteen years of clinical experience with daily haemodialysis. Nephrol Dial Transplant 1998; 13 [Suppl 6]: 148–151 (B)

  355. Burch JM, Agarwal R, et al: The treatment of crotalid envenomation without antivenin . J Trauma 1988; 28: 35-43.

  356. Burgelman M, Vanholder R, Fostier H, Ringoir S. Estimation of parameters in a two-pool urea kinetic model for haemodialysis. Med Engl Phys 1997; 19: 69–76 (B)

  357. Burgess E: Prolonged hemodialysis in methanol intoxication . Pharmacotherapy 1992; 12(3): 238-9.

  358. Burgess JL, Dart RC: Snake venom coagulopathy: Use and abuse of blood products in the treatment of pit viper envenomation . Ann Emerg Med 1991; 20: 795-801.

  359. Burkart J, Schreiber M, Korbet S, et al. Solute clearance approach to adequacy of peritoneal dialysis. Perit Dial Int 1996;16:457-470.

  360. Burke SK, Dillon MA, Hemken DE et al. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients. Adv Ren Replace Ther 2003; 10: 133–145.

  361. Burkhardt KK, Kulig KW: The other alcohols: Methanol, ethylene glycol, and isopropanol . Emerg Med Clinics of North Am 1990; 8(4): 913-28.

  362. Burkhart K: Methanol and ethylene glycol toxicity. J Toxicol Clin Toxicol 1997; 35(2): 149-150.

  363. Burks JS, Walker JE, Rumack BH: Tricyclic antidepressant poisoning. Reversal of coma, choreoathetosis, and myoclonus by physostigmine . JAMA 1974; 230: 1405-7.

  364. Busch EH, Ventura HO, Lavie CJ. Heparin-induced hyperkalemia. South Med J 1987; 80: 1450–1451 (B)

  365. Bush SP, Jansen PW: Severe rattlesnake envenomation with anaphylaxis and rhabdomyolysis . Ann Emerg Med 1995; 25: 845-8.

  366. Bush SP, Thomas TL, Chin ES: Envenomations in children . Pediatr Emerg Med Rep 1997; 2: 1-12.

  367. Bush SP, Thomas TL, Chin ES: Envenomations in children . Pediatric Emergency Medicine Reports 1997; 2: 1-12.

  368. Bush SP, Thomas TL, et al: Envenomations in children . Pediatr Emerg Med Rep 1997; 2: 1-12.

  369. Busvine JR: Disease transmission by insects . 1993; 11-74.

  370. Buturovic J, Ponikvar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: heparin versus citrate versus polygeline: a prospective randomized study. Artif Organs 1998; 22: 945–947

  371. Buturovic J, Zemva Z, Ponikvar R. Filling a dialysis circuit with albumin does not prevent platelet activation during hemodialysis: in vivo study. Artif Organs 1994; 18: 875–879 (B)

  372. Byrne CD. Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype? Atherosclerosis 1999; 145: 1–15 (B)

  373. Caggiula AW, Christakis G, Farrand M, Hulley SB, Johnson R, Lasser NL, Stamler J, Widdowson G: The multiple risk intervention trial (MRFIT). IV. Intervention on blood lipids. Prev Med 10:443-475, 1981

  374. Cameron AP, Drury PJ, Harston GA, Ineson PR. Aluminium and fluoride in the water supply and their removal for haemodialysis. Sci Total Environ 1988; 76: 19–28 (B)

  375. Campbell KM, Johnson CM. Identification of Staphylococcus aureus binding proteins on isolated porcine cardiac valve cells. J Lab Clin Med 1990; 115: 217–223 (B)

  376. Campistol JM, Bernard D, Papastoitsis G et al. Polymerization of normal and intact b2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis. Kidney Int 1996; 50: 1262–1267 (B)

  377. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996;7:198-207.

  378. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300:573-578, 1990

  379. Canadian Erythropoietin Study Group: Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Am J Nephrol 11:23-26, 1991

  380. Canaud B, Assounga A, Kerr P, Aznar R, Mion C. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 924–930 (B)

  381. Canaud B, Assounga A, Kerr P, Aznar R, Mion C. Failure of a daily haemofiltration programme using a highly permeable membrane to return b2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant 1992; 7: 924–930 (B)

  382. Canaud B, Bosc JY, Leray H, Morena M, Stec F. Microbiologic purity of dialysate: rationale and technical aspects. Blood Purif 2000; 18: 200–213 (C)

  383. Canaud B, Bosc JY, Leray H, Stec F. Microbiological purity of dialysate for on-line substitution fluid preparation. Nephrol Dial Transplant 2000; 15 [Suppl 2]: 21–30 (C)

  384. Canaud B, Desmeules S. Vascular access for hemodialysis. In: Ho. rl W, Koch KM, Lindsay RM, Ronco C, Winchester JF, eds. Replacement of Renal Function by Dialysis, 5th edn, Kluwer Academic Publishers, London: 2004; 9: 203–230

  385. Canaud BJ, Mion CM. Water treatment for contemporary haemodialysis. In: Jacobs C, Kjellstrand CM, Koch KM,Winchester JF, eds. Replacement of Renal Function by Dialysis. Kluwer Academic Publishers, Dordrecht, 1996; 231–255 (C)

  386. Canepa A, et al. Nutritional status in children receiving chronic peritoneal dialysis. Perit Dial Int 1996;16:S526-S531.

  387. Canivet E, Lavaud S, Wong T et al. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994; 23: 41–46 (B)

  388. Cano F, Azocar M, Delucchi M, et al. Nitrogen balance studies and Kt/V urea in children undergoing chronic peritoneal dialysis. Adv Perit Dial 2004;20:245-250.

  389. Cano N, Costanzo-Dufetel J, Calaf R et al. Prealbumin-retinolbinding-protein-retinol complex in hemodialysis patients. Am J Clin Nutr 1988; 47: 664–667 (B)

  390. Cantu P, Mangano S, Masini M et al. Prevalence of antibodies against hepatitis C virus in a dialysis unit. Nephron 1992; 61: 337–338 (B)

  391. Capdevila JA, Segarra A, Planes AM et al. Successful treatment of haemodialysis catheter-related sepsis without catheter removal. Nephrol Dial Transplant 1993; 8: 231–234 (B)

  392. Capelli JP, Kushner H, Camiscioli T, Chen SM, Stuccio-White NM. Factors affecting survival of haemodialysis patients utilizing urea kinetic modeling. A critical appraisal of shortening dialysis times. Am J Nephrol 1992; 12: 212–223 (B)

  393. Cappel R, Van Beers D, Liesnard C, Dratwa M. Impaired humoral and cell-mediated immune responses in dialyzed patients after influenza vaccination. Nephron 1983; 33: 21–25 (B)

  394. Cappelli G, Ballestri M, Perrone S, Ciuffreda A, Inguaggiato P, Albertazzi A. Biofilms invade nephrology: effects in haemodialysis.Blood Purif 2000; 18: 224–230 (B)

  395. Cappelli G, DiFelice A, Perrone S et al. Which level of cytokine production is critical in haemodialysis? Nephrol Dial Transplant 1998; 13 [Suppl 7]: 55–60 (C)

  396. Cappelli G, Tetta C, Cornia F et al. Removal of limulus reactivity and cytokine-inducing capacity from bicarbonate dialysis fluids by ultrafiltration. Nephrol Dial Transplant 1993; 8: 1133–1139 (B)

  397. Carney EW: An integrated perspective on the developmental toxicity of ethylene glycol . Reprod Toxicol 1994; 8(2): 99-113.

  398. Carracedo J, Ramirez R, Pintado O et al. Cell aggregation and apoptosis induced by hemodialysis membranes. J Am Soc Nephrol 1995; 6: 1586–1591 (B)

  399. Carroll RR, Hall EL, Kitchens CS: Canebrake rattlesnake envenomation . Ann Emerg Med 1997; 30: 45-8.

  400. Carrozza P, Gabutti L, Gilliet F, Marone C. Heparin-induced systemic inflammatory response syndrome with progressive skin necrosis in haemodialysis. Nephrol Dial Transplant 1997; 12: 2424–2427 (B)

  401. Carter J. Evaluation of recovery filters for use in bacterial retention testing of sterilizing-grade filters. PDA J Pharm SciTechnol 1996; 50: 147–153 (B)

  402. Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ. Heparin free dialysis: comparative data and results in high risk patients. Kidney Int 1987; 31: 1351–1355 (B)

  403. Caruana RJ, Smith MC, Clyne D, Crow JW, Zinn JM, Hall Diehl J. Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis. Blood Purif 1991; 9: 296–304 (B)

  404. Casati S, Graziani G, Ponticelli C. Hemodialysis without anticoagulants in patients with high bleeding risk. Int J Artif Organs 1982; 5: 233–236 (B)

  405. Casati S, Moia M, Graziani G et al. Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol 1984; 21: 102–105 (B)

  406. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood—France, United Kingdom, and United States, January 1988–August 1994. Morb Mortal Wkly Rep 1995; 44: 929–933 (B)

  407. Cases A, Reverter JC, Escolar G et al. In vivo evaluation of platelet activation by different cellulosic membranes. Artif Organs 1997; 21: 330–334 (B)

  408. Cases A, Reverter JC, Escolar G et al. Platelet activation on hemodialysis: influence of dialysis membranes. Kidney Int 1993; 43 [Suppl 41]: S217–S220 (B)

  409. Casino FG, Basile C, Gaudiano V, Lopez T. A modified algorithm of the single pool urea kinetic model. Nephrol Dial Transplant 1990; 5: 214–219 (B)

  410. Casino FG, Lopez T. The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant 1996; 11: 1574–1581 (B)

  411. Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis 1997; 30: S107–S117 (C)

  412. Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron 1996; 73: 421–424 (B)

  413. Centers for Disease Control and Prevention: Recommendations to prevent and control iron deficiency in the United States. MMWR Recomm Rep 47:1-29, 1998

  414. Centers for Disease Control: screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for Elimination of Tuberculosis. Morb Mort Wkly Rep 1995; 44: 19–30 (B)

  415. Centers for Medicare & Medicaid Services. Annual report, end stage renal disease clinical performance measures project. Baltimore, Maryland: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, 2005.

  416. Chadha V, Blowey D, Warady B. Is growth a valid outcome measure of dialysis clearance in children undergoing peritoneal dialysis? Perit Dial Int 2001;21:S179-S184.

  417. Chadha V, et al. What are the clinical correlates of adequate peritoneal dialysis? Pediatr Nephrol 2001;21:480-489.

  418. Chadha V, Jones L, Ramirez Z, et al. Chest wall peritoneal dialysis catheter placement in infants with a colostomy. Adv Perit Dial 2000;16:318-320.

  419. Champoux S, et al. Enhanced response to growth hormone in children on peritoneal dialysis. Perit Dial Int 2001;21:S86.

  420. Chan TM, Wu PC, Lau JY et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 1414–1419 (B)

  421. Chanard J, Bindi P, Lavaud S et al. Carpal tunnel syndrome and type of dialysis membrane. Br Med J 1989; 298: 867–868 (B)

  422. Chanard J, Caudwell V, Valeire J et al. Kinetics of 131-b2 microglobulin in hemodialysis patients: assessment using total body counting. Artif Organs 1998; 22: 574–580 (B)

  423. Chanard J, Caudwell V, Valeire J et al. Kinetics of 131I-beta2 microglobulin in haemodialysis patients: assessment using total body counting. Artif Organs 1998; 22: 574–580 (B)

  424. Chandran PKG, Liggett R, Kirkpatrick B. Patient survival on PANuAN69 membrane hemodialysis: a ten-year analysis. J Am Soc Nephrol 1993; 4: 1199–1204 (B)

  425. Chang PC, Schrander-van der Meer AM, van Dorp WT, van Leer E. Intracutaneous vs intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 1996; 11: 191–193 (A)

  426. Chang Т. М. S., Malave N. The development and first clinical use of semipermiable microcapsules as a coppact artificial kidney//Trans. Amer. Soc. Artif. Int. Or­gans. - 1970. - Vol.16. - P. 141-144.

  427. Chantrel F, Enache I, Bouiller M et al. Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 1999; 14: 129–136 (B) SECTION VII. Vascular disease and risk factors 101

  428. Chapel TA, Chapel J: Toxicodendron Dermatitis . Emergency Medicine - A Comprehensive Study Guide 1996; 4th Edition: 1111-1113.

  429. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 976–982 (A)

  430. Charra B, Calemard E, Chazot C et al. Dose of dialysis: what index? Blood Purif 1992; 10: 13–21 (B)

  431. Charra B, Calemard E, Ruffet M et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286–1291 (B)

  432. Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16: 35–44 (C)

  433. Charra B, Laurent G, Chazot C et al. Haemodialysis trends in time, 1989 to 1998, independent of dose and outcome. Am J Kidney Dis 1998; 32: S63–S70 (C)

  434. Charytan C, Levin N, Al-Saloum M, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001;37:300-307.

  435. Chavers B, Li S, Collins A, et al. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002;62:648-653.

  436. Chavers B, Roberts T, Herzog C, et al. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 2004;65:266-273.

  437. Chazot C, Shahmir E, Matias B, Laidlaw S, Kopple JD: Dialytic nutrition: Provision of amino acids in dialysate during hemodialysis. Kidney Int 52:1663-1670, 1997

  438. Cheesbrough JS, Finch RG, Burden RP. A prospective study of the mechanisms of infection associated with hemodialysis catheters. J Infect Dis 1986; 154: 579–589

  439. Chernow B, Zaloga GP, Willey SC: Glucagon's Chronotrophic Action is Calcium Dependent . J Pharm Exp Therap 1987; 241: 833-837.

  440. Chertow G, Burke S, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.

  441. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium3phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907–2914 (B)

  442. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66–71 (B)

  443. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56: 1872–1878 (B)

  444. Cheung AK, Agodoa LY, Daugirdas JT, Depner TA, Gotch FA, Greene T, Levin NW, Leypoldt JK: Effects of hemodialyzer reuse on clearances of urea and beta2-microglobulin. The Hemodialysis (HEMO) Study Group. J Am Soc Nephrol 10:117-127, 1999

  445. Cheung AK, Chenoweth DE, Otsuka D, Henderson LW. Compartmental distribution of complement activation products in artificial kidneys. Kidney Int 1986; 30: 74–80 (B)

  446. Cheung AK, Hohnolt M, Leypoldt JK, DeSpain M. Hemodialysis membrane biocompatibility: the case of erythropoietin. Blood Purif 1991; 9: 153–163 (B)

  447. Cheung AK, LeWinter M, Chenoweth DE, Lew WYW, Henderson LW. Cardiopulmonary effects of cuprophaneactivated plasma in swine. Kidney Int 1986; 29: 799–806 (B)

  448. Cheung AK, Parker CJ, Hohnolt M. b2 integrins are required for neutrophil degranulation induced by hemodialysis membranes. Kidney Int 1993; 43: 649–660 (B)

  449. Cheung AK, Parker CJ, Wilcox L, Janatova J. Activation of complement by hemodialysis membranes: polyacrylonitrile binds more C3a than cuprophan. Kidney Int 1990; 37: 1055–1059 (B)

  450. Cheung AK, Wu LL, Kablitz C, Leypoldt JK. Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 1993; 22: 271–276 (B)

  451. Cheung AK. Adsorption of unactivated complement proteins by hemodialysis membranes. Am J Kidney Dis 1989; 14: 472–477 (B)

  452. Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1: 150–161 (C)

  453. Cheung AK. Quantitation of dialysis. The importance of membrane and middle molecules. Blood Purif 1994;12: 42–53 (C)

  454. Cheung K, Urech R, Taylor L, et al: Plant cardiac glycosides and digoxin Fab antibody . J Paediatr Child Health 1991; 27: 312-313.

  455. Chia S, Karim M, Elwood RK, FitzGerald JM. Risk of tuberculosis in dialysis patients: a population-based study. Int J Tuberc Lung Dis 1998; 2: 989–991 (B)

  456. Chiang WC, Lin SL, Tsai TJ, Hsieh BS. High resistive index of the radial artery is related to early primary radiocephalic hemodialysis fistula failure. Clin Nephrol 2001; 56: 236–240

  457. Chinali M, de Simone G, Matteucci MC et al. Reduced systolic myocardial function in children with chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 593–598.

  458. Chollet-Martin S, Stamatakis G, Bailly S, Mery JP, Gougerot-Pocidalo MA. Induction of tumour necrosis factoralpha during haemodialysis. Influence of the membrane type. Clin Exp Immunol 1991; 83: 329–332 (B)

  459. Chong B, Castaldi P. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparinassociated thrombocytopenia. Aust N Z J Med 1986; 16: 715–716 (B)

  460. Choo QL, Weiner AJ, Overby LR et al. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46: 423–441 (C)

  461. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258–1262 (C)

  462. Chow MT, et al. Hemodialysis-induced hypophosphatemia in a normophosphate-mic patient dialyzed for ethylene glycol poisoning: treatment with phosphorus-enriched hemodialysis. Artif Organs 1998;22:905-907.

  463. Chow MT, et al. Treatment of acute methanol intoxication with hemodialysis using an ethanol-enriched, bicarbonate-based dialysate. Am J Kidney Dis 1997;30: 568-570.

  464. Church E: Lab testing in alcohol, methanol, ethylene glycol, isopropanol toxicities. J Emerg Med 1997; 15(5): 687-692.

  465. Churchill D, Thorpe K, Nolph K, et al. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998;9: 1285-1292.

  466. Churchill DN, Taylor DW, Cook RJ et al. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 19: 214–234 (B)

  467. Churchill DN, Taylor DW, Tomlinson CW et al. Effect of high-flux haemodialysis on cardiac structure and function among patients with end-stage renal failure. Nephron 1993; 65: 573–577 (A) 30 SECTION II. Haemodialysis adequacy.

  468. Churchill DN. Clinical impact of biocompatible dialysis membranes on patient morbidity and mortality: an appraisal of the evidence. Nephrol Dial Transplant 1995; 10 [Suppl 10]: 52–56 (A)

  469. Chyka PA. Multiple-dose activated charcoal and enhancement of systemic drug clearance: summary of studies in animals and human volunteers. J Toxicol Clin Toxicol 1995;33;399-405.

  470. Clark CJ, Campbell D, Reid WH: Blood carboxyhaemoglobin and cyanide levels in fire survivors . Lancet 1981; 1: 1332-1335.

  471. Clark RF, Harchelroad F: Toxicology screening of the trauma patient: A changing profile . Ann Emerg Med 1991; 20(2): 151-3.

  472. Clark RF, Selden BS, Furbee B: The incidence of wound infection following crotalid envenomation . J Emerg Med 1993; 11: 583-6.

  473. Clark RF, Vance MV: Massive diphenhydramine poisoning resulting in a wide-complex tachycardia: Successful treatment with sodium bicarbonate . Ann Emerg Med 1992; 21: 318-21.

  474. Clark TW, Hirsch DA, Jindal KJ, Veugelers PJ, LeBlanc J. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas. J Vasc Interv Radiol 2002; 13: 51–59

  475. Clark WR, Hamburger RJ, Lysaght MJ. Effect of membrane composition and structure on solute removal and biocompatibility in haemodialysis. Kidney Int 1999; 56: 2005–2015 (C)

  476. Clark WR, Leypoldt JK, Henderson LW et al. Quantifying the effect of changes in the haemodialysis prescription on effective solute removal with a mathematical model. J Am Soc Nephrol 1999; 10: 601–609 (B)

  477. Clemmesen C, Nilsson E. Therapeutic trends in the treatment of barbiturate poi­soning. The Scandinavian method//Clin. Pharmacol. Ther. — 1961. — Vol. 2. №2. — P. 223-235.

  478. Clermont G, Lecour S, Lahet J et al. Alteration in plasma antioxidant capacities in chronic renal failure and hemodialysis patients: a possible explanation for the increased cardiovascular risk in these patients. Cardiovasc Res 2000; 47: 618–623 (B)

  479. Clilton WS: The Chemistry and Mode of Action of Mushroom Toxins . Handbook of Mushroom Poisoning 1994; 2nd Edition: 165-223.

  480. Clyne N, Jogestrand T, Lins LE, Pehrsson SK: Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity. Nephron 67:322-326, 1994

  481. Clyne N, Jogestrand T: Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 60:390-396, 1992

  482. Clyne N, Lins LE, Egberg N. Long-term effects of erythropoietin treatment on the coagulation system during standardized hemodialysis. Clin Nephrol 1995; 43: 260–267 (B)

  483. Coban E, Timuragaoglu A, Meric M: Iron deficiency anemia in the elderly: Prevalence and endoscopic evaluation of the gastrointestinal tract in outpatients. Acta Haematol 110:25-28, 2003

  484. Cocco P, Hua F, Boffetta P: Mortality of Italian lead smelter workers . Scand J Work Environ Health 1997; 23: 15-23.

  485. Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH ‘7-84’ in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348–354.

  486. Cohen G, Haag-Weber M, Mai B, Deicher R, Horl WH. Effect of immunoglobulin light chains from haemodialysis and continuous ambulatory peritoneal dialysis patients on polymorphonuclear leukocyte functions. J Am Soc Nephrol 1995; 6: 1592–1599 (A)

  487. Cohen G, Rudnicki M, Horl WH. Isolation of modified ubiquitin as a neutrophil chemotaxis inhibitor from uraemic patients. J Am Soc Nephrol 1998;9: 451–456 (B)

  488. Coleman J, et al. The optimal route for nutritional support of children with chronic renal failure. Perit Dial Int 1996;16:S517-S520.

  489. Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. ASAIO Trans 1990; 36: M219–M223 (B)

  490. Collins A, Ilstrup K, Hanson G, Berkseth R, Keshaviah P. Rapid high-efficiency haemodialysis. Artif Organs 1986; 10: 185–188 (B)

  491. Collins AJ, Brenner RM, Ofman JJ, et al: Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 46:481-488, 2005

  492. Collins AJ, Kjellstrand CM. Shortening of the haemodialysis procedure and mortality in ‘healthy’ dialysis patients. ASAIO Trans 1990; 36: M145–M148 (B)

  493. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of haemodialysis patient survival. Am J Kidney Dis 1994; 23: 272–282 (B)

  494. Combe C, Pourtein M, de Pre´cigout V et al. Granulocyte activation and adhesion molecules during hemodialysis with cuprophane and a high-flux biocompatible membrane. Am J Kidney Dis 1994; 24: 437–442 (B)

  495. Conley S, Rose G, Robson A, et al. Effects of dietary intake and hemodialysis on protein turnover in uremic children. Kidney Int 1980;17:837-846.

  496. Conly JM, Grieves K, Peters B. A prospective, randomized study comparing transparent and dry gauze dressings for central venous catheters. J Infect Dis 1989;

  497. Connal TP, Wilson SE. Vascular access for hemodialysis. In: Tutherford RB, ed. Vascular Surgery, 4th edn. WB Saunders, Philadelphia, 1994; 1233 (C)

  498. Conner DA, Seldon BS: Scorpion Envenomation . Auerbach PS (ed) Wilderness Medicine: Management of Wilderness and Enviromental 1995; 3: 831-842.

  499. Consroe P, Egan NB, et al: Comparison of a new ovine antigen binding fragment (Fab) antivenin for United States Crotalidae with the commercial antivenin for protection against venom-induced lethality in mice . Am J Trop Med Hyg 1995; 53: 507-10.

  500. Control measures for hepatitis B in dialysis centers. Viral hepatitis investigations and control series. Atlanta Centers for Disease Control and Prevention, 1977 (C)

  501. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest ServiceuBritish Medical Research Council. Am Rev Respir Dis 1991; 143: 700–706 (B)

  502. Converse RJ, Jacobsen T, Toto R, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;327:1912-1918.

  503. Cook JW, Schuman ES, Standage BA, Hein P. Patency and flow characteristics using stapled vascular anastomoses in dialysis grafts. Am J Surg 2001; 181: 24–27

  504. Coppo R, Amore A, Cirina P et al. Bradykinin and nitric oxide generation by dialysis membranes can be blunted by alkaline rinsing solutions. Kidney Int 2000; 58: 881–888 (B)

  505. Coresh J, Longenecker JC, Miller ER III: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-S30, 1998 (suppl)

  506. Corti MC, Guralnik JM, Salive ME et al. Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. Ann Intern Med 1997; 126: 753–760 (B)

  507. Cosio FG, Giebink GS, Le CT, Schiffman G. Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients. Kidney Int 1981; 20: 254–258 (B)

  508. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med 1997; 127: 380–387.

  509. Counts S, Hickman R, Garbaccio A, et al. Chronic home peritoneal dialysis in children. Trans Am Soc Artif Intern Organs 1973;19:157-163.

  510. Court H, Colans GN: Poisoning after overdose with nonsteroidal anti-inflammatory drugs . Adverse Drug React Acute Poisoning Rev 1984; 3: 1-21.

  511. Coyne D, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodilaysis patients with high serum ferritin and low transferrin saturation: results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol 2007;18:975-984.

  512. Coyne DW, Delmez J, Spence G, Windus DW. Impaired delivery of haemodialysis prescriptions: an analysis of causes and an approach to evaluation. J Am Soc Nephrol 1997; 8: 1315–1318 (B)

  513. Craddock PR, Fehr J, Dalmasso AP, Brigham KL, Jacob HS. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977; 59: 879–888 (B)

  514. Cresanta JL, Croft JB, Webber LS, Nicklas TA, Berenson GS: Racial difference in hemoglobin concentration of young adults. Prev Med 16:659-669, 1987

  515. Cressman MD, Heyka RJ, Paganini EP et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992; 86: 475–482 (B)

  516. Cristol JP, Cabaud B, Damon M et al. Platelet-activating factor production during hemodialysis: effect of BN 52021. Prostaglandins Leukot Essent Fatty Acids 1992; 45: 37–42 (B)

  517. Crocker JF, Blecher SR, Safe SH. Chemically induced polycystic kidney disease. Prog Clin Biol Res 1983; 140: 281–296 (B)

  518. Crosnier J. Hepatitis B in haemodialysis: vaccination against HBS antigen. Proc Eur Dial Transplant Assoc 1981; 18: 231–240 (B)

  519. Culleton BF, Wilson PWF: Thrombogenic risk factors for cardiovascular disease in dialysis patients. Semin Dialysis 12:117-125, 1999

  520. Curry SC, et al: Envenomation by the scorpion Centruroides Sculpturatus . Journal Toxicology Clinical Toxicology 1984; 4 & 5: 417-49.

  521. D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31–38.

  522. D’Agata EM, Mount DB, Thayer V, Schaffner W. Hospitalacquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000; 35: 1083–1088 (B)

  523. D’Elia JA, Weinrauch LA, Gleason RE, DeSilva RA, Nesto RW. Preliminary screening of the relationship of serum lipids to survival of chronic dialysis patients. Ren Fail 1993; 15: 203–209 (B)

  524. D’Haese PC, De Broe ME. Adequacy of dialysis: trace elements in dialysis fluids. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 92–97 (B)

  525. D’Haese PC, Shaheen FA, Huraib SO et al. Increased silicon levels in dialysis patients due to high silicon content in the drinking water, inadequate water treatment procedures, and concentrate contamination: a multicentre study. Nephrol Dial Transplant 1995; 10: 1838–1844 (B)

  526. D’Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63(Suppl 85): S73–78.

  527. Daerr WH, Windler ET, Greten H. Peroxidative modification of very-low-density lipoproteins in chronic hemodialysis patients. Nephron 1993; 63: 230–231 (B)

  528. Dalman RL, Harris Jr, EJ, Victor BJ, Coogan SM. Transition to all-autogenous hemodialysis access: the role of preoperative vein mapping. Ann Vasc Surg 2002; 16: 624–630

  529. Danesh FR, Klinkmann J, Yokoo H, Ivanovich P. Fatal cervical spondylarthropathy in a hemodialysis patient with systemic deposition of b2-microglobulin amyloid. Am J Kidney Dis 1999; 33: 563–566 (B)

  530. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082–1085 (A)

  531. Danesh J, Whincup P, WalkerMet al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 2000; 321: 199–204 (A) 314. Pankow JS, Folsom AR, Cushman M et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681–689 (B)

  532. Dart RC, Seifert SA, et al: Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning . Ann Emerg Med 1997; 30: 33-9.

  533. Daschner M, Gfrorer S, Zachariou Z, et al. Laparoscopic tenckhoff cathter implantation in children. Perit Dial Int 2002;22:22-26.

  534. Daugirdas JT, Depner TA, Gotch FA et al. Comparison of methods to predict equilibrated KtV in the HEMO Pilot Study. Kidney Int 1997; 52: 1395–1405 (B)

  535. Daugirdas JT, Potempa LD, Dinh N et al. Plate, coil, and hollow-fiber cuprammonium cellulose dialyzers: discrepancy between incidence of anaphylactic reactions and degree of complement activation. Artif Organs 1987; 11: 140–143 (B)

  536. Daugirdas JT, Schneditz D, Leehey DJ. Effect of access recirculation on the modeled urea distribution volume. Am J Kidney Dis 1996; 27: 512–518 (B)

  537. Daugirdas JT, Schneditz D. Overestimation of haemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis. ASAIO J 1995; 41: M719–M724 (B)

  538. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume KtV: an analysis of error. J Am Soc Nephrol 1993; 4: 1205–1213 (B)

  539. Davey P. Eradication of nasal carriage of Staphylococcus aureus—is it cost-effective? J Hosp Infect 1998; 40 [Suppl B]: S31–S37 (C)

  540. Davidson TM, Eisner J: United States coral snakes . Wilderness Environ Med 1996; 1: 38-45.

  541. Davis CL: Insects, allergy and disease: Allergic and toxic responses to arthropods . 1979; 300-309.

  542. Davis DP, et al.: Ethylene glycol poisoning: Case report of a record-high and a review . J Emerg Med 1997; 15(5): 653-667.

  543. Davis GL. Interferon treatment of viral hepatitis in immunocompromised patients. Semin Liver Dis 1989; 9: 267–272 (B)

  544. Davis-Lewi N: Disease and development: Ciguatera fish poisoning . Soc Sci Med 1986; 23: 983-993.

  545. Dawson JK, Earnshaw SM, Graham CS: Dangerous monoamine oxidase inhibitor interactions are still occuring in the 1990s . J Accid Emerg Med 1995; 12: 49-51.

  546. De Backer WA, Verpooten GA, Borgonjon DJ et al. Hypoxemia during hemodialysis: effects of different membranes and dialysate compositions. Kidney Int 1983; 23: 738–743 (B)

  547. de Boer A, van Schaijk T, Willems H, et al. The necessity of adjusting dialysate volume to body surface area in pediatric peritoneal equilibration tests. Perit Dial Int 1997;17:199-202.

  548. de Boer IH, Rue TC, Kestenbaum B. Serum phosphorus concentrations in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2009; 53: 399–407.

  549. De Deyn PP, Macdonald RL. Guanidino compounds that are increased in cerebrospinal fluid and brain of uraemic patients inhibit GABA and glycine responses on mouse neurons in cell culture. Ann Neurol 1990; 28: 627–633 (B)

  550. de Graaf J, Hak-Lemmers HL, Hectors MP et al. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298–306 (B)

  551. de Klerk G, Wilmink JM, Rosengarten PC, Vet RJ, Goudsmit R: Serum erythropoietin (ESF) titers in anemia of chronic renal failure. J Lab Clin Med 100:720-734, 1982

  552. de Lamballerie X, Olmer M, Bouchouareb D, Zandotti C, De Micco P. Nosocomial transmission of hepatitis C virus in haemodialysis patients. J Med Virol 1996; 49: 296–302 (B)

  553. De Oreo P, Hamburger R. Urea reduction ratio is not a consistent predictor of KtV. J Am Soc Nephrol 1995; 6: 597 (B)

  554. De Palo T, Giordano M, Palumbo F, et al. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 2004;19:337-340.

  555. de Precigout V, Higueret D, Larroumet N et al. Improvement in lipid profiles and triglyceride removal in patients on polyamide membrane hemodialysis. Blood Purif 1996; 14: 170–176 (B)

  556. de Sousa M. Immune cell functions in iron overload. Clin Exp Immunol 1989; 75: 1–6 (C)

  557. De Wachter DS, Verdonck PR, Verhoeven RF, Hombrouckx RO. Red cell injury assessed in a numeric model of a peripheral dialysis needle. ASAIO J 1996; 42: M524–M529 (B) 44

  558. Decker WJ, Corby DG, Hilburn RE: Adsorption of solvents by activated charcoal, polymers, and mineral. vet Hum Toxicol 1981; 23 (suppl.1): 44-46.

  559. Degiannis D, Czarnecki M, Donati D et al. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with ‘high-flux’ polysulfone membranes. Am J Nephrol 1990; 10: 276–282 (B)

  560. Degos F, Jungers P. Viral Infections in Dialysis Patients. Part B: Dialysis Associated Hepatitis. Replacement of Renal Function by Dialysis. J. F. Winchester Kluwer Academic Publishers, Dordrecht, 1996; 1133–1158 (C)

  561. Degoulet P, Legrain M, Reach I et al. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 1982; 31: 103–110 (B)

  562. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 2000; 35: 852–862 (B)

  563. del Cura J, Gil PA, Borque L et al. Lipoprotein (a) in chronic renal failure patients undergoing hemodialysis: does it have an independent role in the development of further cardiovascular complications? Nephron 1993; 65: 644– 645 (B)

  564. Delmez J, Tindira C, Grooms P, et al. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest 1989;83:1349-1355.

  565. Delmez JA, Windus DW. Impaired delivery of dialysis: diagnosis and correction. Am J Nephrol 1996; 16: 29–34 (C)

  566. Depner T, Beck G, Daugirdas J, Kusek J, Eknoyan G. Lessons from the Haemodialysis (HEMO) Study: an improved measure of the actual haemodialysis dose. Am J Kidney Dis 1999; 33: 142–149 (B)

  567. Depner TA, Cheer A. Modeling urea kinetics with two vs. three BUN measurements. A critical comparison. ASAIO Trans 1989; 35: 499–502 (B)

  568. Depner TA, Keshaviah PR, Ebben JP et al. Multicenter clinical validation of an on-line monitor of dialysis adequacy. J Am Soc Nephrol 1996; 7: 464–471 (A)

  569. Deppisch R, Schmitt V, Bommer J et al. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990; 37: 696–706 (B)

  570. Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure. Nephron 1982; 31: 51–54 (B)

  571. Descamps-Latscha B, Goldfarb B, Nguyen AT et al. Establishing the relationship between complement activation and stimulation of phagocyte oxidative metabolism in hemodialyzed patients: a randomized prospective study. Nephron 1991; 59: 279–285 (A)

  572. Descamps-Latscha B, Herbelin A, Nguyen AT et al. Immune system dysregulation in uremia. Semin Nephrol 1994; 14: 253–260 (C)

  573. DeSoi CA, Umans JG. Phosphate kinetics during high-flux hemodialysis. J Am Soc Nephrol 1993; 4: 1214–1218 (B)

  574. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496–500 (B)

  575. Dewitz TS, MacIntire LV, Martin RR. Alteration of human leukocyte chemotaxis, chemiluminescence, and HMP shunt activity caused by mechanical trauma. Artif Organs 1980; 4: 311–317 (B)

  576. Dhondt A, Vanholder R, Glorieux G et al. Vitamin E-bonded cellulose membrane and hemodialysis bioincompatibility: absence of an acute benefit on expression of leukocyte surface molecules. Am J Kidney Dis 2000; 36: 1140–1146 (B)

  577. Dhondt AW, Vanholder RC, Waterloos MAF, Glorieux GL, Ringoir SMG. Leukocyte CD14 and CD45 expression during hemodialysis: polysulfone versus cuprophane. Nephron 1996; 74: 342–348 (B)

  578. Di Filippo S, Andrulli S, Manzoni C, Corti M, Locatelli F. On-line assessment of delivered dialysis dose. Kidney Int 1998; 54: 263–267 (B)

  579. Dickstein ES, Kunkel FW: Foxglove Tea Poisoning . Am J Med 1980; 69: 167-169.

  580. Dienstag JL, Perillo RP, Schiff ER. Bartholomew M, Vicary C, Rubin M. A preliminary trial of Lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 33: 1657–1661 (A)

  581. Dieplinger H, Lackner C, Kronenberg F et al. Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 1993; 91: 397–401 (B)

  582. Dimitrakov D, Kumchev E, Tllkian E: Study of the effect of recombinant erythropoietin on renal anaemia in predialysis patients with chronic renal failure. Folia Med (Plovdiv) 36:31-36, 1994

  583. Dinarello CA. Interleukin-1 and interleukin-1 receptor antagonist production during haemodialysis: which cytokine is a surrogate marker for dialysis-related complications? Nephrol Dial Transplant 1995; 10 [Suppl 3]: 25–28 (C)

  584. Dinarello CA. Interleukin-1 and tumor necrosis factor and their naturally occurring antagonists during haemodialysis. Kidney Int Suppl 1992; 38: S68–S77 (B)

  585. DiPaola RS, Zhang H, Lambert GH, et al: Clinical and biologic activity of an estrogenic herbal combination (PC-SPEC) in prostate cancer . N Eng J Med 1998; 339: 785-791.

  586. Diphteria, Tetanos and pertussis: recommendations for vaccines use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morb Mortal Wkly Rep 1991; 40 (RR-10): 1–28 (B)

  587. Dobkin JF, Miller MH, Steigbigel NH. Septicemia in patients on chronic hemodialysis. Ann Intern Med 1978; 88: 28–33 (B)

  588. Docci D, Bilancioni R, Pistocchi E et al. Evolution of serum pre-albumin following hemodialysis: effect of different dialysis membranes. Nephron 1992; 62: 145–149 (B)

  589. Docci D, Manzoni G, Baldrati L et al. Serum lipoprotein(a) as an independent cardiovascular risk factor for patients undergoing chronic hemodialysis. Nephron 1995; 69: 195 (B)

  590. Docci D, Manzoni G, Bilancioni R et al. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs 1994; 17: 41–45 (B)

  591. Dodd NJ, Gordge MP, Tarrant J, Parsons V, Weston MJ. A demonstration of neutrophil accumulation in the pulmonary vasculature during haemodialysis. Proc Eur Dial Transplant Assoc 1983; 20: 186–189 (B)

  592. Doelman C, Duijm LEM, Liem YS et al. Stenosis detection in failing hemodialysis access fistulas and grafts: Comparison of color Doppler ultrasonography, contrast-enhanced magnetic resonance angiography, and digital subtraction angiography. J Vasc Surg 2005; 42: 739–746

  593. Dolovich J, Evans S, Baurmeister U et al. Antibody responses to hemodialysis-related antigens in chronic hemodialysis patients. Artif Organs 1987; 11: 93–96 (B)

  594. Dolovich J, Marshall CP, Smith EKM et al. Allergy to ethylene oxide in chronic hemodialysis patients. Artif Organs 1984; 8: 334–337 (B)

  595. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181–188 (A)

  596. Dombros N et al. European Best Practice Guidelines for Peritoneal Dialysis. Nephrol Dial Transplant 2005;20 [Suppl 9]:1-36.

  597. Domino L, Domino S, Stockstill M: Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose . British Journal of Clinical Pharmacology 1986; 21: 71-74.

  598. Donaldson LJ, Cavanagh J, Rankin J: The dancing plague: a public health conundrum. . Public Health 1997; 111(4): 201-204.

  599. Donati D, Degiannis D, Combates N, Raskova J, Raska K. Effects of hemodialysis on activation of lymphocytes: analysis by an in vitro dialysis model. J Am Soc Nephrol 1992; 2: 1490–1497 (B)

  600. Donati D, Degiannis D, Homer L, Raska K, Raskova J. Production and kinetics of interleukin-1 in hemodialysis. Am J Nephrol 1991; 11: 451–458 (B)

  601. Done AK, Temple AR. Treatment of salicylate poisoning. Mod Treat 1971;8:528—551.

  602. Donnelly SM, Ali MA, Churchill DN. Effect of n-3 fatty acids from fish oil on hemostasis, blood pressure, and lipid profile of dialysis patients. J Am Soc Nephrol 1992; 2: 1634–1639 (B)

  603. Dorval M, et al. The use of an ethanol- and phosphate-enriched dialysate to main­tain stable serum ethanol levels during haemodialysis for methanol intoxication. NephrolDial Transplant 1999;14:1774-1775.

  604. Dou L, Brunet P, Dignat-George F, Sampol J, Berland Y: Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin. Am J Kidney Dis 31:67-73, 1998

  605. Dou P, Brunet P, Dignat-George F, Sampol J, Berland Y. Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin. Am J Kidney Dis 1998; 31: 67–73 (B)

  606. Doyon S, Roberts JR: The Use of Glucagon in a Case of Calcium Channel Blocker Overdose . Ann Emerg Med 1993; 22: 1229-1233.

  607. Drachman R, et al. Protein losses during peritoneal dialysis in children. In: Fine R, et al., eds. CAPD in children. New York: Springer-Verlag New York, 1985:78-83.

  608. Drake ME Jr: Conversion hysteria and dominant hemisphere lesions. Psychosomatics 524 -529.

  609. Driggers DA, Solbrig K, Steiner JF, et al: Acute oleander poisoning . West J Med 1989; 151: 660-662.

  610. Drueke T, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.

  611. Drueke TB. Beta2-microglobulin and amyloidosis. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 17–24 (C) 91. Port FK, VanDeKerkhove KM, Kunkel SL, Kluger MJ.The role of dialysate in the stimulation of interleukin-1 production during clinical haemodialysis. Am J Kidney Dis 1987; 10: 118–122 (B)

  612. Drueke TB. Renal osteodystrophy: management of hyperphosphataemia. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 32–33 (C)

  613. Drug Information: Nonsteroidal anti-inflammatory agents . American Hospital Formulary service 1988; 993-1048.

  614. Duarte R, Huraib S, Said R et al. Interferon alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis 1995; 25: 40–45 (B)

  615. Dubose jr TD, Molony DA: Nephrotoxicity of Non-steroidal anti-inflammatory drug . Lancet 1994; 344: 515-518.

  616. Dudley C, Johnson RJ, Thomas K, Thomas H, Bakran A, Ansell D. Joint Analyses with UK Transplant in England and Wales UK Renal Registry Report 2005; 5: 69-85

  617. Duijm LE, Liem YS, van der Rijt RH et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. Am J Kidney Dis 2006; 48: 98–105

  618. Dula DJ, DeNaples L: Emergency department presentation of patients with conversion disorder. Academic Emergency Medicine 1995; 2(2): 120-123.

  619. Dumler F, Falla P, Butler R, Wagner C, Francisco K: Impact of dialysis modality and acidosis on nutritional status. ASAIO J 45:413-417, 1999

  620. Dumler F, Galan M: Impact of acidosis on nutritional status in chronic peritoneal dialysis patients. Adv Perit Dial 12:307-310, 1996

  621. Dumler F, Stalla K, Mohini R, Zasuwa G, Levin NW. Clinical experience with short-time haemodialysis. Am J Kidney Dis 1992; 19: 49–56 (B)

  622. Dunn J. Algae kills dialysis patients in Brazil. Br Med J 1996;312: 1183–1184 (B)

  623. duSouich P, Caille G, Larochelle P: Enhancement of nadolol elimination by activated charcoal and antibiotics . Clin Pharmacol Ther 1983; 33: 585-590.

  624. Duval F, Frommherz K, Atger V, Drueke T, Lacour B. Influence of end-stage renal failure on concentrations of free apolipoprotein A-1 in serum. Clin Chem 1989; 35: 963–966 (B)

  625. Dwyer JT, Cunniff PJ, Maroni BJ, Kopple JD, Burrowes JD, Powers SN, Cockram DB, Chumlea WC, Kusek JW, Makoff R, Goldstein DJ, Paranandi L: The hemodialysis pilot study: Nutrition program and participant characteristics at baseline. The HEMO Study Group. J Ren Nutr 8:11-20, 1998

  626. Eastham E, Kirplani H, Francis D, et al. Pediatric continuous ambulatory peritoneal dialysis. Arch Dis Child 1982;57:677-680.

  627. Ebben JP, Hirsch DN, Luehmann DA, Collins AJ,Keshaviah PR. Microbiologic contamination of liquid bicarbonate concentrate for haemodialysis. ASAIO Trans 1987; 33: 269–273 (B)

  628. Eckardt KU: The CREATE trial—Building the evidence. Nephrol Dial Transplant 16:S16-S18, 2001 (suppl 2)

  629. Edefonti A, Paglialonga F, Picca M, et al. A prospective multicentre study of the nutritional status in children on chronic peritoneal dialysis. Nephrol Dial Transplant 2006;21:1946-1951.

  630. Edes TE, Sunderrajan EV. Heparin-induced hyperkalemia. Arch Intern Med 1985; 145: 1070–1072 (B)

  631. Edes TE. Heparin-induced hyperkalemia. Postgrad Med 1990; 87: 104–106 (B)

  632. Edwards L, Lynch PJ: Anaphylactic reaction to kissing bug bites . Arizona Medicine 1984; XLI: 159-161.

  633. Egfjord M, Rosenlund L, Hedegaard B et al. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis. Artif Organs 1998; 22: 633–637 (B)

  634. Ehlerding G, Schaeffer J, Drommer W et al. Alterations of synovial tissue and their potential role in the deposition of b2-microglobulin-associated amyloid. Nephrol Dial Transplant 1998; 13: 1465–1475 (B)

  635. Eickhoff TC, Sherman IL, Serfling OE. Observations on excess mortality associated with epidemic influenza. J Am Med Assoc 1961; 176: 104–110 (B)

  636. Eifinger F, Wahn F, Querfeld U et al. Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 2000; 15: 1892–1894 (B)

  637. Eknoyan G, Lameire N, Barsoum R et al. The burden of kidney disease:improving global outcomes. Kidney Int 2004; 66: 1310–1314.

  638. El Mallah S. Staged basilic vein transposition for dialysis angioaccess. Int Angiol 1998; 17: 65–68

  639. El-Achkar TM, Ohmit SE, McCullough PA, et al: Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 67:1483-1488, 2005

  640. Elisaf MS, Bairaktari H, Germanos N et al. Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients. Int Angiol 1996; 15: 252–256 (B)

  641. Elisaf MS, Germanos NP, Bairaktari HT et al. Effects of conventional vs. low-molecular-weight heparin on lipid profile in hemodialysis patients. Am J Nephrol 1997; 17: 153–157 (A)

  642. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993; 64: 169–181 (B)

  643. Ellenhorn MJ, Barceloux DG: Medical Toxicology: Diagnosis and Treatment of Human Poisoning . 1988; 440-461.

  644. Ellenhorn MJ: Disulfiram . Ellenhorn’s Medical Toxicology 1997; 2: 1356-1362.

  645. Ellenhorn: Ellenhorn's medical toxicology . 1997; 2nd Edition: 1532-1613.

  646. Ellenhorn: Nonsteroidal antiinflammatory drugs . Mecidal Toxicology 1997; 2nd ed: 196-206.

  647. Elseviers MM, Van Waeleghem JP. European Dialysis and Transplant Nurses Association/European Renal Care Association. Identifying vascular access complications among ESRD patients in Europe. A prospective, multicenter study. Nephrol News Issues 2003; 17: 61–64, 66–68, 99.

  648. Ena J, Boelaert JR, Boyken LD et al. Epidemiology of Staphylococcus aureus infections in patients on hemodialysis. Infect Control Hosp Epidemiol 1994; 15: 78–81 (B)

  649. Endres DB, Villanueva R, Sharp Jr CF et al. Measurement of parathyroid hormone. Endocrinol metab clin North Am 1989; 18: 611–629.

  650. Epstein WL, Epstein JH: Emergency treatment of Plant-Induced Dermatitis . Management of Wilderness and Environmental Emergencies 1989; 2nd Edition: 617-635.

  651. Epstein WL, Epstein JH: Plant induced dermatitis . Wilderness Medicine 1995; 3rd edition: 843-861.

  652. Erich JL, Shih RD, O'Connor RE: "Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity. . J Emerg Med 1995; 13: 653-5.

  653. Ericsson CG, Hamsten A, Nilsson J et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849–853 (A)

  654. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956–963 (B)

  655. Ernst E: Harmless herbs? a review of the recent literature . Am J Med 1998; 104: 170-178.

  656. Erslev AJ, Besarab A: The rate and control of baseline red cell production in hematologically stable patients with uremia. J Lab Clin Med 126:283-286, 1995

  657. Eschbach J, Korn D, Finch C. 14C cyanate as a tag for red cell survival in normal and uremic man. J Lab Clin Med 1977;89:823-828.

  658. Eschbach J. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-148.

  659. Eschbach JW Jr, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276:653-658, 1967

  660. Eschbach JW, Adamson JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5, 1985

  661. Esperanca M, et al. Peritoneal dialysis efficiency in relation to body weight. J Pediatr Surg 1966;1:162-169.

  662. Etzel JV: Diphenhydramine-induced acute dystonia . Pharmacotherapy 1994; 14: 492-6.

  663. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal

  664. European Best Practice Guidelines for the management in patients with chronic renal failure. Target haemoglobin concentration for the treatment of anaemia of chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 15]: 11–13 (C)

  665. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Administration of supplemental iron. Nephrol Dial Transplant 1999; 14 [Suppl 5]: S17–S18 (C)

  666. Evans J, Smye S, Brocklebank J. Mathematical modeling of haemodialysis in children. Pediatr Nephrol 1992;6:349-353.

  667. Evans JH, Smye SW, Brocklebank JT. Mathematical modelling of haemodialysis in children. Pediatr Nephrol 1992; 6: 349–353 (B)

  668. Evans JR, Forland SC, Cutler RE. The effect of renal function on the pharmacokinetics of gemfibrozil. J Clin Pharmacol 1987; 27: 994–1000 (B)

  669. Evans RW, Shaten BJ, Hempel JD, Cutler JA, Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947–1953 (B)

  670. Excerpts from USRDS 1999 annual data report. Causes of death. Am J Kidney Dis 1999; 34 [Suppl 1]: S87–S94 (B)

  671. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486–2497 (C)

  672. Fabre J, Fox HM, Dayer P, Balant L. Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents. Clin Pharmacokinet 1980; 5: 441–464 (B)

  673. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal vs intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997; 12: 1204–1211 (A)

  674. Fahy P, Arnold P, Curry SC: Serial serum drug concentrations and prolonged anticholinergic toxicity after benztropine (Cogentin) overdose . Am J Emerg Med 1989; 7: 199-202.

  675. Falkenhagen D, Brown GS, Thomaneck U et al. Behaviour of white blood cells and the complement system. Nephrol Dial Transplant 1993; 8 [Suppl 2]: 8–14 (A)

  676. Farci P, Alter HJ, Wong D et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104 (B)

  677. Farese RV, Biglieri EG, Shackleton CHL, et al: Licorice-induced hypermineralocorticoidism . N Eng J Med 1991; 325(17): 1223-1227.

  678. Farias MA, McClellan W, Soucie JM, Mitch WE. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis 1994; 23: 382–388 (B)

  679. Farrell PC, Ward RA, Schindhelm K, Gotch F. Precise anticoagulation for routine hemodialysis. J Lab Clin Med 1978; 92: 164–176 (B)

  680. Favero MS. Recommended precautions for patients undergoing hemodialysis who have AIDS or non-A, non-B hepatitis. Infect Control 1985; 6: 301–305 (C)

  681. FDA: Pufferfish poisoning. U.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodb 1992; Website: http://vm.cfsan.fda.gov/~mow/chap39.html:.

  682. Feber J, Scharer K, Schaefer F, et al. Residual renal function in children on haemodialysis and peritoneal dialysis. Pediatr Nephrol 1994;8:579-583.

  683. Fehr T, Ammann P, Garzoni D, et al: Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 66:1206-1211, 2004

  684. Feinfeld DA, Mofenson HC, Caraccio T: Poisoning by amatoxin-containing mushrooms in suburban New York: report of four cases . Clinical Toxicology 1994; 32(6): 715-721.

  685. Fenner J, Williamson J, Callanan V: Further understanding of, a new treatment for "Irukandji" (Carukia barnesi) stings . Med J Aust 1988; 145: 569-574.

  686. Fenner P, Willamson J: Worldwide deaths and severe envenomation from jellyfish stings . Med J Aust 1996; 165: 658-661.

  687. Fenner P, Williamson J, Burnett J: The "Irukandji syndrome" and acute pulmonary oedema . Med J Aust 1988; 149: 150-156.

  688. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J: Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Peritoneal Dial Int 13:296-301, 1993

  689. Feriani M, Kimmel PL, Kurantsin-Mills J, Bosch JP. Effect of renal replacement therapy on viscosity in end-stage renal disease patients. Am J Kidney Dis 1992; 19: 131–139 (B)

  690. Fernandez-Martin JL, Canteros A, Alles A, Massari P, Cannata-Andia J. Aluminum exposure in chronic renal failure in iberoamerica at the end of the 1990s: overview and perspectives. Am J Med Sci 2000; 320: 96–99 (C)

  691. Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, et al: Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis 34:508-513, 1999

  692. Finazzi G, Remuzzi G. Heparin-induced thrombocytopenia—background and implications for haemodialysis. Nephrol Dial Transplant 1996; 11: 2120–2122 (B)

  693. Fine R, Ho M, Tejani A, et al. Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr 2003;142:539-545.

  694. Fine R, Ho M. The role of APD in the management of pediatric patients: a report of the North American Pediatric Renal Transplant Cooperative Study. Semin Dial 2002;15:427-429.

  695. Fine R, Kohaut E, Brown D, et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 1994;124:374-382.

  696. Fine R. Growth hormone treatment of children with chronic renal insufficiency, end-stage renal disease and following renal transplantation-update 1997. Pediatr Endocrinol 1997;10:361-370.

  697. Fine R. Renal transplantation for children—the only realistic choice. Kidney Int 1985;17:S15-S17.

  698. Fiorini F, Masturzo P, MijM, Bertolini S. Lipoprotein(a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration. Nephron 1995; 70: 500–501 (B)

  699. Fiorini F, Patrone E, Castelluccio A. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients. Clin Ter 1994; 145: 213–217 (B)

  700. Fischbach M, et al. Dynamic changes of the total pore area available for peritoneal exchange in children. J Am Soc Nephrol 2001;12:1524-1529.

  701. Fischbach M, et al. Impact of fill volume changes on peritoneal dialysis tolerance and effectiveness in children. Adv Perit Dial 1996;16:321-323.

  702. Fischbach M, et al. Optimal volume prescription for children on peritoneal dialysis. Perit Dial Int 2000;20:603-606.

  703. Fischbach M, Terzic J, Becmeur F, et al. Relationship between intraperitoneal hydrostatic pressure and dialysate volume in children on PD. Adv Perit Dial 1996;12:330-334.

  704. Fischbach M, Terzic J, Laugel V, et al. Daily online hemodiafiltration: a pilot trial in children. Nephrol Dial Transplant 2004;19:2360-2367.

  705. Fischbach M, Terzic J, Laugel V, et al. Measurement of hydrostatic intraperitoneal pressure: a useful tool for the improvement of dialysis dose prescription. Pediatr Nephrol 2003;18:976-980.

  706. Fischbach M, Terzic J, Menouer S, et al. Effects of automated peritoneal dialysis on residual daily urinary volume in children. Adv Perit Dial 2001;17:269-273.

  707. Fischbach M, Terzic J, Menouer S, et al. Intensified and daily hemodialysis in children might improve statural growth. Pediatr Nephrol 2006;21:1746-1652.

  708. Fischbach M, Terzic J, Provot E, et al. Intraperitoneal pressure in children: fill-volume related and impacted by body mass index. Perit Dial Int 2003;23:391-394.

  709. Fiser D, Moss M, Walker W: Critical care for clonidine poisoning in toddlers . Critical Care Medicine 1990; 18(10): 1124-1128.

  710. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68:1337-1343, 2005

  711. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uraemia. Kidney Int 1997; 52: 1645–1650 (A)

  712. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H. Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 1997; 52: 1645–1650 (B)

  713. Fishbane S, Lynn RI: The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 44:238-240, 1995

  714. Fishbane S, Ungureanu V, Maesaka J, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.

  715. Fisher JW: Mechanism of the anemia of chronic renal failure. Nephron 25:106-111, 1980

  716. Fitzgerald JT, Schanzer A, Chin AI, McVicar JP, Perez RV, Troppmann C. Outcomes of upper arm arteriovenous fistulas for maintenance hemodialysis access. Arch Surg 2004; 139: 201–208

  717. Flaherty JP, Garcia-Houchins S, Chudy R, Arnow PM. An outbreak of Gram-negative bacteremia traced to contaminated O-rings in reprocessed dialyzers. Ann Intern Med 1993; 119: 1072–1078 (B)

  718. Flament J, Goldman M, Waterlot Y et al. Impairment of phagocyte oxidative metabolism in hemodialyzed patients with iron overload. Clin Nephrol 1986; 25: 227–230 (B)

  719. Flaminio LM, Bergia R, De Angelis L et al. The fate of leached di-(2-ethylhexyl)-phthalate (DEHP) in patients on chronic haemodialysis. Int J Artif Organs 1988; 11: 428–434 (B)

  720. Flaminio LM, De Angelis L, Ferazza M et al. Leachability of a new plasticizer tri-(2-ethylhexyl)-trimellitate from haemodialysis tubing. Int J Artif Organs 1988; 11: 435–441 (B)

  721. Flanigan M, Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. Perit Dial Int 2005;25:132-139.

  722. Flanigan MJ, Fangman J, Lim VS. Quantitating haemodialysis: a comparison of three kinetic models. Am J Kidney Dis 1991;17: 295–302 (B)

  723. Flanigan MJ, Von BJ, Freeman RM, Lim VS. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. Am J Kidney Dis 1987; 9: 147–153 (A)

  724. Fleischmann E, Teal N, Dudley J et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 1999; 55: 1560–1567 (B)

  725. Fleischmann E, Teal N, Dudley J, Bower J, Salahudeen A: Underweight rather than overweight as the independent predictor for death in hemodialysis. J Am Soc Nephrol 8:208A, 1998 (abstr)

  726. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 55:1560-1567, 1999

  727. Fleming SJ, Moran DM, Cooksley WG, Faoagali JL. Poor response to a recombinant hepatitis B vaccine in dialysis 184. Mitsui T, Iwano K, Suzuki S et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989; 10: 324–327 (B) patients. J Infect 1991; 22: 251–257 (B)

  728. Fletcher O, Kessling AM. MTHFR association with arteriosclerotic vascular disease? Hum Genet 1998; 103: 11–21 (B)

  729. Floege J, Ehlerding G. Beta-2-microglobulin-associated amyloidosis. Nephron 1996; 72: 9–26 (C)

  730. Floege J, Granolleras C, Deschodt G et al. High-flux synthetic versus cellulosic membranes for beta 2-microglobulin removal during haemodialysis, haemodiafiltration and haemofiltration. Nephrol Dial Transplant 1989; 4: 653–657 (B)

  731. Floege J, Ketteler M. Beta2-microglobulin-derived amyloidosis: an update. Kidney Int 2001; 59: 164–171 (C)

  732. Floersheim GL: Treatment of human amatoxin mushroom poisoning: myths and advances in therapy . Med Toxicol 1987; 2(1): 1-9.

  733. Fluck S, McKane W, Cairns T et al. Chloramine-induced haemolysis presenting as erythropoietin resistance. Nephrol Dial Transplant 1999; 14: 1687–1691 (B)

  734. Flynn J, Kershaw D, Smoyer W, et al. Peritoneal dialysis for management of pediatric acute renal failure. Perit Dial Int 2001;21:390-394.

  735. Fodinger M, Mannhalter C, Wolfl G et al. Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997; 52: 517–523 (B)

  736. Foland J, Fortenberry J, Warshaw B, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004;32:1771-1776.

  737. Foley RN, Parfrey PS, Morgan J, et al: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000

  738. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112–S119 (B)

  739. Food and Nutrition Board NRCN: Recommended Daily Allowances (ed 10). Washington, DC, National Academy Press, 1989

  740. Ford CV, Folks DG: Conversion disorders: An overview. May; 26(5): 371-383.

  741. Formica C, Atkinson MG, Nyulasi I, McKay J, Heale W, Seeman E: Body composition following hemodialysis: Studies using dual-energy X-ray absorptiometry and bioelectrical impedance analysis. Osteoporosis Int 3:192-197, 1993

  742. Forns X, Caballeria J, Bruguera M: Disulfiram induced hepatitis.Report of four cases and review of the literature . Journal of Hepatology 1994; 21: 853-857.

  743. Forstermann U, Closs EI, Pollock JS et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121–1131 (B)

  744. Forsyth, JCMueller, Paula DBecker, Charles E, Mueller, PD, Becker CE: Hydroxocobalamin as a cyanide antidote: safety, efficacy, and pharmacokinetics in heavily smoking normal volunteers . Clin Tox 1993; 31: 277-294.

  745. Francioli P, Masur H. Complications of Staphylococcus aureus bacteremia. Occurrence in patients undergoing long-term hemodialysis. Arch Intern Med 1982; 142: 1655–1658 (B)

  746. Francois B, Marquet P, Desachy A: Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association. . Intensive Care Med 1997; 23: 122-4.

  747. Fraser CG, Wilkinson SP, Neville RG, Knox JD, King JF, MacWalter RS: Biologic variation of common hematologic laboratory quantities in the elderly. Am J Clin Pathol 92:465-470, 1989

  748. Freedberg RS, Friedman GR, Palu RN: Cardiogenic shock due to antihistamine overdose. Reversal with intra-aortic balloon counterpulsation . JAMA 1987; 257: 660-1.

  749. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005; 64: 428–437.

  750. Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63: 138–145.

  751. Freire-Maia L, Campos JA, Amaral CFS: Approaches to the treatment of scorpion envenoming . Toxicon 1994; 32: 1009-14.

  752. Frenette C, MacLean JD, Gyorkos TW: A large common source outbreak of ciguatera food poisoning . J Infect Dis 1988; 158: 1128-1131.

  753. Freudenthal A, Joseph P: Seabather's eruption . N Engl J Med 1993; 329: 542-544.

  754. Fried L. Higher membrane permeability predicts poorer patient survival. Perit Dial Int 1997;17:387-388.

  755. Frinak S, Polaschegg HD, Levin NW, Pohlod DJ, Dumler F,Saravolatz LD. Filtration of dialysate using an on-line dialysate filter. Int J Artif Organs 1991; 14: 691–697 (B)

  756. Frisancho AR: New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am J Clin Nutr 40:808-819, 1984

  757. Froger CL, Duijm LE, Liem YS et al. Stenosis detection with MR angiography and digital subtraction angiography in dysfunctional hemodialysis access fistulas and grafts. Radiology 2005; 234: 284–291

  758. Frommer DA, Kulig K: Трициклическая передозировка антидепрессанта: Обзор . Журнал Американской Медицинской Ассоциации 1987; 257: 521-526.

  759. Fuchshuber A, Kuhnemund O, Keuth B et al. Pneumococcal vaccine in children and young adults with chronic renal disease. Nephrol Dial Transplant 1996; 11: 468–473 (B)

  760. Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998;79:299-305.

  761. Fujii N, Hamano T, Mikami S et al. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). Nephrol Dial Transplant 2007; 22: 1601–1607.

  762. Fujimori A, Naito H, Miyazaki T. Adsorption of complement, cytokines, and proteins by different dialysis membrane materials: evaluation by confocal laser scanning fluorescence microscopy. Artif Organs 1998; 22: 1014–1017 (B)

  763. Fukunishi I, Honda M. School adjustment of children with end-stage renal disease. Pediatr Nephrol 1995;9:553-557.

  764. Fukunishi I, Kudo H. Psychiatric problems of pediatric end-stage renal failure. Gen Hosp Psychiatry 1995;17:32-36.

  765. Furth S, Hwang W, Yang C, et al. Relation between pediatric experience and treatment recommendations for children and adolescents wtih kidney failure. JAMA 2001;285:1027-1033.

  766. Furth SL, Neu AM, Case B et al. Pneumococcal polysaccharide vaccine in children with chronic renal disease: a prospective study of antibody response and duration. J Pediatr 1996; 128: 99–101 (B)

  767. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18:353-361, 2003

  768. Furuland H, Linde T, Wikstrom B, Danielson BG: Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. J Nephrol 18:80-85, 2005

  769. Fusshoeller A, Plail MGrabensee B, et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004;19:2101-2106.

  770. Gabriel JP, Fellay G, Descombes E. Urea kinetic modeling: an in vitro and in vivo comparative study. Kidney Int 1994; 46: 789–796 (B)

  771. Gadallah MF, Paulson WO, Vickers B, Work J. Accuracy of Doppler ultrasound in diagnosing anatomic stenosis of hemodialysis arteriovenous access as compared with fistulography. Am J Kidney Dis 1998; 32: 273–277

  772. Galli F, Rovidati S, Chiarantini L et al. Bioreactivity and biocompatibility of a vitamin E-modified multi-layer hemodialysis filter. Kidney Int 1998; 54: 580–589 (B)

  773. Galli F, Varga Z, Balla J et al. Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int 2001; 59 [Suppl 78]: S148–S154 (B)

  774. Ganzi GC, Parise PL. The production of pharmaceutical grades of water using continuous deionization post-reverse osmosis. J Parenter Sci Technol 1990; 44: 231–241 (B)

  775. Gao P, D’Amour P. Evolution of the parathyroid hormone (PTH) assay– importance of circulating PTH immunoheterogeneity and of its regulation. Clin lab 2005; 51: 21–29.

  776. Garcia LS, Bruckner DA: Diagnostic medical parasitology . 1997;.

  777. Garcia-Garcia M, Argiles A, Gouin-Charnet A et al. Impaired lysosomal processing of beta2-microglobulin by infiltrating macrophages in dialysis amyloidosis. Kidney Int 1999; 55: 899–906 (B)

  778. Garcia-Leoni ME, Martin-Scapa C, Rodeno P et al. High incidence of tuberculosis in renal patients. Eur J Clin Microbiol Infect Dis 1990; 9: 283–285 (B)

  779. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 1996; 276: 875–881 (B)

  780. Garella S: Nephrology forum: Extracorporeal techniques in the treatment of exogenous intoxications . Nephrology International 1988; 33: 735-54.

  781. Garibotto G, Russo R, Sala MR, Ancarani P, Robaudo C, Sofia A, Deferrari G, Tizianello A: Muscle protein turnover and amino acid metabolism in patients with chronic renal failure. Miner Electrolyte Metab 18:217-221, 1992

  782. Gascon A, Orfao A, Lerma JL et al. Antigen phenotype and cytotoxic activity of natural killer cells in hemodialysis patients. Am J Kidney Dis 1996; 27: 373–379 (B)

  783. Gateau T, Bloom M, Clark R: Responses to specific Centruroides sculpturatus antivenin in 151 cases of scorpion stings . Clinical Toxicology 1994; 32: 165-71.

  784. Gauci C, Moranne O, Fouqueray B et al. Pitfalls of measuring total blood calcium in patients with CKD. J Am Soc Nephrol 2008; 19: 1592–1598.

  785. Gault MH, Duffett AL, Murphy JF, Purchase LH. In search of sterile, endotoxin-free dialysate. ASAIO J 1992; 38: M431–M435 (C)

  786. Gawaz MP, Mujais SK, Schmidt B, Blumenstein M, Gurland HJ. Platelet-leukocyte aggregates during hemodialysis: effect of membrane type. Artif Organs 1999; 23: 29–36 (B)

  787. Geary D, et al. Tube feeding in infants on peritoneal dialysis. Perit Dial Int 1996;16:S517-S520.

  788. Geary D, Harvey E, Balfe J. Mass transfer area coefficients in children. Perit Dial Int 1994;14:30-33.

  789. Geary D, Piva E, Gajaria M, et al. Development of a nocturnal home hemodialysis (NHHD) program for children. Semin Dial 2004;17:115-117.

  790. Geary D, Piva E, Tyrrell J, et al. Home nocturnal hemodialysis in children. J Pediatr 2005;147:383-387.

  791. Geary DF, Gajaria M, Fryer-Keene S, Willumsen J. Low-dose and heparin-free hemodialysis in children. Ped Nephrol 1991; 5: 220–224 (B)

  792. Geerlings W, Tufveson G, Brunner FP et al. Combined report on regular dialysis and transplantation in Europe, XXI, 1990. Nephrol Dial Transplant 1991; 6 [Suppl 4]: 5–29 (B)

  793. Gehan E, George S. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225.

  794. Gejyo F, Odani S, Yamada T et al. Beta 2-microglobulin: a new form of amyloid protein associated with chronic hemodialysis. Kidney Int 1986; 30: 385–390 (B)

  795. Gelmez M, Akcaoglu T, Utkucu U. . Integrated education of nurses on vascular access for haemodialysis. EDTNA/ERCA J 2002; XXVIII: 36–38

  796. Geoffroy O, Tassart M, Le Blanche AF et al. Upper extremity digital subtraction venography with gadoterate meglumine before fistula creation for hemodialysis. Kidney Int 2001; 59: 1491–1497

  797. Gerberding JL. Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996; 125: 497–501 (B)

  798. Gerdemann A, Lemke HD, Nothdurft A et al. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis. Clin Nephrol 2000; 54: 276–283 (B)

  799. Gerdemann A, Lemke HD, Nothdurft A et al. Low-molecular but not high-molecular advanced glycation end products(AGEs) are removed by high-flux dialysis. Clin Nephrol 2000; 54: 276–283 (B)

  800. Gerson A, Butler R, Moxey-Mims M, et al. Neurocognitive outcomes in children with chronic kidney disease: current findings and contemporary endeavors. Ment Retard Dev Disabil Res 2006;12:208-215.

  801. Gessner BD, Middaugh JP, Doucette GJ: Paralytic shellfish poisonong in Kodiak, Alaska . West J Med 1997; 166: 351-353.

  802. Ghysen J, De Plaen JF, van Ypersele de Strihou C. The effect of membrane characteristics on tumour necrosis factor kinetics during haemodialysis. Nephrol Dial Transplant 1990; 5: 270–274 (B)

  803. Gibson TP, Briggs WA, Boone BJ. Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis. J Lab Clin Med 1976; 87: 519–524 (B)

  804. Gillespie R, Seidel K, Symons J. Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. Pediatr Nephrol 2004;19:1394-1399.

  805. Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron 1995; 70: 301–306 (B)

  806. Giordano C, De Santo G, Pluvio M, Di LA, Capodicasa G, Cirillo D, Esposito R, Damiano M: Protein requirement of patients on CAPD: A study on nitrogen balance. Int J Artif Organs 3:11-14, 1980

  807. Giovannucci E. Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 2008; 624: 31–42.

  808. Girndt M, Heisel O, Kohler H. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. Nephrol Dial Transplant 1999; 14: 676–682 (B)

  809. Girndt M, Kohler H, Schiedhelm-Weick E et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559–565 (B)

  810. Glaser DS: Utility of the serum osmolar gap in the diagnosis of methanol or ethylene glycol ingestion. Ann Emerg Med 1996; 27(3): 343-346.

  811. Glaser P, Guesde R, Rouby JJ, Eurin B. Haemodialysis without heparin is possible. Lancet 1979; 2: 579–580 (B)

  812. Glassman A, Stetner F, Walsh T: Heavy smokers, smoking cessation, and clonidine . Journal of the American Medical Association 1988; 259(19): 2863-2866.

  813. Glenn C, Astley S, Watkins S. Dialysis-associated seizures in children and adolescents. Pediatr Nephrol 1992;6:182-186.

  814. Gloggler A, Bulla M, Furst P. Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children. Kidney Int 1989;27:S256-S258.

  815. Gloggler A, Bulla M, Puchstein C, et al. Plasma and muscle carnitine in healthy and hemodialyzed children. Child Nephrol Urol 1988;9:277-282.

  816. Glotzer DE, Weitzman M: Commonly asked questions about childhood lead poisoning . Pediatr Ann 1995; 24: 630-2, 637-9.

  817. Glowacki LS, Hodsman AB, Hammerberg O et al. Surveillance and prophylactic intervention of Staphylococcus aureus nasal colonization in a hemodialysis unit. Am J Nephrol 1994; 14: 9–13 (B)

  818. Goddard AF, McIntyre AS, Scott BB: Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 46:SIV1-SIV5, 2000 (suppl 3-4)

  819. Goddard J: Physician's guide to arthropods of medical importance . 1996;.

  820. Gokal R, Alexander S, Ash S, et al. Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update. (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int 1998;18:11-33.

  821. Gokal R, Mann JI, Oliver DO, Ledingham JG. Dietary treatment of hyperlipidemia in chronic hemodialysis patients. Am J Clin Nutr 1978; 31: 1915–1918 (B)

  822. Gold BS, Wingert WA: Snake venom poisoning in the United States . South Med J 1994; 87: 579-89.

  823. Gold BS: Neostigmine for the treatment of neurotoxicity following envenomation by the Asian cobra . Ann Emerg Med 1996; 28: 87-89.

  824. Gold CH, Buchanan N, Tringham V, Viljoen M, Strickworld B, Moodley GP. Isoniazid pharmacokinetics in patients in chronic renal failure. Clin Nephrol 1976; 6: 365–369 (B)

  825. Gold M, Pottash C, Sweeney D: Opiate withdrawal using clonidine . Journal of the American Medical Association 1980; 243(4): 343-346.

  826. Goldberg AP, Geltman EM, Gavin JR, III et al. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 1986; 42: 311–316 (B)

  827. Goldberg AP, Hagberg JM, Delmez JA, Haynes ME, Harter HR. Metabolic effects of exercise training in hemodialysis patients. Kidney Int 1980; 18: 754–761 (B)

  828. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 104–107 (A)

  829. Goldberg IJ, Kaufman AM, Lavarias VA, Vanni-Reyes T, Levin NW. High flux dialysis membranes improve plasma lipoprotein profiles in patients with end-stage renal disease. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 104–107 (B)

  830. Goldberg LH, Shupp D, Weitz HH: Injection of household spray insecticide. Ann Emerg Med 1982; 11: 626-629.

  831. Goldblum SE, Reed WP. Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 1980; 93: 597–613 (C)

  832. Goldfarb S, Golper TA. Proinflammatory cytokines and haemofiltration membranes. J Am Soc Nephrol 1994; 5: 228–232 (B)

  833. Goldfrank L, Flomenbaum N, Lewin Neal: Golfrank's Toxicologic Emergencies . Appleton and Lange 1990; 4th Edition: 575-85.

  834. Goldfrank L, Flomenbaum NE, Lewin NA: Carbamazepine . Goldfrank's Toxicolgic Emergencies 1994; 594-595.

  835. Goldfrank LR: Disulfiram and Disulfiramlike Reactions . Goldfrank’s: Toxicology Emergencies 1994; 5: 899-903.

  836. Goldfrank LR: Goldfrank's Toxicologic Emergencies . 1994; 577-588.

  837. Goldfrank LR: Mushrooms: Toxic and Hallucinogenic . Goldfrank's toxicologic emergencies 1994; 5th edition: 951-961.

  838. Goldman M, Vanherweghem JL. Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. Adv Nephrol Necker Hosp 1990; 19: 315–332 (B)

  839. Goldstein S, Allsteadt A, Smith C, et al. Proactive monitoring of pediatric hemodialysis vascular access: effects of ultrasound dilution on thrombosis rates. Kidney Int 2002;62:272-275.

  840. Goldstein S, Baronette S, Gambrell T, et al. nPCR assessment and IDPN treatment of malnutrition in pediatric hemodialysis patients. Pediatr Nephrol 2002;17:531-534.

  841. Goldstein S, Brem A, Warady B, et al. Comparison of single-pool and equilibrated Kt/V values for pediatric hemodialysis prescription management: analysis from the Centers for Medicare & Medicaid Services Clinical Performance Measures Project. Pediatr Nephrol 2006;21:1161-1166.

  842. Goldstein S, Brewer E. Logarithmic extrapolation of a 15-minute postdialysis BUN to predict equilibrated BUN and calculate double-pool Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 2000;36:98-104.

  843. Goldstein S, Currier H, Graf C, et al. Outcome in children receiving continuous veno-venous hemofiltration. Pediatrics 2001; 107:1309-1312.

  844. Goldstein S, Currier H, Watters L, et al. Acute and chronic inflammation in pediatric patients receiving hemodialysis. J Pediatr 2003;143:653-657.

  845. Goldstein S, Graham N, Burwinkle T, et al. Health-related quality of life in pediatric patients with ESRD. Pediatr Nephrol 2006;21:846-850.

  846. Goldstein S, Macierowski C, Jabs K. Hemodialysis catheter survival and complications in children and adolescents. Pediatr Nephrol 1997;11:74-77.

  847. Goldstein S, Silverstein D, Leung J, et al. Frequent hemodialysis with NxStageTM system in pediatric paatients receiving maintenance hemodialysis. Pediatr Nephrol 2007;23:129-135.

  848. Goldstein S, Smith C, Currier H. Noninvasive interventions to decrease hospitalization and associated costs for pediatric patients receiving hemodialysis. J Am Soc Nephrol 2003;14:2127-2131.

  849. Goldstein S, Somers M, Baum M, et al. Pediatric patients with multi-organ system dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int 2005;67:653-658.

  850. Goldstein S, Sorof J, Brewer E. Evaluation and prediction of urea rebound and equilibrated Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 1999;34:49-54.

  851. Goldstein S, Sorof J, Brewer E. Natural logarithmic estimages of Kt/V in the pediatric hemodialysis population. Am J Kidney Dis 1999;33:518-522.

  852. Goldstein S. Adequacy of dialysis in children: does small solute clearance really matter? Pediatr Nephrol 2004;19:1-5.

  853. Goldstein S. Advances in renal replacement therapy as a bridge to renal transplantation. Pediatr Transplant 2007;11:463-470.

  854. Goldstein S. Hemodialysis in the pediatric patient: state of the art. Adv Renal Replace Ther 2001;8:173-179.

  855. Goldstein S. Overview of pediatric renal replacement therapy in acute renal failure. Artif Organs 2003;27:781-785.

  856. Goldwasser P, Mittman N, Antignani A et al. Predictors of mortality in hemodialysis patients. J Am Soc Nephrol 1993; 3: 1613–1622 (B)

  857. Golper T, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Am J Kidney Dis 1996;28:428-436.

  858. Gonzalez EA, Sachdeva A, Oliver DA et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004; 24: 503–510.

  859. Gonzalez-Martin G, Diaz-Molinas MS, Martinez AM, Ortiz M. Heparin-induced hyperkalemia: a prospective study. Int J Clin Pharmacol Ther Toxicol 1991; 29: 446–450 (B)

  860. Goodman W, Goldin J, Kuizon B, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-1483.

  861. Goodman WG, Goldin J, Kuizon BD et al. Coronaryartery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–1483 (B)

  862. Gopalakrishnakone P, Tan CK: Clinical features on 12,890 cases of ciguatera (fish poisoning) French polynesia . Proceedings: First Asia-Pacific Congress on Animal, Plant and Microbial Toxins 1987; June 24-27: 372-385.

  863. Gordon SM, Bland LA, Alexander SR, Newman HF, Arduino MJ, Jarvis WR. Hemolysis associated with hydrogen peroxide at a pediatric dialysis center. Am J Nephrol 1990; 10: 123–127 (B)

  864. Gordon SM, Drachman J, Bland LA, Reid MH, Favero M, Jarvis WR. Epidemic hypotension in a dialysis center causedby sodium azide. Kidney Int 1990; 37: 110–115 (C)

  865. Gordon SM, Oettinger CW, Bland LA et al. Pyrogenic reactions in patients receiving conventional, high-efficiency,or high-flux haemodialysis treatments with bicarbonate dialysate containing high concentrations of bacteria and endotoxin. J Am Soc Nephrol 1992; 2: 1436–1444 (B)

  866. Gotch F, Sargent J. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-534.

  867. Gotch FA, Keen M. Care of the patient on haemodialysis. In: Cogan MG, Garovoy MR, eds. Introduction to Dialysis. Churchill Livingstone, New York: 1985; 73–143 (C)

  868. Gotch FA, Levin NW, Port FK, Wolfe RA, Uehlinger DE. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30: 1–15 (B)

  869. Gotch FA, Levin NW, Zasuwa G, Tayeb J Kinetics of beta 2-microglobulin in haemodialysis. Contrib Nephrol 1989; 132–138 (B)

  870. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985; 28: 526–534 (B)

  871. Gotch FA. Kinetic modeling in haemodialysis. In: Nissenson AR, Fine RN, Gentile DE, eds. Clinica Dialysis. Appleton & Lange, Norwalk: 1990; 118–146 (C)

  872. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 [Suppl 6]: 10–14 (C)

  873. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19: 2226–2233 (B)

  874. Grady GF, Lee VA, Prince AM et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978; 138: 625–638 (B)

  875. Graham IM, Daly LE, Refsum HM et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J Am Med Assoc 1997; 277: 1775–1781 (B)

  876. Graham KA, Reaich D, Channon SM, Downie S, Gilmour E, Passlick-Deetjen J, Goodship TH: Correction of acidosis in CAPD decreases whole body protein degradation. Kidney Int 49:1396-1400, 1996

  877. Graham KA, Reaich D, Channon SM, Downie S, Goodship THJ: Correction of acidosis in hemodialysis decreases whole-body protein degradation. J Am Soc Nephrol 8:632-637, 1997

  878. Grau E, Siguenza F, Maduell F et al. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992; 62: 13–17 (B)

  879. Greenbaum L, Benador N, Goldstein S, et al. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 2007;49:814-823.

  880. Greiber S, Weber U, Galle J, Bramer P, Schollmeyer P. Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis. Nephron 1997; 76: 15–19 (B)

  881. Greinacher A, Philippen KH, Kemkes-Matthes B et al. Heparin-associated thrombocytopenia type II in a patient with end-stage renal disease: successful anticoagulation with the low-molecular-weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant 1993; 8: 1176–1177 (B)

  882. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost 1995; 21: 106–116 (B)

  883. Griffin BA, Freeman DJ, Tait GW et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106: 241–253 (B) 102 SECTION VII. Vascular disease and risk factors

  884. Gris JC, Branger B, Vecina F et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994; 46: 807–813 (B)

  885. Grooteman MP, Nube MJ, Daha MR et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997; 8: 1745–1754 (A)

  886. Grooteman MP, Nube MJ, Daha MR et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997; 8: 1745–1754 (B)

  887. Grooteman MPC, Nube´ MJ, Daha MR et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997; 8: 1745–1754 (B)

  888. Grooteman MPC, Nube´ MJ, van Limbeek J, Schoorl M, van Houte AJ. Lymphocyte subsets in dialyser eluates: a new parameter of bioincompatibility? Nephrol Dial Transplant 1996; 11: 1073–1078 (A)

  889. Gross TP: An outbreak of phototoxic dermatitis due to limes . Am J Epid 1987; 125: 509-514.

  890. Grouleau G: Lithium toxicity . Emerg Med Clin North Am 1994; 12: 511-531.

  891. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159: 1670–1678 (C)

  892. Grupe W, Harmon W, Spinozzi N. Protein and energy requirements in children receiving chronic hemodialysis. Kidney Int 1983;15: S6-S10.

  893. Gruskin A, et al. Developmental aspects of peritoneal dialysis kinetics. In: Fine R, ed. Chronic ambulatory peritoneal dialysis (CAPD) and chronic cycling peritoneal dialysis. Boston: Martinus Nijhoff, 1987:33-46.

  894. Grutzmacher P, Scheuermann EH, Siede W et al. Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects. Klin Wochenschr 1986; 64: 910–916 (B)

  895. Guenin DG, Auerbach PS: Trauma and Envenomations From Marine Fauna. In Tintinalli et al. (Eds.) Emergency Medicine: A Comprehensive Study Guide, 4th ed . 1996; 868-73.

  896. Guerin A, Buisson Y, Nutini MT et al. Response to vaccination against tetanus in chronic haemodialysed patients. Nephrol Dial Transplant 1992; 7: 323–326 (B) SECTION VI. Haemodialysis-associated infection 87

  897. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014–1021 (B)

  898. Gueron M, Reuben I, Sofer S: The cardiovascular system after scorpion envenomation. A review . Clinical Toxicology 1992; 30: 245-58.

  899. Guillot M, et al. Advances in peritoneal dialysis. In: Gahl G, et al., ed. Amsterdam: Excerpta Medica, 1981:203-207.

  900. Guisto JA: Severe toxicity from crotalid envenomation after early resolution of symptoms . Ann Emerg Med 1995; 26: 387-9.

  901. Gunderson RW, Concannon MF. Five years experience with a pure water system designed for haemodialysis. Contemp Dial Nephrol 1991; 12: 40–54 (B)

  902. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63–72 (B)

  903. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC: Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104:2263-2268, 2004

  904. Gurland H, et al. Extracorporeal blood purification techniques: plasmapheresis and hemoperfusion. In: Jacobs C, et al, eds. Replacement of renal function by dialy­sis, 4th ed. Dordrecht: Kluwer Academic,1996:472.

  905. Gusmano R, Oleggini R, Perfumo F. Plasma carnitine concentrations and dyslipidemia in children on maintenance hemodialysis. J Pediatr 1981;99:429-432.

  906. Gutierrez A, Alvestrand A, Wahren J, Bergstro¨m J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487–494 (B)

  907. Gutierrez A, Alvestrand A, Wahren J, Bergstrom J: Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 38:487-494, 1990

  908. Gutierrez A, Bergstro¨m J, Alvestrand A. Protein catabolism in sham-hemodialysis: the effect of different membranes. Clin Nephrol 1992; 38: 22–29 (B)

  909. Gutierrez A. Protein catabolism in maintenance haemodialysis: the influence of the dialysis membrane. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 108–111 (C)

  910. Gutierrez OM, Isakova T, Andress DL et al. Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int 2008; 73: 956–962.

  911. Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 52: 495–502 (B)

  912. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008; 336: 1049–1051.

  913. Guyatt GH, Oxman AD, Kunz R et al. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008; 336: 995–998.

  914. Haage P, Krings T, Schmitz-Rode T. Nontraumatic vascular emergencies: imaging and intervention in acute venous occlusion. Eur Radiol 2002; 12: 2627–2643

  915. Haage P, Vorwerk D, Piroth W, Schu. rmann K, Gu. nther RW. Treatment of hemodialysis-related central venous stenosis or occlusion: results of primary Wallstent placement and follow-up in 50 patients. Radiology 1999; 212: 175–180

  916. Haag-Weber M, Deppisch R, Go¨hl H, Ho¨ rl WH. Studies of biocompatibility of different dialyzer membranes: role of complement system, intracellular calcium and inositoltriphosphate. Clin Nephrol 1994; 41: 245–251 (B)

  917. Haag-Weber M, Horl WH. Are granulocyte inhibitory proteins contributing to enhanced susceptibility to infections in uraemia? Nephrol Dial Transplant 1996; 11 [Suppl 2]: 98–100 (C)

  918. Haag-Weber M, Horl WH. Uremia and infection: mechanisms of impaired cellular host defense. Nephron 1993; 63: 125–131 (C)

  919. Haag-Weber M, Mai B, Horl WH. Impaired cellular host defence in peritoneal dialysis by two granulocyte inhibitory proteins. Nephrol Dial Transplant 1994; 9: 1769–1773 (B)

  920. Habermehl GC, Krebs HC, Rasoanaivo P: Severe Ciguatera poisoning in Madagascar: A case report . Toxicon 1994; 32: 1539.

  921. Haddad L, Lee L: Toxic marine life . Clinical management of poisoning and drug overdose 1998; 3rd edition: 386-399.

  922. Haddad LM, et al, eds. Clinical management of poisoning and drug overdose, 3rd ed. Philadelphia: WB Saunders, 1998.

  923. Haddad LM, Winchester JF: Chapter . Clinical Management of Poisoning and Drug Overdose, 2nd ed. 1990; 581-590.

  924. Haddad LM, Winchester JF: Clinical management of poisoning and drug overdose . 1990; 2nd ed: 1475-1476.

  925. Haeffner-Cavaillon N, Cavaillon JM, Cianconi C et al. In vivo induction of interleukin-1 during hemodialysis. Kidney Int 1989; 35: 1212–1218 (B)

  926. Haemodialysis Adequacy Work Group. NKF-DOQI clinical practice guidelines for haemodialysis adequacy, 2000 update. Am J Kidney Dis 2001; 37: S15–S55 (C)

  927. Haffner D, Schaefer F, Nissel R, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med 2000;343:923-930.

  928. Hafner G, Klingel R, Wandel E et al. Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage. Blood Coagul Fibrinolysis 1994; 5: 221–226 (B)

  929. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279–288 (B)

  930. Hakim R, Fearon D, Lazarus J. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984; 26:194-200.

  931. Hakim RM, Breillatt J, Lazarus JM, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med 1984; 311: 878–882 (B)

  932. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661–669 (B)

  933. Hakim RM, Fearon DT, Lazarus JM. Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984; 26: 194–200 (B)

  934. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic haemodialysis patients. Kidney Int 1996; 50: 566–570 (B)

  935. Hakim RM, Held PJ, Stannard DC et al. Effect of the dialysis membrane on mortality of chronic hemodialysis patients. Kidney Int 1996; 50: 566–570 (B)

  936. Hakim RM, Levin NW. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993; 21: 125–137 (C)

  937. Hakim RM, Lowrie E. Obesity and mortality in ESRD: is it good to be fat? Kidney Int 1999; 55: 1580–1581 (C)

  938. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF III. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic haemodialysis patients. J Am Soc Nephrol 1996; 7: 472–478 (A)

  939. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF. The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996; 7: 472–478 (A)

  940. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484–494 (C)

  941. Hakim RM. Influence of high-flux biocompatible membrane on carpal tunnel syndrome and mortality. Am J Kidney Dis 1998; 32: 338–340 (C)

  942. Hakim RM. Influence of high-flux biocompatible membrane on carpal tunnel syndrome and mortality. Am J Kidney Dis 1998; 32: 338–343 (C)

  943. Hall AV, Clark WF, Parbtani A. Heparin-induced thrombocytopenia in renal failure. Clin Nephrol 1992; 38: 86–89 (B)

  944. Halstead BW: Current status of marine biotoxicology: An overview . International Biotoxicological Center, World Life Research Institute 1980;.

  945. Hamazaki T, Nakazawa R, Tateno S et al. Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients. Kidney Int 1984; 26: 81–84 (B)

  946. Han KM, Duijm LE, Thelissen GR et al. Failing hemodialysis access grafts: evaluation of complete vascular tree with 3D contrast-enhanced MR angiography with high spatial resolution: initial results in 10 patients. Radiology 2003; 227: 601–605

  947. Handbook of Dialysis. Ed. Daugirdas JT, Ing TS. 2ndedition. 1994.

  948. Hanes K: Serotonin, Psilocybin and Body Dysmorphic Disorders: A Case Report . J Clin Psychoparmacology April 1996; 16 (2): 188-89.

  949. Harada T, Morita T, Iwanaga S, Nakamura S, Niwa M. Anew chromogenic

  950. Haraldsson B. Assessing the peritoneal dialysis capacities of individual patients. Kidney Int 1995;47:1187-1198.

  951. Harris DC, Yuill E, Chesher DW: Correcting acidosis in hemodialysis: Effect on phosphate clearance and calcification risk. J Am Soc Nephrol 6:1607-1612, 1995

  952. Harris T, Cook EF, Garrison R, Higgins M, Kannel W, Goldman L: Body mass index and mortality among nonsmoking older persons. The Framingham Heart Study. JAMA 259:1520-1524, 1988

  953. Harter HR, Goldberg AP. Endurance exercise training. An effective therapeutic modality for hemodialysis patients. Med Clin North Am 1985; 69: 159–175 (B)

  954. Hartigan MF. Vascular access and nephrology nursing practice: existing views and rationales for change. Adv Renal Replacement Ther 1994; 1: 155–162

  955. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am J Kidney Dis 1997; 30: 366–373 (A)

  956. Hartnell GG, Hughes LA, Finn JP, Longmaid III, HE, Magnetic resonance angiography of the central chest veins. A new gold standard? Chest 1995; 107: 1053–1057

  957. Harty J, Conway L, Keegan M, Curwell J, Venning M, Campbell I, Gokal R: Energy metabolism during CAPD: A controlled study. Adv Perit Dial 11:229-233, 1995

  958. Harvey E, Secker D, Braj B, et al. The team approach to the management of children on chronic peritoneal dialysis. Adv Renal Replace Ther 1996;3:3-13.

  959. Hathiwala S. Dialysis without anticoagulation. Int J Artif Organs 1983; 6: 64–66 (B)

  960. Hauk M, Kuhlmann MK, Riegel W, Kohler H. In vivo effects of dialysate flow rate on KtV in maintenance haemodialysis patients. Am J Kidney Dis 2000; 35: 105–111 (B)

  961. Hauser AC, Hagen W, Rehak PH et al. Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. Am J Kidney Dis 2001; 37: 758–765 (B)

  962. Hayashi T, Suzuki A, Shoji T, et al: Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 35:250-256, 2000

  963. Hayes J. The role of nurses in maintenance of vascular access function. EDTNA/ERCA J 1998; XXIV: 9–12

  964. Haynes BE, Bessen HA, Wightman WD, et al: Oleander tea: Herbal draught of death . Ann Emerg Med 1985; 14: 350-353.

  965. Healey RJ. Reverse osmosis and distribution. Contemp Dial Nephrol 1992; 13: 24–33 (C)

  966. Heaney RP. Optimal vitamin D status. J Bone Miner Res 2009; 24: 755.

  967. Heath MJ, Pachar JV, Perez AL: An Exceptional Case of Lethal Disulfiram-Alcohol Reaction. . Forensic Science International 1992; 56: 45-50.

  968. Heimburger O, Stenvinkel P, Berglund L, et al. Increased plasma lipoprotein (a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996;72: 135-144.

  969. Held PJ, Port FK, Gaylin DS et al. Comorbid conditions and correlations with mortality risk among 3,399 incidient hemodialysis patients. Am J Kidney Dis 2001; 20 [Suppl 2]: 32–38 (B)

  970. Held PJ, Port FK, Wolfe RA et al. The dose of haemodialysis and patient mortality. Kidney Int 1996; 50: 550–556 (B)

  971. Henderson LW, Sanfelippo ML, Beans E. ‘On line’ preparation of sterile pyrogen-free electrolyte solution. ASAIO Trans 1978; 24: 465–467 (B)

  972. Hendrickx L, Kuypers D, Evenepoel P, Maes B, Messiaen T, Vanrenterghem Y. A comparative prospective study on the use of low concentrate citrate lock versus heparin lock in permanent dialysis catheters. Int J Artif Organs 2001; 24: 208–211

  973. Henle T, Deppisch R, Beck W et al. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 1999; 14: 1968–1975 (B)

  974. Henning P, Tomlinson L, Rigden S, et al. Long term outcome of treatment of end stage renal failure. Arch Dis Child 1988;63:35-40.

  975. Henny CP, ten Cate H, Surachno S et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 1985; 54: 460–462 (A)

  976. Henriksson AE, Bergqvist D. Steal syndrome of the hemodialysis vascular access: Diagnosis and treatment. J Vasc Access 2004; 5: 62–68

  977. Henry DA, Lowe JM, Donnelly T: Jaundice during cyproheptadine treatment . Br Med J 1978; 1: 753.

  978. Henry JA: Epidemiology and relative toxicity of antidepressant drugs in overdose . Drug Safety 1997; 16: 374-90.

  979. Herbelin A, Nguyen AT, Urena P, Descamps-Latscha B. Induction of cytokines by dialysis membranes in normal whole blood: a new in vitro assay for evaluating membrane biocompatibility. Blood Purif 1992; 10: 40–52 (B)

  980. Herget-Rosenthal S, Marggraf G, Pietruck F et al. Procalcitonin for accurate detection of infection in haemodialysis. Nephrol Dial Transplant 2001; 16: 975–979 (B)

  981. Hernandez AF, Montero MN, Pla A: Fatal moclobemide overdose or death caused by serotonin syndrome . J Forensic Sci 1995; 40: 128-30.

  982. Herselman M, Moosa MR, Kotze TJ et al. Protein-energy malnutrition as a risk factor for increased morbidity in longterm hemodialysis patients. J Ren Nutr 2000; 10: 7–15 (B)

  983. Hershko C, Peto TE, Weatherall DJ. Iron and infection. Br Med J (Clin Res Ed) 1988; 296: 660–664 (B)

  984. Hertel J, Kimmel PL, Phillips TM, Bosch J. Eosinophilia and cellular cytokine responsiveness in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1244–1252 (B)

  985. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799–805 (C)

  986. Heymsfield SB, Tighe A, Wang Z-M: Nutritional assessment by anthropometric and biochemical methods, in Shils ME, Olson JA, Shike M (eds): Modern Nutrition in Health and Disease. Philadelphia, PA, Lea and Febiger, 1984, pp 812-841

  987. Hickman R. Nine years experience with chronic peritoneal dialysis in childhood. Dial Transplant 1978;7:803.

  988. Hill RL, Fisher AP, Ware RJ, Wilson S, Casewell MW. Mupirocin for the reduction of colonization of internal jugular cannulae—a randomized controlled trial. J Hosp Infect 1990; 15: 311–321 (A)

  989. Hillman RS, Finch CA: Red Cell Manual (ed 7). Philadelphia, PA, Davis, 1996

  990. Himmelfarb J, Ault KA, Holbrook D, Leeber DA, Hakim RM. Intradialytic granulocyte reactive oxygen species production: a prospective, crossover trial. J Am Soc Nephrol 1993; 4: 178–186 (B)

  991. Himmelfarb J, Hakim RM. Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 1994; 9 [Suppl 2]: 138–144 (C)

  992. Himmelfarb J, Lazarus JM, Hakim R. Reactive oxygen species production by monocytes and polymorphonuclear leukocytes during dialysis. Am J Kidney Dis 1991; 17: 271–276 (B)

  993. Himmelfarb J, MacMonagle E, Holbrook D, Toth C. Soluble complement receptor 1 inhibits both complement and granulocyte activation during ex vivo hemodialysis. J Lab Clin Med 1995; 126: 392–400 (B)

  994. Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis—a prospective, randomized controlled trial. Kidney Int 1992; 41: 388–395 (B)

  995. Hingorani A, Ascher E, Kallakuri S, Greenberg S, Khanimov Y. Impact of reintervention for failing upper-extremity arteriovenous autogenous access for hemodialysis. J Vasc Surg 2001; 34: 1004–1009

  996. Hirata K, Kikuchi S, Saku K et al. Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients withuwithout diabetes mellitus. Kidney Int 1993; 44: 1062–1070 (B)

  997. Hirsch MS, Tolkoff-Rubin NE, Kelly AP, Rubin RH. Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis. J Infect Dis 1983; 148: 335 (B)

  998. Hirschberg M, Ludolph A, Grotemeyer KH: Development of A Subacute Tetraparesis after Disulfiram Intoxication - Case report . European Neurology 1987; 26: 222-228.

  999. Hisano S, et al. Immune status of children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 1992;6:179-181.

  1000. HIV transmission in a dialysis center—Colombia, 1991–1993. Morb Mortal Wkly Rep 1995; 44: 404–402 (B)

  1001. Ho CH, Chau WK, Hsu HC, Gau JP, You JY, Chen CC: Predictive risk factors and prevalence of malignancy in patients with iron deficiency anemia in Taiwan. Am J Hematol 78:108-112, 2005

  1002. Ho¨ rl WH, Steinhauer HB, Schollmeyer PJ. Plasma levels of granulocyte elastase during hemodialysis: effects of different dialyzer membranes. Kidney Int 1985; 28: 791–796 (B)

  1003. Hodges TC, Fillinger MF, Zwolak RM, Walsh DB, Bech F, Cronenwett JL. Longitudinal comparison of dialysis access methods: risk factors for failure. J Vascular Surg 1997; 26: 1009–1019

  1004. Hodgman CH: Conversion and somatization in pediatrics. Pediatrics in Review 1995; 16(1): 29-34.

  1005. Hodis HN. Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 1999; 99: 2852–2854 (B)

  1006. Hoen B, Kessler M, Hestin D, Mayeux D. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377–381 (B)

  1007. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–876

  1008. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–876 (A)

  1009. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–876 (B)

  1010. Hoenich NA, Thompson J, Varini E, MacCabe J, Appleton D. Particle spallation and plasticiser (DEHP) release from extracorporeal circuit tubing materials. Int J Artif Organs 1990; 13: 55–62 (B)

  1011. Hoenich NA, Woffindin C, Stamp S, Roberts SJ, Turnbull J.Synthetically modified cellulose: an alternative to synthetic membranes for use in haemodialysis? Biomaterials 1997; 18: 1299–1303 (B)

  1012. Hoenich NA. Spallation and plasticizer release from hemodialysis blood tubing: a cause of concern? Semin Dial 1991; 4: 227–230 (C)

  1013. Hofbauer R, Moser D, Frass M et al. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int 1999; 56: 1578–1583 (B)

  1014. Hoffman DR: Allergic reactions to biting insects . Monograph on Insect Allergy 1981; 69-74.

  1015. Hoffman J. Congenital heart disease. Pediatr Clin North Am 1990;37:25-44.

  1016. Hoffman RS, Goldfrank LR: The poisoned patient with altered mental status: controversies in the use of the "coma cocktail" . JAMA 1995; 274: 562-568.

  1017. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266–275.

  1018. Hollinger FB, Troisi CL, Pepe PE. Anti-HBs responses to vaccination with a human hepatitis B vaccine made by recombinant DNA technology in yeast. J Infect Dis 1986; 153: 156–159 (B)

  1019. Hollis BW, Wagner CL. Normal serum vitamin D levels. N Engl J Med 2005; 352: 515–516.

  1020. Hollis BW. Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr Opin Endocrinol Diabetes Obes 2008; 15: 489–494.

  1021. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317–322.

  1022. Holloway M, et al. Pediatric peritoneal dialysis training: characteristics and impact on peritonitis rates. Perit Dial Int 2001;21:401-404.

  1023. Hollowell JG, van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C: Hematological and iron-related analytes—Reference data for persons aged 1 year and over: United States, 1988-94.

  1024. Holmes DT, Levin A, Forer B et al. Preanalytical influences on DPC IMMULITE 2000 intact PTH assays of plasma and serum from dialysis patients. Clin Chem 2005; 51: 915–917.

  1025. Holt JT, DeWandler MJ, Arvan DA: Spurious elevation of the electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 77:561-567, 1982

  1026. Holtta T, Ronnholm K, Jalanko H, et al. Clinical outcome of pediatric patients on peritoneal dialysis under adequacy control. Pediatr Nephrol 2000;14:889-897.

  1027. Hombrouckx RO, De Vos JY, Larno LA et al. (A)typical symptoms during single needle dialysis. ASAIO Trans 1990; 36: M335–M337 (B)

  1028. Honkanen E, Gro¨nhagen-Riska C, Teppo AM, Maury CPJ, Meri S. Acute-phase proteins during hemodialysis: correlations with serum-1b levels and different dialysis membranes. Nephron 1991; 57: 283–287 (A)

  1029. Horkko S, Huttunen K, Kesaniemi YA. Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment. Kidney Int 1995; 47: 1732–1740 (B)

  1030. Hörl W. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007;22:480-489.

  1031. Horl WH, Haag-Weber M, Georgopoulos A, Block LH. Physicochemical characterization of a polypeptide present in uraemic serum that inhibits the biological activity of polymorphonuclear cells. Proc Natl Acad Sci USA 1990; 87: 6353–6357 (B)

  1032. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high- flux dialysis. J Am Soc Nephrol 1992; 3: 1227–1237 (B)

  1033. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227–1237 (B)

  1034. Hornberger JC, Chernew M, Petersen J, Garber AM. A multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227–1237 (B)

  1035. Hornberger JC. The haemodialysis prescription and cost effectiveness. Renal Physicians Association Working Committee on Clinical Guidelines. J Am Soc Nephrol 1993; 4: 1021–1027 (C)

  1036. Hornberger JC. The haemodialysis prescription and qualityadjusted life expectancy. Renal Physicians Association Working Committee on clinical guidelines. J Am Soc Nephrol 1993; 4: 1004 –1020 (C)

  1037. Hornfeldt CS: A report of acute ethanol poisoning in a child: Mouthwash vs cologne, perfume and aftershave . J Toxicol Clin Toxicol 1992; 30(1): 115-21.

  1038. Hornych A, Re´my P, Luong N, Aumont J, Barie´ty J. Biocompatibility of haemodialysis membranes: haemodialysisrelated leukotriene B4 and C4 generation. Nephron 1996; 74: 11–18 (B)

  1039. Horowitz BZ, Rhee KJ: Massive Verapamil Ingestion: A Report of Two Cases and a Review of the Literature . Am J Emerg Med 1989; 7: 624-631.

  1040. Hoshii S, Honda M, Itami N, et al. Sclerosing encapsulating peritonitis in pediatric peritoneal dialysis patients. Pediatr Nephrol 2000;14:275-279.

  1041. Hottelart C, Achard JM, Moriniere P et al. Heparin-induced hyperkalemia in chronic hemodialysis patients: comparison of low molecular weight and unfractionated heparin. Artif Organs 1998; 22: 614–617 (A)

  1042. Hotz M, Kniepmann K, Kohn L: Occupational therapy in pediatric lead exposure prevention . Am J Occup Ther 1998; 52: 53-9.

  1043. Hou FF, Chertow GM, Kay J et al. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Kidney Int 1997; 51: 1514–1519 (B)

  1044. House AA, Wells GA, Donnelly JG, Nadler SP, Hebert PC. Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids. Nephrol Dial Transplant 2000; 15: 1029–1034 (A)

  1045. Howard AD, Moore J Jr, Welch PG, Gouge SF: Analysis of the quantitative relationship between anemia and chronic renal failure. Am J Med Sci 297:309-313, 1989

  1046. Howland MA, Weisman RS: Nonsteroidal Anti-inflammatory Agents . Goldfrank's Toxicologic Emergencies 1994; 513-519.

  1047. Hsia SL, Perez GO, Mendez AJ et al. Defect in cholesterol transport in patients receiving maintenance hemodialysis. J Lab Clin Med 1985; 106: 53–61 (B)

  1048. Hsu CY, Bates DW, Kuperman GJ, Curhan GC: Relationship between hematocrit and renal function in men and women. Kidney Int 59:725-731, 2001

  1049. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504-510, 2002

  1050. Huan J, Olgaard K, Nielsen LB et al. Parathyroid hormone 7-84 induces hypocalcemia and inhibits the parathyroid hormone 1-84 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 2006; 17: 1923–1930.

  1051. Huang T, Lin C. Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis. Am J Nephrol 1995;15:312-317.

  1052. Huber TS, Carter JW, Carter RL, Seeger JM. Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodialysis accesses: a systematic review. J Vasc Surg 2003; 38: 1005–1011

  1053. Hultgren HN, Walter FG, et al: First Aid for Snakebites . J Wild Med 1994; 5: 216-21.

  1054. Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol 2000; 20: 2140–2147 (B)

  1055. Human immunodeficiency virus infection in hemodialysis patients. Baltimore-Boston Collaborative Study Group. Arch Intern Med 1988; 148: 617–619 (B)

  1056. Humar A, Oxley C, Sample ML, Garber G. Elimination of an outbreak of Gram-negative bacteremia in a hemodialysis unit. Am J Infect Control 1996; 24: 359– 363 (B)

  1057. Hume L, Forfar JC: Hyperkalaemia and overdose of antihypertensive agents . Lancet 1977; 2: 1182.

  1058. Hurlbut KM, Dart RC, et al: Reliability of clinical presentation for predicting significant pit viper envenomation . Ann Emerg Med 1988; 438-9.

  1059. Hursting MJ: Трициклические специфические для антидепрессанта потрясающие фрагменты изменяют распространение и устранение desipramine в кролике: Модель для передозировка treament . Журнал Токсикологии и Клиническая Токсикология 1989; 27: 53-66.

  1060. Hussein MM, Bakir N, Roujouleh H. Tuberculosis in patients undergoing maintenance dialysis. Nephrol Dial Transplant 1990; 5: 584–587 (B)

  1061. Huting J. Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 1994; 105: 383–388 (B)

  1062. Huxtable RJ: The harmful potential of herbal and other plant products . Drug Safety 1990; 5 (Suppl. 1): 126-136.

  1063. Hyatt M, Braun N, Briscoe G: The use of midazolam for hypnosedative interviews. General Hospital Psychiatry 1993; 15: 260-262.

  1064. Hyde D, Glancy G, Omerod P: Abuse of Indigenous Psilocybin Mushrooms: A New Fashion and Some Psychiatric Complications . Brit J Psychiatry 1978; 132: 602-4.

  1065. Hymes L, Hawthorne S, Chavers B. Impaired response to recombinant human erythropoietin therapy in children with peritonitis. Dial Transplant 1994;23:462-463.

  1066. Ibels LS, Alfrey AC, Huffer WE et al. Arterial calcification and pathology in uremic patients undergoing dialysis. Am J Med 1979; 66: 790–796 (B)

  1067. Ifudu O, Mayers JD, Matthew JJ, Fowler A, Friedman EA. Haemodialysis dose is independent of type of surgically-created vascular access. Nephrol Dial Transpl 1998; 13: 2311–2316

  1068. Iida Y, Miyata T, Inagi R, Sugiyama S, Maeda K. b2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages. Role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Comm 1994; 201: 1235–1241 (B)

  1069. Ikizler TA, Fkakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during hemodialysis. Kidney Int 1994; 46: 830–837 (B)

  1070. Ikizler TA, Flakoll PJ, Parker RA, Hakim RM: Amino acid and albumin losses during hemodialysis. Kidney Int 46:830-837, 1994

  1071. Ikizler TA, Greene JH, Yenicesu M, Schulman G, Wingard RL, Hakim RM: Nitrogen balance in hospitalized chronic hemodialysis patients. Kidney Int Suppl 57:S53-S56, 1996

  1072. Ikizler TA, Hakim RM. Nutrition in end-stage disease. Kidney Int 1996; 50: 343–357 (C)

  1073. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM. Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 1999; 55: 1945–1951 (B)

  1074. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim RM: Increased energy expenditure in hemodialysis patients. J Am Soc Nephrol 7:2646-2653, 1996

  1075. Imani F, Horii Y, Suthanthiran M et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 1993; 178: 2165–2172 (B)

  1076. Infection risks of haemodialysis—some preventive aspects. A report to the Public Health Laboratory Service by the Working Party on Haemodialysis Units. Br Med J 1968; 3: 454–460 (C)

  1077. Ing TS, Yu AW, Wong FK et al. Collection of a representative fraction of total spent hemodialysate. Am J Kidney Dis 1995; 25: 810–812 (B)

  1078. Ingelfinger JR. Risks and benefits to the living donor. N Engl J Med 2005;353:447-9

  1079. Ingram AJ, Parbtani A, Churchill DN. Effects of two low-flux cellulose acetate dialysers on plasma lipids and lipoproteins—a cross-over trial. Nephrol Dial Transplant 1998; 13: 1452–1457 (B)

  1080. Internet Web Site: National Geographic on Tarantulas . www.nationalgeographic.com/modules/tarantulas/.

  1081. Internet Web Site: Tarantula Related Links . www.concentric.net/~Dmartin/links.html.

  1082. Internet Web Site: Tarantulas as Pets . www.concentric.net/~Lottery/spider.shtml.

  1083. Internet Web Site: The American Tarantula Society . www.concentric.net/~Dmartin/ats.

  1084. Internet Web Site: The Tarantula Research Page . www.tiger.towson.edu/~skirby1/spider.html.

  1085. Ioannou GN, Rockey DC, Bryson CL, Weiss NS: Iron deficiency and gastrointestinal malignancy: A population-based cohort study. Am J Med 113:276-280, 2002

  1086. Ioannou GN, Spector J, Scott K, Rockey DC: Prospective evaluation of a clinical guideline for the diagnosis and management of iron deficiency anemia. Am J Med 113:281-287, 2002

  1087. Ireland H, Lane DA, Curtis JR. Objective assessment of heparin requirements for hemodialysis in humans. J Lab Clin Med 1984; 103: 643–652 (B)

  1088. Ireland H, Lane DA, Flynn A, Anastassiades E, Curtis JR. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Thromb Haemost 1986; 55: 271–275 (B)

  1089. Irish A. Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133–139 (B)

  1090. Irish AB, Green FR. Factor VII coagulant activity (VIIc) and hypercoagulability in chronic renal disease and dialysis: relationship with dyslipidaemia, inflammation, and factor VII genotype. Nephrol Dial Transplant 1998; 13: 679–684 (B)

  1091. Irish AB, Simons LA, Savdie E, Hayes JM, Simons J. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Aust N Z J Med 1992; 22: 243–248 (B)

  1092. Irish AB, Thompson CH. The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure. Nephrol Dial Transplant 1996; 11: 2223–2228 (B)

  1093. Irish AB. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis. Metabolism 1997; 46: 36–40 (B)

  1094. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 1993; 44: 115–119 (B)

  1095. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956–1960 (B)

  1096. Ishii Y, Yano S, Kanai H et al. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 1996; 73: 407–412 (B)

  1097. Ishimura E, Nishizawa Y, Okuno S, et al: Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. J Nephrol 11:83-86, 1998

  1098. Islam KN, O’Byrne D, Devaraj S et al. Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 2000; 150: 217–224 (B)

  1099. Ismail M: The scorpion envenoming syndrome . Toxicon 1995; 33: 825-58.

  1100. Ismail M: The treatment of the scorpion envenoming syndrome: the saudi experience with serotherapy . Toxicon 1994; 32: 1019-26.

  1101. Itabe H, Yamamoto H, Imanaka T et al. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37: 45–53 (B)

  1102. Ivie GW: Natural toxicants in human foods: Psoralens in raw and cooked parsnip root . Science 1981; 213: 909-910.

  1103. Iwarson S, Ahlmen J, Eriksson E et al. Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members. J Infect Dis 1977; 135: 473–477 (B)

  1104. Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999; 58: 139–144 (B)

  1105. Jaber BL, Gonski JA, Cendoroglo M et al. New polyether sulfone dialyzers attenuate passage of cytokine-inducing substances from Pseudomonas aeruginosa contaminated dialysate. Blood Purif 1998; 16: 210–219 (B)

  1106. Jackson BM, Beck-Sague CM, Bland LA, Arduino MJ, Meyer L, Jarvis WR. Outbreak of pyrogenic reactions and gram-negative bacteremia in a haemodialysis center. Am J Nephrol 1994; 14: 85–89 (B)

  1107. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem 1995; 41: 1135–1138 (B ).

  1108. Jackson RT: Separate hemoglobin standards for blacks and whites: A critical review of the case for separate and unequal hemoglobin standards. Med Hypotheses 32:181-189, 1990

  1109. Jacobs AA, Ward RA, Wellhausen SR, MacLeish KR. Polymorphonuclear leukocyte function during hemodialysis: relationship to complement activation. Nephron 1989; 52: 119–124 (B)

  1110. Jacobsen G, McMartin KE. Antidotes for methanol and ethylene glycol poiso­ning. / Toxicol Clin Toxicol 1997;35:127-143.

  1111. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022–1025 (B)

  1112. Jadoul M, Garbar C, Noe¨l H et al. Histological prevalence of b2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. Kidney Int 1997; 51: 1928–1932 (B)

  1113. Jadoul M, Garbar C, Noel H et al. Histological prevalence of beta 2-microglobulin amyloidosis in haemodialysis: a prospective post-mortem study. Kidney Int 1997; 51: 1928–1932 (B)

  1114. Jadoul M, Ueda Y, Yasuda Y et al. Influence of haemodialysis membrane type on pentosidine plasma level, a marker of ‘carbonyl stress’. Kidney Int 1999; 55: 2487–2492 (B)

  1115. Jain S, Smith L, Brewer E, et al. Non-invasive intravascular monitoring in the pediatric hemodialysis population. Pediatr Nephrol 2001;16:15-18.

  1116. Janssen MJ, Deegens JK, Kapinga TH et al. Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996; 49: 806–813 (A)

  1117. Janssen MJ, Huijgens PC, Bouman AA et al. Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993; 8: 1228–1233 (B)

  1118. Janssen MJ, van der Meulen J. The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med 1996; 48: 198–207 (B)

  1119. Jatzidis H., Oreopoulos D., TriantaphiHidis D. Treatment of severe barbiturate poisoning //Lancet. — 1965. — Vol 2. — P. 216-217.

  1120. Jilg W, Lorbeer B, Schmidt M et al. Clinical evaluation of a recombinant hepatitis B vaccine. Lancet 1984; 2: 1174–1175 (B)

  1121. Jo¨ rres A, Jo¨ rres D, Gahl GM, Schulz E, Mahiout A. Leukotriene release from neutrophils of patients on hemodialysis with cellulose membranes. Int J Artif Organs 1992; 15: 84–88 (B)

  1122. Jochimsen EM, Frenette C, Delorme M et al. A cluster of bloodstream infections and pyrogenic reactions among hemodialysis patients traced to dialysis machine waste-handling option units. Am J Nephrol 1998; 18: 485–489 (B)

  1123. Johansen KL, Chertow GM, Ng AV et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 2000; 57: 2564–2570 (B)

  1124. Johnson D, Mudge D, Blizzard S, et al. A comparison of peritoneal equilibration tests performed 1 and 4 weeks after PD commencement. Perit Dial Int 2004;24:460-465.

  1125. Johnson-Spear MA, Yip R: Hemoglobin difference between black and white women with comparable iron status: Justification for race-specific anemia criteria. Am J Clin Nutr 60:117-121, 1994

  1126. Johnsson E, Attman PO, Samuelsson O, Haraldsson B. Improved clearance of iohexol with longer haemodialysis despite similar KtV for urea. Nephrol Dial Transplant 1999; 14: 2407–2412 (B)

  1127. Joly D, Drueke TB, Alberti C et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross sectional study. Am J Kidney Dis 2008; 51: 987–995.

  1128. Jone, J, Dougherty J, Cannon L: Diphenhydramine-induced toxic psychosis . Am J Emerg Med 1986; 4: 169-71.

  1129. Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, Sandroni S, Bernard D, Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz R, Knight T, Kraus AJ, McDonald L, Hartnett M, Weaver M, Martis L, Moran J: Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: Results of a multicenter outpatient study. Am J Kidney Dis 32:761-769, 1998

  1130. Jonsson B, Johannesson M, Kjekshus J et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001–1007 (B)

  1131. Jonsson B, Johannesson M. Cost-benefit analysis of lipid lowering therapy. Eur Heart J 1997; 18: 165–166 (B)

  1132. Joosten E, Ghesquiere B, Linthoudt H, et al: Upper and lower gastrointestinal evaluation of elderly inpatients who are iron deficient. Am J Med 107:24-29, 1999

  1133. Jorstad S, Smeby LC, Balstad T, Wideroe TE. Generation and removal of anaphylatoxins during haemofiltration with five different membranes. Blood Purif 1988; 6: 325–335 (B)

  1134. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux haemodialysis. Am J Kidney Dis 1992; 20: 361–366 (B)

  1135. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high-flux hemodialysis. Am J Kidney Dis 1992; 20: 361–366 (B)

  1136. Joven J, Rubies-Prat J, Espinel E et al. Apoprotein A-I and high density lipoprotein subfractions in patients with chronic renal failure receiving hemodialysis. Nephron 1985; 40: 451–454 (B)

  1137. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD. Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 1993; 43: 410–418 (B)

  1138. Juarez-Congelosi M, Orellana P, Goldstein S. Normalized protein catabolic rate versus serum albumin as a nutrition status marker in pediatric patients receiving hemodialysis. J Ren Nutr 2007;17:269-274.

  1139. Juckett G: Plant dermatitis . Postgraduate Med 1996; 100: 159-171.

  1140. Jung K, Neumann R, Precht K, Nugel E, Scholz D. Lecithin: cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis. Enzyme 1980; 25: 273–275 (B)

  1141. Jungers P, Massy ZA, Nguyen-Khoa T et al. Longer duration of predialysis nephrological care is associated with improved longterm survival of dialysis patients. Nephrol Dial Transplant 2001; 16: 2357–2364

  1142. Juranovic LR, Park DL: Foodborne toxins of marine origin: Ciguatera . Rev Environ Contam Toxicol 1991; 117: 51.

  1143. Jurkovich GJ, Luterman A, et al: Complications of Crotalidae antivenin therapy . J Trauma 1988; 21: 1032-7.

  1144. Kabanda A, Jadoul M, Pochet JM et al. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance haemodialysis. Kidney Int 1994; 45: 1689–1696 (B)

  1145. Kagan A, et al. Role of peritoneal loss of albumin in the hypoalbuminemia of continuous ambulatory peritoenal dialysis patients: relationship to peritoneal transport of solutes. Nephrology 1995;71:314-320.

  1146. Kahn RC, Shechter Y: Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas . Goodman and Gilman's: The pharmacologic basis of therapeutics, 8th edition 1993; 1463-1484.

  1147. Kaiser B, Potter D, Bryant R, et al. Acid-base changes and acetate metabolism during routine and high-efficiency hemodialysis in children. Kidney Int 1981;19:70-79.

  1148. Kaiser JP, Oppermann M, Gotze O et al. Significant reduction of factor D and immunosuppressive complement fragment Ba by haemofiltration. Blood Purif 1995; 13: 314–321 (B)

  1149. Kaizu Y, Kimura M, Yoneyama T et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93–100 (B)

  1150. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G- and N-G,N9-G-dimethyl-arginine, N-epsilonmono-, di-, and trimethyllysine, and glucosylgalact. J Biol Chem 1970; 245: 5751–5758 (B)

  1151. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995

  1152. Kalman PG, Lindsay TF, Clarke K, Sniderman KW, Vanderburgh L. Management of upper extremity central venous obstruction using interventional radiology. Ann Vasc Surg 1998; 12: 202–206

  1153. Kamen R. Impaired development of oral-motor functions required for normal oral feeding as a consequence of tube feeding during infancy. Adv Perit Dial 1990;6:276-278.

  1154. Kandoussi AM, Hugue V, Parra HJ et al. Apolipoprotein AI and apolipoprotein B containing particle analysis in normolipidemic hemodialyzed patients: evidence of free apolipoprotein E. Am J Nephrol 1996; 16: 287–292 (B)

  1155. Kang SW, Lee SW, Lee IH, Kim BS, Choi KH, Lee HY, Han DS: Impact of metabolic acidosis on serum albumin and other nutritional parameters in long-term CAPD patients. Adv Perit Dial 13:249-252, 1997

  1156. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs 1997; 54 [Suppl 3]: 32–40 (C)

  1157. Kaplan AA, Halley SE, Lapkin RA, Graeber CW: Dialysate protein losses with bleach processed polysulphone dialyzers. Kidney Int 47:573-578, 1995

  1158. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. A prospective study of infections in hemodialysis patients: patient hygiene and other risk factors for infection. Infect Control Hosp Epidemiol 1988; 9: 534–541 (A)

  1159. Kaplowitz LG, Comstock JA, Landwehr DM, Dalton HP, Mayhall CG. Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. J Clin Microbiol 1988; 26: 1257–1262 (B)

  1160. Karalliedde L: Animal toxins. Br J Anaesthesia 1995; 74: 319-327.

  1161. Kario K, Matsuo T, Kobayashi H et al. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost 1995; 74: 1020–1024 (B)

  1162. Kasiske BL, Snyder JJ, Matas MD, at al. Pre-emptive kidney transplantation: The advantage and the advantaged. J Am Soc Nephrol 2002;13:1358-6

  1163. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 32: S142–S156 (C)

  1164. Kates DM, Haas L, Brunzell J, Sherrard DJ. Risk factors for cardiovascular disease in end-stage renal failure patients: A 21 year study. J Am Soc Nephrol 1995; 6: 540 (Abstract) (B)

  1165. Katoh S, Terashima S, Nakahara Y et al. Hypersensitivity to heparin, a case report. Nippon Jinzo Gakkai Shi Jap J Nephrol 1993; 35: 411–414 (B)

  1166. Katsoulidou A, Paraskevis D, Kalapothaki V et al. Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis. Nephrol Dial Transplant 1999; 14: 1188–1194 (B)

  1167. Katyal A, Mahale A, Khanna R. Antibiotic prophylaxis before peritoneal dialysis catheter insertion. Adv Perit Dial 2002;18:112-115.

  1168. Kausz A, Watkins S, Hansen C, et al. Intraperitoneal erythropoietin in children on peritoneal dialysis: a study of pharmacokinetics and efficacy. Am J Kidney Dis 1999;34:651-656.

  1169. Kausz AT, Obrador GT, Pereira BJ: Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36:S39-S51, 2000 (suppl 1)

  1170. Kawagishi T, Nishizawa Y, Konishi T et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995; 48: 820–826 (B)

  1171. Kawano M, Muramoto H, Yamada M et al. Fatal cardiac beta 2-microglobulin amyloidosis in patients on long-term hemodialysis. Am J Kidney Dis 1998; 31: E4 (B)

  1172. Kay NE, Raij L. Differential effect of hemodialysis membranes on human lymphocyte natural killer function. Artif Organs 1987; 11: 165–167 (B)

  1173. Kaysen G, Chertow G, Adhikarla R, et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001;60:333-340.

  1174. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW. The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 2000; 58: 346–352 (B)

  1175. Kaysen GA. Inflammation nutritional state and outcome in end stage renal disease. Miner Electrolyte Metab 1999; 25: 242–250 (C)

  1176. Keane WF, Collins AJ. Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 1994; 24: 1010–1018 (B)

  1177. Keane WF, Shapiro FL, Raij L. Incidence and type of infections occurring in 445 chronic hemodialysis patients. ASAIO Trans 1977; 23: 41–47 (B)

  1178. Keegan HL: Scorpions of Medical Importance . University Press of Mississippi 1980; 1: 1-140.

  1179. Keller F, Seemann J, Preuschof L, Offermann G. Risk factors of system clotting in heparin-free haemodialysis. Nephrol Dial Transplant 1990; 5: 802–807 (B)

  1180. Kelley TD, Wasserman G: Editorial - The Dangers of Pet Tarantulas: Experience of the marseilles Poison Centre . J Toxicol Clin Toxicol 1998; 36: 55-56.

  1181. Kelton JG, Warkentin TE. Diagnosis of heparin-induced thrombocytopenia. Still a journey, not yet a destination. Am J Clin Pathol 1995; 104: 611–613 (B)

  1182. Kelton JG. The serological investigation of patients with autoimmune thrombocytopenia. Thromb Haemost 1995; 74: 228–233 (B)

  1183. Kent DA, Tomasson K, Coryell: Course and outcome of conversion and somatization disorders: A four-year follow-up. Psychosomatics 1995; 36: 138-144.

  1184. Kern K, Kline J, Ford MD: B-Blocker and Calcium Channel Blocker Toxicity . Emergency Medicine Clinics of North America 1994; 12: 365-390.

  1185. Kerns W, Schroeder D, Williams C: Insulin improves survival in a canine model of acute B-blocker Toxicity . Ann of Emerg Med 1997; 29: 748-757.

  1186. Kerr PB, Argiles A, Flavier JL, Canaud B, Mion CM. Comparison of haemodialysis and haemodiafiltration: a longterm longitudinal study. Kidney Int 1992; 41: 1035–1040 (B)

  1187. Kerr PG, Argiles A, Canaud B, Flavier JL, Mion CM. Accuracy of KtV estimations in high-flux haemodiafiltration using per cent reduction of urea: incorporation of urea rebound. Nephrol Dial Transplant 1993; 8: 149–153 (B)

  1188. Keshaviah P, Luehmann D. The importance of water treatment in haemodialysis and haemofiltration. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 111–131 (C)

  1189. Keshaviah P, Star RA. A new approach to dialysis quantification: an adequacy index based on solute removal. Semin Dial 1994; 7: 85–90 (C)

  1190. Keshaviah P. The solute removal index—a unified basis for comparing disparate therapies. Perit Dial Int 1995; 15: 101–104 (B)

  1191. Kessler C, Spitzer C, Stauske D et al. The apolipoprotein E and beta-fibrinogen GuA-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease. Arterioscler Thromb Vasc Biol 1997; 17: 2880–2884 (B) 106 SECTION VII. Vascular disease and risk factors

  1192. Kessler E, Ritchey NP, Castro F et al. Urea reduction ratio and urea kinetic modeling: a mathematical analysis of changing dialysis parameters. Am J Nephrol 1998; 18: 471–477 (B)

  1193. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993; 64: 95–100

  1194. Kessler M, Hoen B, Mayeux D, Hestin D, Fontenaille C. Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey. Nephron 1993; 64: 95–100 (B)

  1195. Kessler M, Netter P, Azoulay E, Mayeux D, Pere P. Dialysisassociated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. Br J Rheumatol 1992; 31: 157–162 (B)

  1196. Ketteler M, Brandenburg V, Jahnen-Dechent Wet al. Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol Dial Transplant 2005; 20: 673–677.

  1197. Kherlakian GM, Roedersheimer LR, Arbaugh JJ, Newmark KJ, King LR. Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. Am J Surg 1986; 152: 238–243

  1198. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int 2001; 59 [Suppl 78]: S9–S13 (C)

  1199. Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600 (B)

  1200. Kielstein JT, Boger RH, Bode-Boger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594–600 (B)

  1201. Killian C, Roberge R, Krenzelok E: "Cloniderm" toxicity: Another manifestation of clonidine overdose . Pediatric Emergency Care 1997; 13(5): 340-341.

  1202. Kim ST. Characteristics of protein removal in haemodiafiltration. Contrib Nephrol 1994; 108: 23–37 (B)

  1203. Kimak E, Solski J, Janicka L, Wojtysiak B, Zagojska M. Effect of dialysis membranes on lipoprotein profile of serum in haemodialysed patients. Int Urol Nephrol 1998; 30: 789–798 (B)

  1204. Kimberly K, Washburn K, Currier H, et al. Surgical technique for peritoneal dialysis catheter placement in the pediatric patient: a North American survey. Adv Perit Dial 2004;20:218-221.

  1205. Kimoto M, Whitley GS, Tsuji H, Ogawa T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem (Tokyo) 1995; 117: 237–238 (B)

  1206. Kimura K, Saika Y, Otani H et al. Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S238–S241 (B)

  1207. Kingwatanakul P, Warady B. Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. Adv Perit Dial 1997;13:280-283.

  1208. Kirk MA: Anticholinergics and antihistamines . Clinical Management of Poisoning and Drug Overdose - - Haddad, Shannon, Whinches 1998; 3rd ed: 641-649.

  1209. Kirmani N, Tuazon CU, Murray HW, Parrish AE, Sheagren JN. Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med 1978; 138: 1657–1659 (B)

  1210. Kirubakaran V, Faiman MD, Liskow B: Plasma Measurements of Disulfiram and its Metabolites in a Case of Severe Disulfiram-Ethanol Reaction . Psychiatr J Univ Ottawa 1986; 11(3): 166-168.

  1211. Kitchens CS, Van Mierop LHS: Envenomation by the eastern coral snake (Micrurus fulvius fulvius): a study of 39 victims . JAMA 1987; 258(12): 1615-1618.

  1212. Kizer K: Marine envenomations . J Toxicolo Clin Toxicol 1984; 212: 527-555.

  1213. Klaber R: Phyto-photo-dermatitis . Brit J Dermatol 1943; 54: 193-211.

  1214. Klahr S, Breyer JA, Beck GJ, et al: Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5:2037-2047, 1995

  1215. Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006;21:151-159.

  1216. Kline JA, Tomaszewski C, Schroeder JD: Hyperinsulinemic-Euglycemic Treatment Improves Survival During Severe Verapamil Toxicity (abstract) . Ann Emerg Med 1993; 22: 895.

  1217. Klinkmann H, Buscaroli A, Stefoni S. b2-Microglobulin and low-flux synthetic dialyzers. Artif Organs 1998; 22: 585–590 (B)

  1218. Kloppenburg WD, Stegeman CA, Hooyschuur M et al. Assessing dialysis adequacy and dietary intake in the individual haemodialysis patient. Kidney Int 1999; 55: 1961–1969 (B)

  1219. Ko RJ: Adulterants in Asian patent medicine (letter) . N Eng J Med 1998; 339: 847.

  1220. Koch M, Kutkuhn B, Grabensee B, Ritz E. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 2603– 2611 (B)

  1221. Koch M, Kutkuhn B, Trenkwalder E et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889–1898 (B)

  1222. Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: 1113–1117 (B)

  1223. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101 (B)

  1224. Koda Y, Nishi S, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome SECTION II. Haemodialysis adequacy 29 and mortality of haemodialysis patients. Kidney Int 1997; 52: 1096–1101 (B)

  1225. Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S251–S253 (B)

  1226. Koda Y, Nishi SI, Miyazaki S et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997; 52: 1096–1101 (B)

  1227. Koenig P, Vogel W, Umlauft F et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994; 45: 1507–1509 (B)

  1228. Kohaut E, Alexander S. Ultrafiltration in the young patient on CAPD. In: Moncrief J, Popovich R, eds. CAPD update. New York: Masson, 1981:221-226.

  1229. Kohaut E, Waldo F, Benfield M. The effect of changes in dialysate volume on glucose and urea equilibration. Perit Dial Int 1994;14:236-239.

  1230. Kohaut E. Continuous ambulatory peritoneal dialysis: a preliminary pediatric experience. Am J Dis Child 1981;135:270-271.

  1231. Kohaut E. Effects of dialysate volume on ultrafiltration in young patients treated with CAPD. Int J Pediatr Nephrol 1986;7:13-16.

  1232. Kolb G, Fischer W, Seitz R et al. Hemodialysis and blood coagulation: the effect of hemodialysis on coagulation factor XIII and thrombin-antithrombin III complex. Nephron 1991; 58: 106–108 (B)

  1233. Kollef MH: Labetalol overdose successfully treated with amrinone and alpha-adrenergic receptor agonists . Chest 1994; 105: 626-627.

  1234. Kolmos HJ. Bacterial contamination of the blood compartment originating from the dialysate in haemodialysers. J Hosp Infect 1984; 5: 70–75 (B)

  1235. Konner K, Hulbert-Shearon TE, Roys EC, Port FK. Tailoring the initial vascular access for dialysis patients. Kidney Int 2002; 62: 329–338

  1236. Konner K. Venous preservation. Blood Purif 2002; 19: 115

  1237. Kooistra MP, Vos J, Koomans HA, Vos PF. Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998; 13: 2853–2860 (B)

  1238. Kooman JP, Deutz NE, Zijlmans P, van dA, Gerlag PG, van HP, Leunissen KM: The influence of bicarbonate supplementation on plasma levels of branched-chain amino acids in haemodialysis patients with metabolic acidosis. Nephrol Dial Transplant 12:2397-2401, 1997

  1239. Kopanati S, Baum M. Peritoneal protein losses in children with steriod-resistant nephrotic syndrome on continuous-cycler peritoneal dialysis. Pediatr Nephrol 2006;21:1013-1019.

  1240. Koppel C, Ibe K, Tenczer J: Clinical symptomatology of diphenhydramine overdose: An evaluation of 136 cases in 1982 to 1985 . J Toxicol Clin Toxicol 1987; 25: 53-70.

  1241. Kopple JD, Bernard D, Messana J, Swartz R, Bergstrom J, Lindholm B, Lim V, Brunori G, Leiserowitz M, Bier DM, Stegink L, Martis L, Algrim Boyle C, Serkes K, Vonesh E, Jones M: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47:1148-1157, 1995

  1242. Kopple JD, Blumenkrantz MJ, Jones MR, Moran JK, Coburn JW: Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 36:395-402, 1982

  1243. Kopple JD, Gao XL, Qing DP: Dietary protein, urea nitrogen appearance and total nitrogen appearance in chronic renal failure and CAPD patients. Kidney Int 52:486-494, 1997

  1244. Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS: Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study. Kidney Int 52:778-791, 1997

  1245. Kopple JD, Shinaberger JH, Coburn JW, Sorensen MK, Rubini ME: Optimal dietary protein treatment during chronic hemodialysis. ASAIO Trans 15:302-308, 1969

  1246. Kopple JD, Swendseid ME, Shinaberger JH, Umezawa CY: The free and bound amino acids removed by hemodialysis. ASAIO Trans 19:309-313, 1973

  1247. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weightfor-height relationships predict mortality in maintenance haemodialysis patients. Kidney Int 1999; 56: 1136–1148 (B)

  1248. Kopple JD, Zhu X, Lew NL, Lowrie EG. Body weight-forheight relationships predict mortality in maintenance hemodialysis patients. Kidney Int 1999; 56: 1136–1148 (B)

  1249. Kopple JD, Zhu X, Lew NL, Lowrie EG: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int 56:1136-1148, 1999

  1250. Kopple JD: Dietary protein and energy requirements in ESRD patients. Am J Kidney Dis 32:S97-104, 1998

  1251. Koury SI, Stone CK, Thomas SH: Amrinone as an Antidote in Experimental Verapamil Overdose . Acad Emerg Med 1996; 3: 762-767.

  1252. Koutsikos D, Fourtounas C, Kapetanaki A et al. A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis. Int J Artif Organs 1996; 19: 467–471 (B)

  1253. Kovalik EC, Raymond JR, Albers FJ et al. A clustering of epidural abscesses in chronic hemodialysis patients: risks of salvaging access catheters in cases of infection. J Am Soc Nephrol 1996; 7: 2264–2267 (B)

  1254. Krause I, Shamir R, Davidovits M, et al. Intradialytic parenteral nutrition in malnourished children treated with hemodialysis. J Ren Nutr 2002;12:55-59.

  1255. Krause RS: Immune system disorders, hypersensitivity . Emergency Medicine, The Core Curriculum 1998; 417-422.

  1256. Krauss JK, Mohadjer M, Wakhloo AK: Dystonia and Akinesia due to Pallidoputaminal Lesions after Disulfiram Intoxication . Movement Disorders 1991; 6 (2): 166-170.

  1257. Krenzelok EP, Jacobsen TD, Aronis JM: Plant exposures: a state profile of the most common species . Vet Human Toxicol 1996; 38 (4): 289-98.

  1258. Kriley M, Warady B. Vitamin status of pediatric patients recieving long-term peritoneal dialysis. Am J Clin Nutr 1991;53:1476-1479.

  1259. Kroes AC, van Bommel EF, Kluytmans JA, Weimar W. Hepatitis B and hemodialysis: the impact of universal precautions in preventing the transmission of bloodborne viruses. Infect Control Hosp Epidemiol 1998; 19: 508–510 (B)

  1260. Kronenberg F, Kathrein H, Konig P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Aterioscler Thromb 1994; 14: 1405–1411 (B)

  1261. Kronenberg F, Konig P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol 1995; 43: 399–404 (B)

  1262. Kronenberg F, Konig P, Neyer U et al. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study. Thromb Haemost 1995; 74: 1025–1028 (B)

  1263. Kronenberg F, Konig P, Neyer U et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6: 110–120 (B)

  1264. Kronenberg F, Kronenberg MF, Kiechl S et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck study. Circulation 1999; 100: 1154–1160 (B)

  1265. Kronenberg F, Neyer U, Lhotta K et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 1999; 10: 1027–1036 (B)

  1266. Kronenberg F, Trenkwalder E, Sturm W et al. LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients. Clin Genet 1997; 52: 377– 386 (B)

  1267. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis 1996; 27: 1–25 (C)

  1268. Ku Y, et al. Clinical pilot study on high-dose intraarterial chemotherapy with di­rect hemoperfusion under hepatic venous isolation in patients with advanced hepa-tocellular carcinoma. Surgery 1995;117:510-519.

  1269. Ku¨ chle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996; 16: 484–488 (A)

  1270. Kubatiev A, Rudko I, Ermolenko V. Complement activation and neutrophil aggregation changes during haemodialysis. Int J Clin Pharmacol Res 1993; 13: 293–299 (B)

  1271. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL: Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 272:205-211, 1994

  1272. Kulig K. Initial management of ingestions of toxic substances. N Engl J Med 1992;326:1677-1681.

  1273. Kumano K, Yokota S, Nanbu M, Sakai T. Do cytokineinducing substances penetrate through dialysis membranes and stimulate monocytes? Kidney Int Suppl 1993; 41:S205–S208 (B)

  1274. Kunkel DB, Connor DA: Coprine-Containing Mushrooms . Spoerke's and Rumack's Handbook of Mushroom Poisoning: Diagnosis and Treatment, 1994; pp. 303-307.

  1275. Kunkel DB, Kulig K, Marcus S: Hydrocarbons . Poisindex 1997;.

  1276. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77:176-185, 1997

  1277. Kushner RF: Body weight and mortality. Nutr Rev 51:127-136, 1993

  1278. Kuwahara T, Markert M, Wauters JP. Proteins adsorbed on hemodialysis membranes modulate neutrophil activation. Artif Organs 1989; 13: 427–431 (B)

  1279. Labriola L, Wallemacq P, Gulbis B et al. The impact of the assay for measuring albumin on corrected (‘adjusted’) calcium concentrations. Nephrol Dial Transplant 2009; 24: 1834–1838.

  1280. LaClair RE, Hellman RN, Karp SL et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45: 1026–1033.

  1281. Lacour B, Roullet JB, Beyne P et al. Comparison of several atherogenicity indices by the analysis of serum lipoprotein composition in patients with chronic renal failure with or without haemodialysis, and in renal transplant patients. J Clin Chem Clin Biochem 1985; 23: 805–810 (B)

  1282. Lacson E Jr, Ofsthun N, Lazarus JM: Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis 41:111-124, 2003

  1283. Lai KN, Ho K, Li M, Szeto CC. Use of single dose lowmolecular-weight heparin in long hemodialysis. Int J Artif Organs 1998; 21: 196–200 (B)

  1284. Lai KN, Wang AY, Ho K et al. Use of low-dose low molecular weight heparin in hemodialysis. Am J Kidney Dis 1996; 28: 721–726 (B)

  1285. Landwehr P, Tschammler A, Schaefer RM, Lackner K. The value of color-coded duplex sonography of a dialysis shunt. Rofo Fortschr Geb Ro.ntgenstr Neuen Bildgeb Verfahr 1990; 153: 185–191

  1286. Lane AS, Woodward A, Goldman M: Massive propranolol overdose poorly responsive to pharmacologic therapy: use of the intr-aortic ballon pump . Ann Emerg Med 1987; 16: 1381-1383.

  1287. Lane DA, Flynn A, Ireland H, Anastassiades E, Curtis JR. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure. Haemostasis 1986; 16 [Suppl 2]: 38–47 (B)

  1288. Lane RP, Crosskey RW: Medical insects and arachnids . 1993;.

  1289. Lange WR: Pufferfish poisoning. Am Fam Physician 1990; 42: 1029-1033.

  1290. Langemeijer JJ, deWildt DJ, deGroot G: Centrally induced respiratory arrest: a main cause of death in beta-adrenocepor antagonist intoxication . Hum Toxicol 1986; 5: 65.

  1291. Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968; 279: 856–858 (C)

  1292. Langley RL, Morrow WE: Deaths resulting from animal attacks in the United States . Wild Environ Med 1997; 8: 8-16.

  1293. Lapeyraque A, Haddad E, Andre J, et al. Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis. Am J Kidney Dis 2003;42:E3-E9.

  1294. Laplane D, Attal N, Sauron B: Lesions of basal ganglia due to disulfiram neurotoxicity . J Neuro Neurosurg Psychiatry 1992; 55: 925-929.

  1295. Lappe JM, Travers-Gustafson D, Davies KM et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85: 1586–1591.

  1296. Lapuz M, Avram MM, Lustig A et al. Fall of cholesterol with time on dialysis: impact on atherogenicity. ASAIO Trans 1989; 35: 258–260 (B)

  1297. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J Am Med Assoc 1999; 282: 2340–2346 (A)

  1298. LaRosa JC, Hunninghake D, Bush D et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990; 81: 1721–1733 (C)

  1299. Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg 1989; 9: 677–681 (B)

  1300. Laurent G, Charra B. The results of an 8 h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 1998; 13 [Suppl 6]: 125–131 (B)

  1301. Lawrence WT, Giannopoulos A, Hansen A: Pitviper bites: Rational management in locales in which copperheads and cottomouths predominate . Ann Plast Surg 1996; 36: 276-85.

  1302. Lazarus JM, Owen WF. Role of bioincompatibility in dialysis morbidity and mortality. Am J Kidney Dis 1994; 24: 1019–1032 (B)

  1303. Le Blanche AF, Tassart M, Deux JF, Rossert J, Bigot JM, Boudghene F. Gadolinium-enhanced digital subtraction angiography of hemodialysis fistulas: a diagnostic and therapeutic approach. AJR Am J Roentgenol 2002; 179: 1023–1028

  1304. Le Pogam S, Le Chapois D, Christen R et al. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998; 36: 3040–3043 (B) SECTION VI. Haemodialysis-associated infection 85

  1305. Leads from the MMWR. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood-borne pathogens in health-care settings. J Am Med Assoc 1988; 260: 462–465 (C)

  1306. Leblanc M, Charbonneau R, Lalumiere G, Cartier P, Deziel C.Postdialysis urea rebound: determinants and influence on dialysis delivery in chronic haemodialysis patients. Am J Kidney Dis 1996; 27: 253–261 (B)

  1307. Leblanc M, et al. Lithium poisoning treated by high-performance arteriovenous and venovenous hemodiafiltration. Am J Kidney Dis 1996;27:365—372.

  1308. Leblanc M, Roy LF, Legault L et al. Severe skin necrosis associated with heparin in hemodialysis. Nephron 1994; 68: 133–137 (B)

  1309. Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23: 37–43 (C)

  1310. Ledebo I. On-line haemodiafiltration: technique and therapy.Adv Ren Replace Ther 1999; 6: 195–208 (C)

  1311. Ledermann S, Scanes M, Fernando O, et al. Long-term outcome of peritoneal dialysis in infants. J Pediatr 2000;136:24-29.

  1312. Leehey D, Gantt C, Lim V. Heparin-induced hypoaldosteronism. Report of a case. J AmMed Assoc 1981; 246: 2189–2190 (B)

  1313. Leehey DJ, Kanak RJ, Messmore HL et al. Heparin-associated thrombocytopenia in maintenance hemodialysis patients. Int J Artif Organs 1987; 10: 390–392 (B)

  1314. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE et al. Noncompliance in haemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 32: 139–145 (B)

  1315. Leijn E, Monnens L, Cornelissen E. Intravenous iron supplementation in children on hemodialysis. J Nephrol 2004;17:423-426.

  1316. Leiken JB, Palouchek FP: Poisoning and toxicology handbook 1996-1997 ..

  1317. Leitch R, Ouwendyk M, Ferguson E et al. Nursing issues related to patient selection, vascular access, and education in quotidian hemodialysis. Am J Kidney Dis 2003; 42 [Supp 1]: S56–S60

  1318. Leitienne P, Trzeciak MC, Adeleine P et al. Comparison of hemostasis with two high-flux hemocompatible dialysis membranes. Int J Artif Organs 1991; 14: 227–233 (A)

  1319. Lemke HD, Heidland A, Schaefer RM. Hypersensitivity reactions during haemodialysis: role of complement fragments and ethylene oxide antibodies. Nephrol Dial Transplant 1990; 5: 264–269 (B)

  1320. Lemson MS, Leunissen KM, Tordoir JH. Does pre-operative duplex examination improve patency rates of Brescia-Cimino fistulas? Nephrol Dial Transpl 1998; 13: 1360–1361

  1321. Leong ASY, Disney APS, Gove DW. Spallation and migration of silicone from blood-pump tubing in patients on hemodialysis. N Engl J Med 1982; 306: 135–140 (B)

  1322. Lerner G, Kale A, Warady B, et al. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 2002;17:933-937.

  1323. Lerner G, Warady B, Sullivan E, et al. Chronic dialysis in children and adolescents. The 1996 annual report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1999;13:404-417.

  1324. Lesaffer G, De Smet R, Lameire N et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000;15:50–57 (B)

  1325. Leu JG, Liou HH, Wu SC, Yang WC, Huang TP. Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis. J Form Med Assoc 1998; 97: 49–54 (B)

  1326. Level C, Chauveau P, Delmas Y et al. Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 2001; 16: 980–986 (B)

  1327. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin

  1328. Levin A, Djurdjev O, Thompson C, et al: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 46:799-811, 2005

  1329. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36:S24-S30, 2000 (suppl 1)

  1330. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999

  1331. Levin A: How should anaemia be managed in pre-dialysis patients? Nephrol Dial Transplant 14:S66-S74, 1999 (suppl 2)

  1332. Levin J. The Limulus amebocyte lysate test: perspectives and problems. Prog Сlin Biol Res 1987; 231: 1–23 (C)

  1333. Levin L, Balfe J, Geary D, et al. Gastrostomy tube feeding in children on CAPD. Perit Dial Bull 1987;7:223-226.

  1334. Levy M, Balfe J. Optimal aproach to the prevention and treaetment of peritonitis in children undergoing continuous ambulatory and continuous cycling peritoneal dialysis. Semin Dial 1994;7:442-449.

  1335. Lewis LM, Flechtner TW, Kerkay J, Pearson KH, Nakamoto S. Bis(2-ethylhexyl)phthalate concentrations in the serum of hemodialysis patients. Clin Chem 1978; 24: 741–746 (B)

  1336. Leypoldt JK, Cheung AK, Agodoa LY et al. Hemodialyzer mass transfer-area coefficients for urea increase at high dialysate flow rates. The Haemodialysis (HEMO) Study. Kidney Int 1997; 51: 2013–2017 (B)

  1337. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic haemodialysis patient survival. Am J Kidney Dis 1999; 33: 349–355 (B)

  1338. Leypoldt JK, Cheung AK, Carroll CE et al. Effect of dialysis membranes and middle molecule removal on chronic hemodialysis patient survival. Am J Kidney Dis 1999; 33: 349–355 (B)

  1339. Leypoldt JK, Cheung AK, Deeter RB. Rebound kinetics of beta 2-microglobulin after haemodialysis. Kidney Int 1999; 56: 1571–1577 (B)

  1340. Leypoldt JK, Cheung AK, Deeter RB. Single compartment models for evaluating beta 2-microglobulin clearance during haemodialysis. ASAIO J 1997; 43: 904–909 (B)

  1341. Lhotta K, Wu¨ rzner R, Kronenberg F, Oppermann M, Ko¨ nig P.Rapid activation of the complement system by cuprophane depends on complement component C4. Kidney Int 1998; 53: 1044–1051 (B)

  1342. Li P, Chow K, Wong T, et al. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 2003;139:105-112.

  1343. Lian JD, Cheng CH, Chang YL, Hsiong CH, Lee CJ. Clinical experience and model analysis on beta-2-microglobulin kinetics in high-flux hemodialysis. Artif Organs 1993; 17: 758–763 (B)

  1344. Likes K, Banner Jr W, Chaves M: Centruroides exilicauda envenomation in Arizona . The Western Journal of Medicine 1984; 141: 634-63.

  1345. Lim BL: Venomous land snakes of Malaysia . Snakes of Medical Importance (Asia-Pacific) Region 1990; 387-417.

  1346. Lim J, Gasson C, Kaji DM. Urea inhibits NaK2Cl cotransport in human erythrocytes. J Clin Invest 1995; 96: 2126–2132 (B)

  1347. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680–2687 (B)

  1348. Lim VS, Bier DM, Flanigan MJ, Sum-Ping ST. The effect of hemodialysis on protein metabolism. A leucine kinetic study. J Clin Invest 1993; 91: 2429–2436 (B)

  1349. Lim VS, Fangman J, Flanigan MJ, DeGowin RL, Abels RT: Effect of recombinant human erythropoietin on renal function in humans. Kidney Int 37:131-136, 1990

  1350. Lin JL, Kou MT, Leu ML: Effect of long-term low-dose aluminum-containing agents on hemoglobin synthesis in patients with chronic renal insufficiency. Nephron 74:33-38, 1996

  1351. Lin YF, Chang DM, Shaio MF et al. Cytokine production during hemodialysis: effects of dialytic membrane and complement activation. Am J Nephrol 1996; 16: 293–299 (B)

  1352. Lin YF, Shieh SD, Diang LK, Lin SH, Chyr SH, Li BL, Lu KC: Influence of rapid correction of metabolic acidosis on serum osteocalcin level in chronic renal failure. ASAIO Journal 40:M440-M444, 1994

  1353. Lincoff G, Mitchell DH: Chapter . Toxic and Hallucinogenic Mushroom Poisoning: A Handbook for Physicians and Mushr 1977;.

  1354. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to longterm mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 1139–1147 (A)

  1355. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697–701 (B)

  1356. Lindsay RM, Spanner E, Heidenheim P, Kortas C, Blake PG. PCR, KtuV and membrane. Kidney Int 1993; 43 [Suppl 41]: S268–S273 (C)

  1357. Link A, Buttner K. Steam sterilization: a suitable alternative? Med Device Technol 1992; 3: 45–47 (C)

  1358. Link MS, Foote CB, Sloan SB: Torsade de pointes and prolonged QT interval from surreptitious use of sotalol: use of drug levels in diagnosis . Chest 1997; 112: 556-7.

  1359. Linnemann CC Jr, First MR, Schiffman G. Response to pneumococcal vaccine in renal transplant and hemodialysis patients. Arch Intern Med 1981; 141: 1637–1640 (B)

  1360. Linnemann CC Jr, First MR, Schiffman G. Revaccination of renal transplant and hemodialysis recipients with pneumococcal vaccine. Arch Intern Med 1986; 146: 1554–1556 (B)

  1361. Linnenweber S, Lonnemann G. Pyrogen retention by the Asahi APS-650 polysulfone dialyzer during in vitro dialysis with whole human donor blood. ASAIO J 2000; 46: 444–447 (B)

  1362. Linton A.S., Luke R. G., Briggs J.D. Methods of forsed diuresis and its application in barbiturate poisoning//Lancet. — 1967. — Vol. 2. — P. 377-380.

  1363. Lioy PJ, Yiin LM, Adgate J: the effectiveness of a home cleaning intervention strategy in reducing potential dust and lead exposures . J Expo Anal Environ Epidemiol 1998; 8: 17-35.

  1364. LitLitovitz TL, Smilkstein M, Felberg L: 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . Am J Emerg Med 1997; 15: 447-500.

  1365. Litovitz T, Bailey K, Schmitz B: Annual report of the American Association of Poison Control Centers National Data Collection Systems . American Journal of Emergency Medicine 1990; 9: 479.

  1366. Litovitz TL, Clark L, Soloway R: 1993 Annual Report of the American Poison Control Centers Toxic Exposure Surveillance Systems . Am J EM 1994; 12: 546-584..

  1367. Litovitz TL, et al. 1998 annual report of the American Association of Poison Control Centers toxic exposure surveillance system. Am J Emerg Med 1999; 17:435-487.

  1368. Litovitz TL, et. al: 1996 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . The American Journal of Emergency Medicine Sept. 1997; volume 15, number 5: pp. 447-500.

  1369. Litovitz TL, Felberg L, Soloway R: 1994 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . Am J EM 1995; 13: 551-597.

  1370. Litovitz TL, Felberg L, White S: 1995 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . Am J EM 1996; 14: 487-537.

  1371. Litovitz TL, Smilkstein M, et al: 1996 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . The American Journal of Emergency Medicine 1997; 15: 447-500.

  1372. Litovitz TL, Smilkstein M, et al: 1996 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . The American Journal of Emergency Medicine 1997; 15: 447-500..

  1373. Litovitz TL, Smilkstein M, Felberg L et al.: 1996 Annual report of the American association of poison control centers toxic exposure surveillance system . Am J Emerg Med 1997; 15: 447-500.

  1374. Litovitz TL, Smilkstein M, Felberg L: 1996 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . Am J EM 1997; 15: 447-500.

  1375. Litovitz TL, Smilkstein M, Felberg L: 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System . Am J Emerg Med 1997; 15: 447-500.

  1376. Litovitz TL, White D: Levothyroxine Ingestion in Children: An Analysis of 78 Cases . American Journal of Emergency Medicine 1985; 4: 297-300.

  1377. Ljungberg B, Blomback M, Johnsson H, Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987; 27: 31–35 (B)

  1378. Ljungberg B, Jacobson SH, Lins LE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992; 38: 97–100 (B)

  1379. Ljunggren B: Severe phototoxic burn following celery ingestion . Arch Dermatol 1990; 126: 1334-1336.

  1380. Lloyd GG: Acute behaviour disturbances . Journal of Neurology, Neurosurgery, and Psychiatry 1993; 56: 1149-1156.

  1381. Lo W, Bargman J, Burkart J, et al. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int 2006;26:520-522.

  1382. Lo W, Lui S, Chan T, et al. Minimal and optimal peritoneal Kt/V targets: results of an anuric peritoneal dialysis patient's survival analysis. Kidney Int 2005;67:2032-2038.

  1383. Locatelli F, Aljama P, Barany P, et al: Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19:Sii1-Sii47, 2004 (suppl 2)

  1384. Locatelli F, Buoncristiani U, Canaud B, et al. Dialysis dose and frequency. Nephrol Dial Transplant 2005;20:285-296.

  1385. Locatelli F, Conte F, Marcelli D: The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity—The experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 13:1642-1644, 1998

  1386. Locatelli F, Marcelli D, Conte F et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. Kidney Int 1999; 55: 286–293 (B)

  1387. Locatelli F, Marcelli D, Conte F et al. Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto. Kidney Int 1999; 55: 286–293 (B)

  1388. Locatelli F, Mastrangelo F, Raedelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. Kidney Int 1996; 50: 1293–1302 (A)

  1389. Locatelli F, Mastrangelo F, Redaelli B et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. Kidney Int 1996; 50: 1293–1302 (B)

  1390. Lockhart ME, Robbin ML, Allon M. Preoperative sonographic radial artery evaluation and correlation with subsequent radiocephalic fistula outcome. J Ultras Med 2004; 23: 161–168

  1391. Lofberg E, Wernerman J, Anderstam B, Bergstrom J: Correction of acidosis in dialysis patients increases branched-chain and total essential amino acid levels in muscle. Clin Nephrol 48:230-237, 1997

  1392. Longfield RN, Wortham WG, Fletcher LL, Nauscheutz WF. Clustered bacteremias in a hemodialysis unit: crosscontamination of blood tubing from ultrafiltrate waste. Infect Control Hosp Epidemiol 1992; 13: 160–164 (B)

  1393. Lonnemann G, Haubitz M, Schindler R. Haemodialysisassociated induction of cytokines. Blood Purif 1990; 8: 214–222(B)

  1394. Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies on the ability of haemodialysis membranes to induce, bind, and clear human interleukin-1. J Lab Clin Med 1988; 112:76–86 (B)

  1395. Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies on the ability of hemodialysis membranes to induce, bind, and clear human interleukin-1. J Lab Clin Med 1988; 112: 76–86 (B)

  1396. Lonnemann G, Krautzig S, Koch KM. Quality of water and dialysate in haemodialysis. Nephrol Dial Transplant 1996;11: 946–949 (C)

  1397. Lonnemann G, Schindler R, Lufft V, Mahiout A, Shaldon S,Koch KM. The role of plasma coating on the permeation of cytokine-inducing substances through dialyser membranes. Nephrol Dial Transplant 1995; 10: 207–211 (B)

  1398. Lonnemann G. Chronic inflammation in haemodialysis:the role of contaminated dialysate. Blood Purif 2000; 18:214–223 (C)

  1399. Lonnemann G. Dialysate bacteriological quality and the permeability of dialyzer membranes to pyrogens. Kidney Int Suppl 1993; 41: S195–S200 (C)

  1400. Lonnemann G. Should ultra-pure dialysate be mandatory? Nephrol Dial Transplant 2000; 15 [Suppl 1]: 55–59 (C)

  1401. Lonnemann G. The quality of dialysate: an integrated approach. Kidney Int 2000; 58 [Suppl 76]: S112–S119 (C)

  1402. Looareesuwan S, Viravan C, Warrell DA: Factors contributing to fatal snake bite in rural tropics: Analysis of 46 cases in Thailand . Trans Roy Soc Trop Med Hyg 1988; 82: 930-934.

  1403. Lorentz WB, Hamilton RW, Disher B, et al. Home peritoneal dialysis during infancy. Clin Nephrol 1981;15(4):194-197.

  1404. Lornoy W, Becaus I, Billiouw JM, Sierens L, Van Malderen P.Remarkable removal of beta 2-microglobulin by on-line haemodiafiltration. Am J Nephrol 1998; 18: 105–108 (B)

  1405. Loughrey CM, Young IS, Lightbody JH et al. Oxidative stress in haemodialysis. Q J Med 1994; 87: 679–683 (B)

  1406. Loughrey CM, Young IS, Lightbody JH et al. Oxidative stress in haemodialysis. Q J Med 1994; 87: 679–683 (B)

  1407. Love JN, Litovitz TL, Howell JM: Characterization of fatal beta blocker ingestion: a review of the american association of poison control centers data form 1985 to 1995 . Clinical Tox 1997; 35: 353-359.

  1408. Love JN: Beta blocker toxicity after overdose: when do symptoms develop in adults? . J Emerg Med 1994; 12: 799-802.

  1409. Love JN: Beta-blocker toxicity: a clinical diagnosis . Am J Emerg Med 1994; 12: 356-357.

  1410. Low BW, Corfield BWR: Acetylcholine receptor alpha-toxin binding site - theoretical and model studies . Asia Proc J Pharmacol 1987; 2: 115-127.

  1411. Low CL, Bailie G, Morgan S, Eisele G. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Clin Nephrol 1996; 45: 120–124 (A)

  1412. Lowenthal D, Matzek K, MacGregor T: Clinical pharmacokinetics of clonidine . Clinical Pharmacokinetics 1988; 14: 287-310.

  1413. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. Br Med J 1998; 316: 894–898 (A)

  1414. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. The urea [clearance3dialysis time] product (Kt) as an outcomebased measure of haemodialysis dose. Kidney Int 1999; 56: 729–737 (B)

  1415. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the haemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981; 305: 1176–1181 (B)

  1416. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–482 (B)

  1417. Lowrie EG, Lew NL. The urea reducton ratio (URR): a simple method for evaluating haemodialysis treatment. Contemp Dial Nephrol 1991; 12: 11–20 (C)

  1418. Lowrie EG, Zhu X, Lew NL. Primary associates of mortality among dialysis patients: trends and reassessment of KtV and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis 1998; 32: S16–S31 (C)

  1419. Lowrie EG, Zhu X, Lew NL: Primary associates of mortality among dialysis patients: Trends and reassessment of Kt/V and urea reduction ratio as outcome-based measures of dialysis dose. Am J Kidney Dis 32:S16-S31, 1998 (suppl)

  1420. Lowrie EG. Acute-phase inflammatory process contributes tomalnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 1998; 32: S105–S112 (C)

  1421. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339: 520–532 (C)

  1422. Lu KC, Shieh SD, Li BL, Chu P, Jan SY, Lin YF: Rapid correction of metabolic acidosis in chronic renal failure: Effect on parathyroid hormone activity. Nephron 67:419-424, 1994

  1423. Lucchi L, Banni S, Botti B et al. Conjugated diene fatty acids in patients with chronic renal failure: evidence of increased lipid peroxidation? Nephron 1993; 65: 401–409 (B)

  1424. Lucchi L, Bergamini S, Botti B et al. Influence of different hemodialysis membranes on red blood cell susceptibility to oxidative stress. Artif Organs 2000; 24: 1–6 (B)

  1425. Lucchi L, Bonucchi D, Acerbi MA et al. Improved biocompatibility by modified cellulosic membranes: the case of hemophan. Artif Organs 1989; 13: 417–421 (B)

  1426. Ludlow MK. Heparin-free dialysis. ANNA J 1989; 16: 295–298 (B)

  1427. Lumley J, Williamson J, Fenner P: Fatal envenomation by Chironex fleckeri, the north Australian box jellyfish: the continuing search for lethal mechanism . Med J Aust 1988; 148: 527-534.

  1428. Lundin AP, Adler AJ, Berlyne GM, Friedman EA. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979; 67: 597–602 (B)

  1429. Lutes R, Perlmutter J, Holley J, et al. Loss of residual renal function in patients on peritoneal dialysis. Adv Perit Dial 1993;9:165-168.

  1430. Lynch PJ, Pinnas JL: Kissing bug bites: Triatoma species as an important cause of insect bites in the southwest . Cutis 1978; 22: 585-591.

  1431. Ma KW, Greene EL, Raij L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505–513 (B)

  1432. MacAllister RJ, Rambausek MH, Vallance P et al. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996; 11: 2449–2452 (B)

  1433. MacCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in chronic hemodialysis patients using polysulfone dialyzers. Am J Kidney Dis 1997; 29: 576–583 (B)

  1434. MacDonald MJ, Martin LG, Hughes JD, Kikeri D, Scout DC, Harker LA. Distribution and severity of stenoses in functioning arteriovenous grafts: a duplex and angiographic study. J Vasc Technol 1996; 20: 131–136

  1435. MacDonald SP, Coates PTH, Disney APS. Amyloid, advanced glycation end products, and dialysis related arthropathy. Ann Rheum Dis 1998; 57: 193–195 (C)

  1436. Mace CJ: Hysterical conversion I: A history. J of Psychiatry 1992; 161: 369-377.

  1437. MacRae JM, Ahmed A, Johnson N, Levin A, Kiaii M. Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 2005; 51: 77–81

  1438. Mactier R, et al. Role of peritoneal cavity lymphatic absorption in peritoneal dialysis. Kidney Int 1987;32:65-72.

  1439. Mactier R, Khanna R, Moore H, et al. Kinetics of peritoneal dialysis in children: role of lymphatics. Kidney Int 1988;34:82-88.

  1440. Mactier R, Van Stone J, Cox A, et al. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987;28:222-226.

  1441. Madden S, Ledermann S, Guerrero-Blanco M, et al. Cognitive and psychosocial outcome of infants dialysed in infancy. Child Care Health Dev 2003;29:55-61.

  1442. Maddux FW. Heparin-induced hyperkalemia.NCMed J 1987; 48: 75–76 (B)

  1443. Madsen RF, Nielsen B, Olsen OJ, Raaschou F. Reverse osmosis as a method of preparing dialysis water. Nephron 1970; 7: 545–558 (B)

  1444. Maduell F, Garcia-Valdecasas J, Garcia H et al. Urea reduction ratio considering urea rebound. Nephron 1998; 78: 143–147 (B)

  1445. Maduell F, Garcia-Valdecasas J, Garcia H et al. Validation of different methods to calculate KtV considering postdialysis rebound. Nephrol Dial Transplant 1997; 12: 1928–1933 (B)

  1446. Maeda K, Shinzato T, Ota T et al. Beta-2-microglobulin generation rate and clearance rate in maintenance haemodialysis patients. Nephron 1990; 56: 118–125 (B)

  1447. Maggi E, Bellazzi R, Falaschi F et al. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int 1994; 45: 876–883 (B)

  1448. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869–876 (B)

  1449. Mahajan, P, Lieh-Lai MW, Sarnaik A: Basal Ganglia Infarction in a Child With Disulfiram Poisoning . Pediatrics 1997; 99(4): 605-608.

  1450. Mahan J, Warady B. Consensus Committee. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol 2006;21:917-930.

  1451. Mahoney C, Arieff A. Uremic encephalopathies: clinical, biochemical, and experimental features. Am J Kidney Dis 1982;2:324-336.

  1452. Mai FM: "Hysteria" in Clinical Neurology. Can. J. Neurol. Sci 1995; 22: 101-110.

  1453. Mai M, Emmett M, Sheikh M, et al. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989;36:690-695.

  1454. Makita Z, Bucala R, Rayfield EJ et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519–1522 (B)

  1455. Makita Z, Radoff S, Rayfield EJ et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836–842 (B)

  1456. Malatino LS, Benedetto FA, Mallamaci F et al. Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. J Nephrol 1999; 12: 256–260 (B)

  1457. Malberti F, Surian M, Farina M et al. Effect of hemodialysis and hemodiafiltration on uremic neuropathy. Blood Purif 1991; 9: 285–295 (B)

  1458. Malchesky R, Ellis P, Nosse C, Magnusson M, Lankhorst B, Nakamoto S. Direct quantification of dialysis. Dial Transplant 1982; 11: 42–49 (B)

  1459. Malluche HH, Mawad H, Trueba D et al. Parathyroid hormone assays– evolution and revolutions in the care of dialysis patients. Clin Nephrol 2003; 59: 313–318.

  1460. Malovrh M. Native arteriovenous fistula: preoperative evaluation. Am J Kidney Dis 2002; 39: 1218–1225

  1461. Malovrh M. Non-invasive evaluation of vessels by duplex sonography prior to construction of arteriovenous fistulas for haemodialysis. Nephrol Dial Transpl 1998; 13: 125–129

  1462. Man NK, Degremont A, Darbord JC, Collet M, Vaillant P.Evidence of bacterial biofilm in tubing from hydraulic pathway of haemodialysis system. Artif Organs 1998; 22:596–600 (C)

  1463. Manns BJ, Burgess ED, Hyndman ME et al. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34: 669–677 (B) 108 SECTION VII. Vascular disease and risk factors

  1464. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE: Body weight and mortality among women. N Engl J Med 333:677-685, 1995

  1465. Man-Son-Hing M, Gage BF, Montgomery AA, et al: Preference-based antithrombotic therapy in atrial fibrillation: Implications for clinical decision making. Med Decis Making 25:548-559, 2005

  1466. Manzoni C, Di Filippo S, Corti M, Locatelli F. Ionic dialysance as a method for the on-line monitoring of delivered dialysis without blood sampling. Nephrol Dial Transplant 1996; 11: 2023–2030 (B)

  1467. Marchais SJ, Metivier F, Guerin AP, London GM. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol Dial Transplant 1999; 14: 2178–2183 (B)

  1468. Marchant A, Tielemans C, Husson C et al. Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation. Nephrol Dial Transplant 1996; 11: 657–662 (B)

  1469. Marcovina SM, Koschinsky ML. Lipoprotein(a) concentration and apolipoprotein(a) size: a synergistic role in advanced atherosclerosis? Circulation 1999; 100: 1151–1153 (B)

  1470. Mari M, Blasi R, Lamberti P: Unilateral Pallidal Lesion after Acute Disulfiram Intoxication: A Clinical and Magnetic Resonance Study . Movement Disorders 1993; 8(2): 247-249.

  1471. Marini-Bettolo GB: Present aspects of the use of plants in traditional medicine . J Ethnopharmacol 1980; 2: 183-8.

  1472. Marmion BP, Tonkin RW. Control of hepatitis in dialysis units. Br Med Bull 1972; 28: 169–179 (C)

  1473. Marr KA, Kong L, Fowler VG et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients.Kidney Int 1998; 54: 1684–1689 (B)

  1474. Marr KA, Sexton DJ, Conlon PJ et al. Catheter-related bacteremia and outcome of attempted catheter salvage in patients undergoing hemodialysis. Ann Intern Med 1997; 127: 275–280 (B)

  1475. Marsenic O, Pavlicic D, Peco-Antic A, et al. Prediction of equilibrated urea in children on chronic hemodialysis. ASAIO J 2000;46:283-287.

  1476. Marshall CP, Pearson FC, Sagona MA et al. Reactions during hemodialysis caused by allergy to ethylene oxide gas sterilization. J Allergy Clin Immunol 1985; 75: 563–567 (B)

  1477. Martin FIR, Hansen N, Warne GL: Attempted suicide by insulin overdose in insulin requiring diabetics . Med J Aust 1977; 1: 58-60.

  1478. Martin-Malo A, Carracedo J, Ramirez R et al. Effect of uremia and dialysis modality on mononuclear cell apoptosis. J Am Soc Nephrol 2000; 11: 936–942 (B)

  1479. Martin-Malo A, Castillo D, Castro M et al. Biocompatibility of dialysis membranes: a comparative study. Nephrol Dial Transplant 1991; 6 [Suppl 2]: 55–58 (B)

  1480. Martiny SS, et al. Treatment of severe digitalis intoxication with digoxin-specific antibody fragments: a clinical review. Crit Care Med 1988;16:629-635.

  1481. Mascie-Taylor BH, Widdop B, Davison AM: Camphor intoxicatiuon treated by charcoal haemoperfusion . Postgrad Med J 1981; 57: 725-726.

  1482. Massry SG, Smogorzewski M. Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uraemia. Semin Nephrol 1994; 14: 219–231 (C)

  1483. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188–198 (A)

  1484. Massy ZA. Hyperhomocyst(e)inaemia in renal failure—what are the implications? Nephrol Dial Transplant 1996; 11:2392–2393 (C)

  1485. Massy ZA. Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 2000; 15 [Suppl 5]:81–91 (C)

  1486. Massy ZA. Reversal of hyperhomocyst(e)inaemia in chronic renal failure-is folic or folinic acid the answer? Nephrol Dial Transplant 1999; 14: 2810–2812 (B)

  1487. Massy ZA: Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 15:81-91, 2000

  1488. Matsuo T, Kario K, Kodama K, Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin Thromb Hemost 1992; 18: 155–160 (B)

  1489. Matsuoka H, Itoh S, Kimoto M et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247 (B)

  1490. Matsuura JH, Rosenthal D, Clark M et al. Transposed basilica vein versus polytetrafluorethylene for brachial-axillary arteriovenous fistulas. Am J Surg 1998; 176: 219–221

  1491. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Hepatitis B vaccine: efficacy in high-risk settings, a two-year study. Intervirology 1978; 10: 196–208 (B)

  1492. Mayer JH, Herlocher JE, Parisian J: Esophageal rupture after mushroom-alcohol ingestion . New Engl J Med 1971; 285: 1323.

  1493. Mayr HU, Stec F, Mion CM. Standard methods for the microbiological assessment of electrolyte solution prepared on line for haemofiltration. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 454–460 (B)

  1494. McCabe JL: Сравнение гипертонизирующего солончака, гидрокарбоната натрия, и hyperventilation в строгой трициклической передозировке антидепрессанта в свинье . Ветеринар и Человеческая Токсикология 1993; 35: 367.

  1495. McCahill M: Somatoform and related disorders: Delivery of diagnosis as first step. American Family Physician 1995; 52(1): 193-203.

  1496. McCauley L, et al. Enhanced growth in children on peritoneal dialysis (PD): dialysis dose, nutrition, and metabolic control. Perit Dial Int 2000;20:S89.

  1497. McClellan W, Aronoff SL, Bolton WK, et al: The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20:1501-1510, 2004

  1498. McDonald A: Mushrooms and Madness . Can J Psychiatry 1980; 25: 586-92.

  1499. McDonald S, Craig J. Long-term survival of children with end-stage renal disease. N Engl J Med 2004;350:2654-2662.

  1500. McElwee NE, Veltri JC: A prospective population-based study of acute ibuprofen overdose:Complications are rare and routine-serum levels are not warranted . Ann Emerg Med 1990; 6: 143-162.

  1501. McEneny J, Loughrey CM, McNamee PT, Trimble ER, Young IS. Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997; 129: 215–220 (B)

  1502. McEvoy GK: Drug Information 1986 . 1986;.

  1503. McGoldrick J, Marx J: Marine evenomations Part 2: invertebrates . J Emerg Med 1992; 10: 71-77.

  1504. McGonigle R, Boineau F, Beckman B, et al. Erythropoietin and inhibitors of in vitro erythropoiesis in the development of anemia in children with renal disease. J Lab Clin Med 1985;105:449-458.

  1505. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437-444, 1984

  1506. McIntyre C. Update on peritoneal dialysis solutions. Kidney Int 2007;71:486-490.

  1507. McKenna A, Keating L, Vigneux A, et al. Quality of life in children with chronic kidney disease—patient and caregiver assessments. Nephrol Dial Transplant 2006;21:1899-1905.

  1508. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430, 2000

  1509. McMahon LP, McKenna MJ, Sangkabutra T, et al: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999

  1510. McNulty J. The proper sizing of ultrapure water delivery systems. Contemp ial Nephrol 1991; 12: 30–36 (B)

  1511. McPartland J, Vilgalys R, Cubeta M: Mushroom Poisoning . American Family Physician 1997; 55: 1797-1809.

  1512. McVey FK, Corke CF: Extracorporeal circulation in the management of massive propanolol overdose . Anaethesia 1991; 46: 744-746.

  1513. Mege JL, Olmer M, Purgus R et al. Haemodialysis membranes modulate chronically the production of TNF a, IL1b and IL6. Nephrol Dial Transplant 1991; 6: 868–875 (B)

  1514. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. Transplantation 2002;74(10):1377-81

  1515. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000;58:1311-7.

  1516. Meireles C, Price S, Pereira A, et al. Nutrition and chronic renal failure in rats: what is an optimal dietary protein? J Am Soc Nephrol 1999;10:2367-2373.

  1517. Melamed ML, Eustace JA, Plantinga LC et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650–1658.

  1518. Mellits D, Cheek D. The assessment of body water and fatness from infancy to adulthood. Monogr Soc Res Child Dev 1970;35:12-26.

  1519. Memoli B, Libetta C, Rampino T et al. Interleukin-6 production of uraemic haemodialysed patients: effects of different membranes. Nephrol Dial Transplant 1991; 6 [Suppl 2]: 96–98 (C)

  1520. Memoli B, Marzano L, Bisesti V, Andreucci M, Guida B. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999; 10: 2171–2176 (B)

  1521. Memoli B, Marzano L, Bisesti V, et al. Hemodialysis-related lymphomononuclear release of interleukin-12 in patients with end-stage renal disease. J Am Soc Nephrol 1999;10:2171-2176.

  1522. Memoli B, Postiglione L, Cianciaruso B et al. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000; 58: 417–424 (B)

  1523. Memoli B. Cytokine production in haemodialysis. Blood Purif 1999; 17:149-158.

  1524. Mendez AJ, Perez GO, Hsia SL. Defect in cholesteryl ester transport in serum of patients with uremia receiving maintenance hemodialysis: increased inhibitor activity for cholesteryl ester transfer. J Lab Clin Med 1988; 111: 677–683 (B)

  1525. Mendley S, Majkowski N, Schoeller D. Validation of estimates of total body water in pediatric dialysis patients by deuterium dilution. Kidney Int 2005;67:2056-2062.

  1526. Menegazzo D, Laissy JP, Durrbach A et al. Hemodialysis access fistula creation: preoperative assessment with MR venography and comparison with conventional venography. Radiology 1998; 209: 723–728

  1527. Menegazzo D, Laissy JP, Durrbach A et al. Hemodialysis access fistula creation: preoperative assessment with MR venography and comparison with conventional venography. Radiology 209; 723–728: 1998

  1528. Meptebhoe: Lethal poisoning of a child with clonidine . Sud Med Ekspert 1989; 32(2): 54-55.

  1529. Mermel LA, Farr BM, Sherertz RJ et al. Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32: 1249–1272

  1530. Mermel LA, Farr BM, Sheretz RJ, Raad II, O’Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. Clin Inf Dis 2001; 32: 1249–1272 (C)

  1531. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391–402 (C)

  1532. Messmore HL. Clinical efficacy of heparin fractions: issues and answers. Crit Rev Clin Lab Sci 1986; 23: 77–94 (B)

  1533. Mettang T, Schenk U, Thomas S et al. Low-dose intradermal vs intramuscular hepatitis B vaccination in patients with end-stage renal failure. A preliminary study. Nephron 1996; 72: 192–196 (B)

  1534. Meyers LD, Habicht JP, Johnson CL: Components of the difference in hemoglobin concentrations in blood between black and white women in the United States. Am J Epidemiol 109:539-549, 1979

  1535. Meytes D, Bogin E, Ma A, et al. Effect of parathyroid hormone on erythropoiesis. J Clin Invest 1981;67:1263-1269.

  1536. Michael M, Brewer E, Goldstein S. Blood volume monitoring to achieve target weight in pediatric hemodialysis patients. Pediatr Nephrol 2004;19:432-437.

  1537. Michelot D: Poisonings by Coprinus atramentarius . Nat Toxins 1992; 1: 73-80.

  1538. Mihmanli I, Besirli K, Kurugoglu S et al. Cephalic vein and hemodialysis fistula: surgeon’s observation versus color Doppler ultrasonographic findings. J Ultras Med 2001; 20: 217–222

  1539. Mikawa K, Maekawa N, Nishina K: Efficacy of oral clonidine premedication in children . Anesthesiology 1993; 79: 926-931.

  1540. Miles MV: Rapid Loading of Critically Ill Patients with Carbamazepine Suspension . Pediatrics 1990; 86: 263-66.

  1541. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999; 33: 356–360 (B)

  1542. Miller OK: Mushrooms of North America . Dutton 1982; 368.

  1543. Mills AR, Passmore R: Pelagic paralysis. Lancet 1988; 161-164.

  1544. Milman N. Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 1982;17:77-81.

  1545. Mines D, Stahmer S, Shepherd S: Poisonings-Food, Fish, Shellfish . Emergency Medicine Clinics of North America 1997; 15:1: 170-172.

  1546. Mingardi G, Perico N, Pusineri F et al. Heparin for hemodialysis: practical guidelines for administration and monitoring. Int J Artif Organs 1984; 7: 269–274 (B)

  1547. Minton SA: Bites by non-native venomous snakes in the United States . Wild Environ Med 1996; 4: 297-303.

  1548. Minton SA: Paraspecific Protection by Elapid and Sea Snake Antivenins . Toxicon 1967; 5: 47-55.

  1549. Minton SA: Paraspecific protection by elapid and seasnake antivenins . Toxicon 1967; 5: 47-55.

  1550. Mion CM, Canaud B, Garred LJ, Stec F, Nguyen QV. Sterile and pyrogen-free bicarbonate dialysate: a necessity for haemodialysis today. Adv Nephrol Necker Hosp 1990; 19:275–314 (C)

  1551. Mitch WE, Clark AS: Specificity of the effects of leucine and its metabolites on protein degradation in skeletal muscle. Biochem J 222:579-586, 1984

  1552. Mitsnefes M, Stablein D. Hypertension in pediatric patients on long-term dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Kidney Dis 2005;45:309-315.

  1553. Mitsui T, Iwano K, Suzuki S et al. Combined hepatitis B immune globulin and vaccine for postexposure prophylaxis of accidental hepatitis B virus infection in hemodialysis staff members: comparison with immune globulin without vaccine in historical controls. Hepatology 1989; 10: 324–327 (B)

  1554. Mitsuoka JC. A calculator program to determine heparin requirements during hemodialysis. Comput Biol Med 1983; 13: 239–243 (C)

  1555. Mittelman MW, Jornitz MW, Meltzer TH. Bacterial cell size and surface charge characteristics relevant to filter validation studies. PDA J Pharm Sci Technol 1998; 52: 37–42 (B)

  1556. Mitterbauer C, Schwarz C, Haas M et al. Effects of bisphosphonates on bone loss in the first year after renal transplantation–a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2006; 21: 2275–2281.

  1557. Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 1996; 73: 417–420 (B)

  1558. Mitwalli A. Tuberculosis in patients on maintenance dialysis. Am J Kidney Dis 1991; 18: 579–582 (B)

  1559. Miura Y, Ishiyama T, Inomata A et al. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis. Nephron 1992; 60: 268–273 (B)

  1560. Miyata T, Fu MX, Kurokawa K et al. Autoxidation products of both carbohydrates and lipids are increased in uraemic plasma: is there oxidative stress in uraemia? Kidney Int 1998; 54: 1290–1295 (B)

  1561. Miyata T, Hori O, Zhang J et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-b2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J Clin Invest 1996; 98: 1088–1094 (B)

  1562. Miyata T, Iida Y, Ueda Y et al. Monocyteumacrophage response to b2-microglobulin modified with advanced glycation end products. Kidney Int 1996; 49: 538–550 (B)

  1563. Miyata T, Inagi R, Iida Y et al. Involvement of b2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521–528 (B)

  1564. Miyata T, Inagi R, Iida Y et al. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of haemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. J Clin Invest 1994; 93: 521–528 (B)

  1565. Miyata T, Inagi R, Wada Y et al. Glycation of human beta 3-microglobulin in patients with hemodialysis-associated amyloidosis: identification of the glycated sites. Biochemistry 1994; 33: 12215–12221 (B)

  1566. Miyata T, Oda O, Inagi R et al. b2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92: 1243–1252 (B)

  1567. Miyata T, Taneda S, Kawai R et al. Identification of pentosidine as a native structure for advanced glycation end products in b2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93: 2353–2358 (B)

  1568. Miyata T, Ueda Y, Shinzato T et al. Accumulation of albuminlinked and free-form pentosidine in the circulation of uraemic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7: 1198–1206 (B)

  1569. Miyata T, Ueda Y, Yoshida A et al. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997; 51: 880–887 (B)

  1570. Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of ‘carbonyl stress’ in longterm uremic complications. Kidney Int 1999; 55: 389–399 (C)

  1571. Miyata T, Van Ypersele dS, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of ‘carbonyl stress’ in long-term uremic complications. Kidney Int 1999; 55: 389–399 (B)

  1572. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51: 1170–1181 (B)

  1573. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 2000; 101: 1002–1006 (B)

  1574. MMWR: Tetrodotoxin poisoning associated with eating puffer fish transported from Japan---California 1996. MMWR 1996; 45: 389-390.

  1575. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classi-fication of renal osteodystrophy: a position statement from Kidney Disease:Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945–1953.

  1576. Moe SM, Sprague SM. Chapter 52: Mineral bone disorders in chronic kidney disease. In: Brenner and Rector’s The Kidney, 8th edn. WB Saunders Company: Philadelphia, PA, 2007, pp 1784–1807.

  1577. Moeslinger T, Friedl R, Volf I et al. Urea induces macrophage proliferation by inhibition of inducible nitric oxide synthesis. Kidney Int 1999; 56: 581–588 (B)

  1578. Moffitt JE, Yates AB, Stafford CT: Allergy to insect stings: A need for improved preventive management . Postgraduate Medicine 1993; 93, No. 8: 197-208.

  1579. Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Annali Ital Med Interna 1997; 12: 67–71 (A)

  1580. Moll S, De Moerloose P, Reber G, Schifferli J, Leski M. Comparison of two hemodialysis membranes, polyacrylonitrile and cellulose acetate, on complement and coagulation systems.Int J Artif Organs 1990; 13: 273–279 (B)

  1581. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460–1468.

  1582. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A. Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol 1989; 37: 415–418 (B)

  1583. Montecalvo MA, Shay DK, Patel P et al. Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996; 156: 1458–1462 (B)

  1584. Monteon FJ, Laidlaw SA, Shaib JK, Kopple JD: Energy expenditure in patients with chronic renal failure. Kidney Int 30:741-747, 1986

  1585. Montgomery VL, Richman BJ, Goldsmith LJ: Severity and carbamazepine level at time of initial poison center contact correlate with outcome in carbamazepine poisoning . J Toxicology 1995; 33: 311-23.

  1586. Mooser V, Marcovina SM, Wang J, Hobbs HH. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clin Genet 1997; 52: 387–392 (B)

  1587. Mordacchini M, Teodori T, Collodel L et al. Flow-cytometric study of granulocyte activation during hemodialysis with different membranes. Blood Purif 1995; 13: 322–326 (B)

  1588. Morduchowicz G, Boner G. Hospitalizations in dialysis endstage renal failure patients. Nephron 1996; 73: 413–416 (B)

  1589. Morena M, Cristol JP, Dantoine T et al. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 389–395 (B)

  1590. Morens DM: Mass Faintings at Medieval Rock Concerts . NEJM 1995; 333: 1361.

  1591. Morgan H, Gautam M, Geary D. Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 2001;16:779-783.

  1592. Morgenstern B, Mahoney D, Warady B. Estimating total body water in children on the basis of height and weight: a reevaluation of the formulas of Mellits and Cheek. J Am Soc Nephrol 2002;13:1884-1888.

  1593. Morgenstern B, Nair K, Lerner G, et al. Impact of total body water errors on Kt/V estimates in children on peritoneal dialysis. Adv Perit Dial 2001;17:260-263.

  1594. Morgenstern B, Pyle W, Gurskin A, et al. Transport characteristics of the pediatric peritoneal membrane. Kidney Int 1984;25:259-264.

  1595. Morgenstern B, Wuhl E, Sreekumaran Nair K, et al. Anthropometric prediction of total body water in children who are on pediatric peritoneal dialysis. J Am Soc Nephrol 2006;17:285-293.

  1596. Morgenstern B. Equilibration testing: close but not quite right. Pediatr Nephrol 1993;7:290-291.

  1597. Morin P. Identification of the bacteriological contamination of a water treatment line used for haemodialysis and its disinfection. J Hosp Infect 2000; 45: 218–224 (B)

  1598. Morris MW, Davey FR: Basic examination of blood, in Henry JB (ed): Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, PA, WB Saunders, 1996, pp 549-593

  1599. Morti SM, Zydney AL. Protein-membrane interactions during haemodialysis: effects on solute transport. ASAIO J 1998; 44: 319–326 (B)

  1600. Morti SM, Zydney AL. Protein-membrane interactions during hemodialysis. Effects on solute transport. ASAIO J 1998; 44: 319–326 (B)

  1601. Morton M, Reynolds J, Garralda M, et al. Psychiatric adjustment in end-stage renal disease: a follow up study of former paediatric patients. J Psychosom Res 1994;38:293-303.

  1602. Motomiya Y, Oyama N, Iwamoto H, Uchimura T, Maruyama I. N epsilon-(carboxymethyl)lysine in blood from maintenance hemodialysis patients may contribute to dialysisrelated amyloidosis. Kidney Int 1998; 54: 1357–1366 (B)

  1603. Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 55–69 (C)

  1604. Moustapha A, Naso A, Nahlawi M et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease [published erratum appears in Circulation 1998; 97: 711]. Circulation 1998; 97: 138–141 (B)

  1605. Movilli E, Bossini N, Viola BF, Camerini C, Cancarini GC, Feller P, Strada A, Maiorca R: Evidence for an independent role of metabolic acidosis on nutritional status in haemodialysis patients. Nephrol Dial Transplant 13:674-678, 1998

  1606. Movilli E, Filippini M, Brunori G, Sandrini M, Costantino E, Cristinelli L, Maiorca R: Influence of protein catabolic rate on nutritional status, morbidity and mortality in elderly uraemic patients on chronic haemodialysis: A prospective 3-year follow-up study. Nephrol Dial Transplant 10:514-518, 1995

  1607. Movilli E, Mombelloni S, Gaggiotti M, Maiorca R: Effect of age on protein catabolic rate, morbidity, and mortality in uraemic patients with adequate dialysis. Nephrol Dial Transplant 8:735-739, 1993

  1608. Movilli E, Pertica N, Camerini C, et al: Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 39:850-853, 2002

  1609. Movilli E. Simplified approaches to calculate KtV. It’s time for agreement. Nephrol Dial Transplant 1996; 11: 24–27 (C)

  1610. Moy JA, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. Muciporine-resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol 1990; 22: 893–895 (B)

  1611. Mrowka C, Schiffl H. Comparative evaluation of b2-microglobulin removal by different hemodialysis membranes: a six-year follow-up [letter]. Nephron 1993; 63: 368–369 (B)

  1612. Mrowka C, Schiffl H. Comparative evaluation of beta 2-microglobulin removal by different hemodialysis membranes: a six-year follow-up. Nephron 1993; 63: 368–369 (B)

  1613. Mu¨ ller TF, Seitz M, Eckle I, Lange H, Kolb G. Biocompatibility differences with respect to dialyzer sterilization method. Nephron 1998; 78: 139–142 (B)

  1614. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal haemodialysis. Kidney Int 1998; 53: 1399–1404 (B)

  1615. Mucsi I, Hercz G, Uldall R et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998; 53: 1399–1404 (B)

  1616. Mueller M, Borland C: Delayed cyanide poisoning following acetonitrile ingestion . Postgrad Med J 1997; 73: 299-300.

  1617. Mueller UR: Insect sting allergy: Clinical picture, diagnosis, and treatment . 1990; 144-147.

  1618. Mujais SK, Chimeh H. Heparin free hemodialysis using heparin coated hemophan. ASAIO J 1996; 42: M538–M541 (A)

  1619. Mujais SK, Schmidt B, Hacker H, Opatrny K, Gurland HJ. Synthetic modification of PAN membrane: biocompatibility and functional characterization. Nephrol Dial Transplant 1995; 10 [Suppl 3]: 46–51 (A)

  1620. Muller-Wiefel D, Sinn H, Gilli G, et al. Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 1977;8:481-486.

  1621. Mullins ME, Horowitz BZ, Linden DHJ: Life-Threatening Mibefradil Interaction With Beta-Blockers and Dihydropyridine Calcium Channel Blockers . J A M A 1998; 280: 157-159.

  1622. Munch G, Keis R, Wessels A et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669–677 (B)

  1623. Munda R, First MR, Alexander JW et al. Polytetrafluoroethylene graft survival in hemodialysis. J Am Med Assoc 1983; 249: 219–222 (B)

  1624. Murakami R, Momota T, Yoshiya K, et al. Serum carnitine and nutritional status in children treated with continuous ambulatory peritoneal dialysis. J Pediatr Gastroenterol 1990;11:371-374.

  1625. Murphy GJ, Nicholson ML. Autogeneous elbow fistulas: the effect of diabetes mellitus on maturation, patency, and complication rates. Eur J Vasc Endovasc 2002; 23: 452–457

  1626. Murphy GJ, Saunders R, Metcalfe M, Nicholson ML. Elbow fistulas using autogeneous vein: patency rates and results of revision. Postgrad Med J 2002; 78: 483–486

  1627. Mydlik M, Derzsiova K, Zemberova E. Metabolism of vitamin B6 and its requirement in chronic renal failure. Kidney Int 2001; 56: 56–59 (C)

  1628. Nadig C, Leidig M, Schmiedeke T, Hoffken B. The use of ultrasound for the placement of dialysis catheters. Nephrol Dial Transplant 1998; 13: 978–981

  1629. Naets JP, Garcia JF, Tousaaint C, Buset M, Waks D: Radioimmunoassay of erythropoietin in chronic uraemia or anephric patients. Scand J Haematol 37:390-394, 1986

  1630. Najem GR, Louria DB, Thind IS et al. Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. J Am Med Assoc 1981; 245: 153–157 (B)

  1631. Najjar MF, Rowland M: Anthropometric reference data and prevalence of overweight, United States, 1976-80. DHHS Pub nr (PHS) 87-1688. Washington, DC, US Government Publications Office, Vital and Health Statistics, Series 11, Nr 238, 1987

  1632. Nakahama H, Nakanishi T, Uyama O et al. Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis. Renal Fail 1993; 15: 189–193 (B)

  1633. Nankivell BJ, Allen RD, O’Connell PJ, Chapman JR: Erythrocytosis after renal transplantation: Risk factors and relationship with GFR. Clin Transplant 9:375-382, 1995

  1634. Nassberger L, Arbin A, Ostelius J. Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis. Nephron 1987; 45: 286–290 (B)

  1635. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114:555-576.

  1636. National Kidney Foundation K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;22:S1-S290.

  1637. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for 2006 updates. Hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006; 48:S1-S322.

  1638. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47:S1-S146.

  1639. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50:471-530.

  1640. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005; 46: S1–121.

  1641. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005;46(Suppl 1):S1-S121.

  1642. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1–201.

  1643. National Kidney Foundation. K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2000;35(Suppl 2):S1-S140.

  1644. National Kidney Foundation: DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. Am J Kidney Dis 30:S192-S240, 1997 (suppl 3)

  1645. National Kidney Foundation: KDOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238, 2001 (suppl 1)

  1646. National Kidney Foundation: Kidney Early Evaluation Program. Am J Kidney Dis 45:S1-S135, 2005 (suppl 2)

  1647. National Research Council. Recommended dietary allowances. Washington, DC: National Academy Press, 1989:1-284.

  1648. Natov SN, Pereira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial 2000; 13: 393–398 (C)

  1649. Nauck M, Kramer-Guth A, Bartens W et al. Is the determination of LDL cholesterol according to Friedewald accurate in CAPD and HD patients? Clin Nephrol 1996; 46: 319–325 (B) SECTION VII. Vascular disease and risk factors 103

  1650. Navab M, Berliner JA, Subbanagounder G et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481–488 (B)

  1651. Navarro JA, Parra OE, Romero RA. Aluminum determination in whole blood, dialysis solution, and tap water samples from Maracaibo dialysis units (Venezuela) by graphite furnace atomic absorption spectrometry. J Trace Elem Electrolytes Health Dis 1988; 2: 3–8 (B)

  1652. Neary RH, Gowland E. The effect of renal failure and haemodialysis on the concentration of free apolipoprotein A-1 in serum and the implications for the catabolism of high-density lipoproteins. Clin Chim Acta 1988; 171:239–245 (B)

  1653. Nelson EE, Hong CD, Pesce AL, Peterson DW, Singh S, Pollak VE: Anthropometric norms for the dialysis population. Am J Kidney Dis 16:32-37, 1990

  1654. Nestel PJ, Fidge NH, Tan MH. Increased lipoprotein-remnant formation in chronic renal failure. N Engl J Med 1982; 307: 329–333 (B)

  1655. Neu A, Ho P, McDonald R, et al. Chronic dialysis in children and adolescents. The 2001 NAPRTCS annual report. Pediatr Nephrol 2002;17:656-663.

  1656. Neu A, Kohaut E, Warady B. Current approach to peritoneal access in North American children: a report of the Pediatric Peritoneal Dialysis Study Consortium. Adv Perit Dial 1995;11:289-292.

  1657. Neveceral P, Markert M, Wauters JP. Role of protein adsorption on haemodialysis-induced complement activation and neutrophil defects. Nephrol Dial Transplant 1995; 10: 372–376 (B)

  1658. Nguyen AT, Lethias C, Zingraff J et al. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within micro amounts of whole blood. Kidney Int 1985; 28: 158–167 (B)

  1659. Nguyen MH, Yu VL, Morris AJ. Candida infection of the arteriovenous fistula used for hemodialysis. Am J Kidney Dis 1996; 27: 596–598 (B)

  1660. Nguyen-Khoa T, Massy ZA, De Bandt JP et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16: 335–340 (B)

  1661. Nguyen-Khoa T, Massy ZA, Witko-Sarsat V et al. Critical evaluation of plasma and LDL oxidant-trapping potential in hemodialysis patients. Kidney Int 1999; 56: 747–753 (B)

  1662. Nhachi CF, Kasilo OM: Poisoning due to insect and scorpion stings/bites . Human & Experimental Toxicology 1993; 12: 123-125.

  1663. NHLBI, NIH publication No 95-3045. Recommendations regarding public screening for measuring blood cholesterol, 1995 (C)

  1664. Nichols M, King W, James L: Clonidine poisoning in Jefferson County, Alabama . Annals of Emergency Medicine 1997; 29(4): 511-517.

  1665. Nielsen J, Kolmos HJ, Espersen F. Staphylococcus aureus bacteraemia among patients undergoing dialysis—focus on dialysis catheter-related cases. Nephrol Dial Transplant 1998; 13: 139–145 (B)

  1666. Nielsen J, Ladefoged SD, Kolmos HJ. Dialysis catheter-related septicaemia—focus on Staphylococcus aureus septicaemia. Nephrol Dial Transplant 1998; 13: 2847–2852

  1667. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32: 1741–1753 (B)

  1668. Nishizawa Y, Shoji T, Emoto M et al. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients. Clin Nephrol 1995; 43: 268–277 (B)

  1669. Nissenson AR, Korbet S, Faber M, et al: Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5:1517-1529, 1995

  1670. Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid b2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187–194 (B)

  1671. Niwa T, Katsuzaki T, Miyazaki S et al. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51: 187–194 (B)

  1672. Niwa T, Katsuzaki T, Miyazaki S et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 1997; 99: 1272–1280 (B)

  1673. Niwa T, Katsuzaki T, Momoi T et al. Modification of b2-m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996; 49: 861–867 (B)

  1674. Niwa T, Miyazaki S, Katsuzaki T et al. Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 1995; 48: 771–778 (B)

  1675. Niwa T, Sato M, Katsuzaki T et al. Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50: 1303–1309 (B)

  1676. Niwa T, Sato M, Katsuzaki T et al. Amyloid–b2-microglobulin is modified with N«-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996; 50: 1303–1309 (B)

  1677. NKF DOQI Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 35 [Suppl 2]: S20–S21 (C)

  1678. NKF DOQI Clinical practice guidelines. Target hemoglobinu hematocrit. Am J Kidney Dis 2000; 37 [Supp 11]: S190–S193 (C)

  1679. Nockher WA, Scherberich JE. Monocyte cell-surface CD14 expression and soluble CD14 antigen in haemodialysis: evidence for chronic exposure to LPS. Kidney Int 1995; 48: 1469–1476 (B)

  1680. Noghnogh AA, et al. Preparation of ethanol-enriched, bicarbonate-based hemodia-lysates. Artif Organs 1999;23:208-209.

  1681. Nolph K. Peritoneal anatomy and transport physiology. In: Drukker W, et al., eds. Replacement of renal function by dialysis. Boston: Martinus Nijhoff, 1983:440-456.

  1682. none: Jamaican Vomiting Sickness . MMWR 1992; 41: 53-55.

  1683. Norman ME, Mazur AT, Borden St et al. Early diagnosis of juvenile renal osteodystrophy. J Pediatr 1980; 97: 226–232.

  1684. Normann S: Antihistamines . POISINDEX(R) Toxicologic Management 1988;.

  1685. Norris Jr. RL: Snake Venom Poisoning in the United States: Assessment and Management . Emerg Med Rep 1995; 16: 87-94.

  1686. Norris RL, Dart RC: Apparent coral snake envenomation in a patient without fang marks . Am J Emerg Med 1989; 7(4): 402-405.

  1687. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). 2006 Annual report. 2007.

  1688. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). 2007 Annual report 2007.

  1689. Norton J, Spiezio R, LaManna L, DeLorme B. Varying heparin requirements in hemodialysis patients receiving erythropoietin. ANNA J 1940; 19: 367–372 (B)

  1690. Nourooz-Zadeh J. Effect of dialysis on oxidative stress in uraemia. Redox Rep 1999; 4: 17–22 (B)

  1691. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997; 109: 354–358 (B)

  1692. Nsouli KA, Lazarus M, Schoenbaum SC et al. Bacteremic infection in hemodialysis. Arch Intern Med 1979; 139: 1255–1258 (B)

  1693. Nurmohamed MT, ten Cate J, Stevens P et al. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans 1991; 37: M459–M461 (A)

  1694. Nygard O, Nordrehaug JE, Refsum H et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236 (B)

  1695. O’Dwyer H, Fotheringham T, O’Kelly P et al. A prospective comparison of two types of tunneled hemodialysis catheters: the Ash Split versus the PermCath. Cardiovasc Intervent Radiol 2005; 28: 23–29

  1696. O’Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27: 84–91 (B)

  1697. O’Neill WC. The fallacy of the calcium-phosphorus product. Kidney Int 2007; 72: 792–796.

  1698. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ: Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10:1793-1800, 1999

  1699. Oda H, Keane WF. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998; 13 [Suppl 1]: 45–49 (C)

  1700. Oda H, Yorioka N, Okushin S et al. Remnant-like particle cholesterol may indicate atherogenic risk in patients on chronic hemodialysis. Nephron 1997; 76: 7–14 (B)

  1701. Odamaki M, Furuya R, Ohkawa S et al. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2427–2432 (B)

  1702. Odell RA, Slowiaczek P, Moran JE, Schindhelm K. Beta 2-microglobulin kinetics in end-stage renal failure. Kidney Int 1991; 39: 909–919 (B)

  1703. Odetti P, Cosso L, Pronzato MA, Dapino D, Gurreri G. Plasma advanced glycosylation end-products in maintenance haemodialysis patients. Nephrol Dial Transplant 1995;10: 2110–2113 (B)

  1704. Oguzkurt L, Tercan F, Kara G, Torun D, Kizilkilic O, Yildirim T. US-guided placement of temporary internal jugular vein catheters: immediate technical success and complications in normal and high-risk patients. Eur J Radiol 2005; 55: 125–129

  1705. Oh J, et al. Nasal carriage of Staphylococcus aureus in families of children on peritoneal dialysis. Adv Perit Dial 2000;16:324-327.

  1706. Oh J, et al. Nasal mupirocin prophylaxis reduces the incidence of PD-related S. aureus infections in children: results of a double-blind, placebo-controlled multicenter trial. Perit Dial Int 2002; 22(Suppl 1):S74.

  1707. Oi K, Hirano T, Sakai S, Kawaguchi Y, Hosoya T. Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S227–S228 (B)

  1708. Olesen LL: Amatoxin intoxication . Scand J Urol Nephrol 1990; 24: 231-234.

  1709. Oliver JC, Bland LA, Oettinger CW et al. Bacteria and endotoxin removal from bicarbonate dialysis fluids for use in conventional, high-efficiency, and high-flux haemodialysis. Artif Organs 1992; 16: 141–145 (B)

  1710. Oliver MJ, McCann RL, Indridason OS, Butterly DW, Schwab SJ. Comparison of transposed brachiobasilic fistulas to upperarm grafts and brachiocephalic fistulas. Kidney Int 2001; 60: 1532–1539

  1711. Olmer M, Bouchouareb D, Zandotti C, De Micco P, de Lamballerie X. Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection. Clin Nephrol 1997; 47: 263–270 (B)

  1712. Oniscu GC, Brown H, Forsythe, JLR. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005;16:1859-65

  1713. Oniscu GC, Schalkwijk AA, Johnson RJ, Brown H, Forsythe JL. Equity of access to renal transplant waiting list and renal transplantation in Scotland: cohort study. BMJ. 2003; 327(7426):1261

  1714. Opatrny K Jr, Bouda M, Kohoutkova L, Vit L, Sefrna F. A clinical study to assess the effect of heparin in dialyzer rinsing solutions. Int J Artif Organs 1997; 20: 112–118 (A)

  1715. Opatrny K, Krouzecky A, Wirth J, Vit L, Eiselt J. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis. Artif Organs 1998; 22: 816–820 (B)

  1716. O'Regan S, Garel L. Percutaneous gastrojejunostomy for caloric supplementation in children on peritoneal dialysis. Adv Perit Dial 1990;6:273-275.

  1717. Orellana P, Juarez-Congelosi M, Goldstein S. Intradialytic parenteral nutrition treatment and biochemical marker assessment for malnutrition in adolescent maintenance hemodialysis patients. J Ren Nutr 2005;15:312-317.

  1718. Oreopoulos D, Katirtzoglou A, Arbus G, et al. Dialysis and transplantation in young children. Br Med J 1979;16:1628-1629.

  1719. Ori Y, Korzets A, Katz M et al. The contribution of an arteriovenous access for hemodialysis to left ventricular hypertrophy. Am J Kidney Dis 2002; 40: 745–752

  1720. Orlando MP, Dillon ME, O’Dell MW. Heparin-induced hyperkalemia confirmed by drug rechallenge. Am J Phys Med Rehabil 2000; 79: 93–96 (B)

  1721. Ortega T, Ortega F, Diaz-Corte C, Rebollo P, Ma Baltar J, Alvarez-Grande J. The timely construction of arteriovenous fistulae: a key to reducing morbidity and mortality and to improving cost management. Nephrol Dial Transplant 2005; 20:598–603

  1722. Osorio A, Seidel F, Warady B. Hypercalcemia and pancreatitis in a child with adynamic bone disease. Pediatr Nephrol 1997;11:223-225.

  1723. Osorio AM, Melius J: Lead poisoning in construction . Occup Med 1995; 10: 353-61.

  1724. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am JMed 1995; 98: 575–586 (B)

  1725. Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. Semin Dial 2000; 13: 181–187 (B)

  1726. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG. Dose of haemodialysis and survival: differences by race and sex. J Am Med Assoc 1998; 280: 1764–1768 (B)

  1727. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing haemodialysis. N Engl J Med 1993; 329: 1001–1006 (B)

  1728. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627–636 (B)

  1729. Pacini S, Aterini S, Salvadori M et al. Cellular proliferation and second messenger formation altered by dialysis membranes. Nephrol Dial Transplant 1997; 12: 500–504 (B)

  1730. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol 1997; 17: 3542–3556 (B)

  1731. Padberg FT, Lee BC, Curl GR. Hemoaccess site infection. Surg Gynecol Obstet 1992; 174: 10–108 (B)

  1732. Paksoy Y, Gormus N, Tercan MA. Three-dimensional contrastenhanced magnetic resonance angiography (3-D CE-MRA) in the evaluation of hemodialysis access complications, and the condition of central veins in patients who are candidates for hemodialysis access. J Nephrol 2004; 17: 57–65

  1733. Palatnik W, Redman LW, et al: Methanol half-life during ethanol administration: Implications for management of methanol poisoning . Ann Emerg Med 1995; 26(2): 202-7.

  1734. Palder SB, Kirkman RL, Whittemore AD et al. Vascular access for hemodialysis. Patency rates and results of revision. Ann Surg 1985; 202: 235–239 (B)

  1735. Palmer SC, McGregor DO, Macaskill P et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147: 840–853.

  1736. Palmer R, Newell J, Gray J, et al. Treatment of chronic renal failure by prolonged peritoneal dialysis. N Engl J Med 1966;274:248-254.

  1737. Palmer R, Quinton W, Gray J. Prolonged peritoneal dialysis for chronic renal failure. Lancet 1964;1:700-702.

  1738. Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis 2005; 45: 638–649.

  1739. Palo TD, Atti M, Bellantuono R, Giordano M, Caringella DA.Chlorine dioxide: a new agent for dialysis monitor disinfection in a pediatric center. Blood Purif 1997; 15: 188–194 (B)

  1740. Pan WH, Habicht JP: The non-iron-deficiency-related difference in hemoglobin concentration distribution between blacks and whites and between men and women. Am J Epidemiol 134:1410-1416, 1991

  1741. Paniagua R, Amato D, Vonesh E, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal diaysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13: 1307-1320.

  1742. Panichi V, Casarosa L, Gattai V et al. Protein layer on hemodialysis membranes: a new immunohistochemistry technique. Int J Artif Organs 1995; 18: 305–308 (B)

  1743. Panichi V, De Pietro S, Andreini B et al. Cytokine production in haemodiafiltration: a multicentre study. Nephrol Dial Transplant 1998; 13: 1737–1744 (B)

  1744. Panichi V, Migliori M, De Pietro S et al. The link of biocompatibility to cytokine production. Kidney Int 2000; 58 [Suppl 76]: S96–S103 (C)

  1745. Panzetta O, Cominacini L, Garbin U et al. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol 1995; 44: 303–309 (B)

  1746. Papadimitriou M, Memmos D, Metaxas P. Tuberculosis in patients on regular haemodialysis. Nephron 1979; 24: 53–57 (B)

  1747. Pappas AA, Ackerman BH, et al: Isopropanol ingestion: A report of six episodes with isopropanol and acetone serum concentration time data . J Toxicol Clin Toxicol 1991; 20(1): 11-21.

  1748. Parazell MA: Lead and the kidney: nephropathy, hypertension, and gout . Conn Med 1996; 60: 521-6.

  1749. Parekh R, Carroll C, Wolfe R, et al. Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 2002;141:191-197.

  1750. Parfitt AM. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens 2003; 12: 387–403.

  1751. Parfitt AM. Bone and plasma calcium homeostasis. Bone 1987; 8(Suppl 1): S1–8.

  1752. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE: Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 11:1277-1285, 1996

  1753. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180-2189, 2005

  1754. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606–1615 (C)

  1755. Parker TF III, Husni L, Huang W, Lew N, Lowrie EG. Survival of haemodialysis patients in the United States is improved with a greater quantity of dialysis. Am J Kidney Dis 1994; 23: 670–680 (B)

  1756. Parker TF, Wingard RL, Husni L et al. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996; 49: 551–556 (A)

  1757. Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991; 40: 1148–1152 (B)

  1758. Parrish HM, Khan MS: Bites by coral snakes: report of 11 representative cases . Am J Med Sci 1967; 253: 561-568.

  1759. Parrott K, et al. Plasma vitamin A levels in children on CAPD. Perit Dial Bull 1987;7:90-92.

  1760. Parsy D, Dracon M, Cachera C et al. Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 1988; 3: 51–56 (B)

  1761. Pascual M, Schifferli JA. Adsorption of complement factor D by polyacrylonitrile dialysis membranes. Kidney Int 1993; 43: 903–911 (B)

  1762. Pass T, Wright R, Sharp B, Harding GB. Culture of dialysis fluids on nutrient-rich media for short periods at elevated temperatures underestimate microbial contamination. Blood Purif 1996; 14: 136–145 (B)

  1763. Pasternack A, Vanttinen T, Solakivi T, Kuusi T, Korte T. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987; 27: 163–168 (B)

  1764. Patel H, Goldstein S, Mahan J, et al. A standard, noninvasive monitoring of hematocrit algorithm improves blood pressure control in pediatric hemodialysis patients. Clin J Am Soc Nephrol 2007;2:252-257.

  1765. Patel ST, Hughes J, Mills Sr, JL. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality initiative guidelines for hemodialysis access. J Vasc Surg 2003; 38: 439–445

  1766. Paterakis GS, Laoutaris NP, Alexia SV, et al: The effect of red cell shape on the measurement of red cell volume. A proposed method for the comparative assessment of this effect among various haematology analysers. Clin Lab Haematol 16:235-245, 1994

  1767. Paterson KR, Paice BJ, Lawson DH: Undesired effects of biguanide therapy . Adverse Drug React Acute Poisoning Rev 1984; 3: 173-182.

  1768. Pathak MA: Photosensitization of skin in vivo by furocoumarins (psoralens) . Biochim. Biophys. Acta 1969; 195: 197-206.

  1769. Pathak MA: The presently known distribution of furocoumarins (psoralens) in plants . J Invest Derm 1962; 39: 225-236.

  1770. Patrick AW, Williams G: Adverse effects of exogenous insulin. Clinical features, management, and prevention . Drug Safety 1993; 8: 427-444.

  1771. Paydas S, Kocak R, Erturk F: Poisoning due to amatoxin-containing Lepiota species . BJCP 1990; 44 (11): 450-453.

  1772. Pearn J: The sea, stingers, and surgeons: the surgeons' role in prevention, first aid and management of marine evenomations . J Pediatric Surg 1995; 30: 105-110.

  1773. Pearson F, Bruszer G, Lee W et al. Ethylene oxide sensitivity in hemodialysis patients. Artif Organs 1987; 11: 100–103 (B)

  1774. Pearson TA. Lipid-lowering therapy in low-risk patients. J Am Med Assoc 1998; 279: 1659–1661 (C)

  1775. Pedrini LA, De Cristofano V, Pagliari B, Sama F. Mixed predilution and postdilution online haemodiafiltration compared with the traditional infusion modes. Kidney Int 2000; 58: 2155–2165 (B)

  1776. Pedrini LA, Zereik S, Rasmy S. Causes, kinetics and clinical implications of post-haemodialysis urea rebound. Kidney Int 1988; 34: 817–824 (B)

  1777. Pedro BJ, Senti M, Rubies PJ, Pelegri A, Romero R. When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelines. Nephrol Dial Transplant 1996; 11: 308–313 (B)

  1778. Pegues DA, Oettinger CW, Bland LA et al. A prospective study of pyrogenic reactions in haemodialysis patients using bicarbonate dialysis fluids filtered to remove bacteria and endotoxin. J Am Soc Nephrol 1992; 3: 1002–1007 (B)

  1779. Pelegri A, Romero R, Senti M et al. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant 1992; 7: 623–626 (B)

  1780. Pereira A, Hamani N, Nogueira P, et al. Oral vitamin intake in children receiving long-term dialysis. J Ren Nutr 2000;10:24-29.

  1781. Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981–999 (C)

  1782. Pereira BJ, Snodgrass BR, Hogan PJ, King AJ. Diffusive and convective transfer of cytokine-inducing bacterial products across haemodialysis membranes. Kidney Int 1995; 47: 603–610 (B)

  1783. Pereira BJ, Sundaram S, Barrett TW et al. Transfer of cytokine-inducing bacterial products across hemodialyzer membranes in the presence of plasma or whole blood. Clin Nephrol 1996; 46: 394–401 (B)

  1784. Perez GO, Ortiz C, De Medina M, Schiff E, Bourgoignie JJ. Lack of transmission of human immunodeficiency virus in chronic hemodialysis patients. Am J Nephrol 1988; 8: 123–126 (B)

  1785. Perez-Garcia R, Anaya F, Chisvert J, Valderrabano F. Association of high-flux dialysers and bacterial contamination of dialysate-induced chronic release of cytokines in haemodialysis patients. Nephrol Dial Transplant 1995; 10:2164–2166 (B)

  1786. Perez-Garcia R, Rodriguez-Benitez PO. Why and how to monitor bacterial contamination of dialysate? Nephrol Dial Transplant 2000; 15: 760–764 (C)

  1787. Perini S, LaBerge JM, Pearl JM et al. Tesio catheter: radiologically guided placement, mechanical performance, and adequacy of delivered dialysis. Radiology 2000; 215: 129–137

  1788. Perkowski SZ, Havill AM, Flynn JT, Gee MH. Role of intrapulmonary release of eicosanoids and superoxide anion as mediators of pulmonary dysfunction and endothelial injury in sheep with intermittent complement activation. Circ Res 1983; 53: 574–583 (B)

  1789. Perna AF, Ingrosso D, De Santo NG et al. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997; 8: 1899–1905 (B)

  1790. Perriatos A. Daily nocturnal home hemodialysis. Kidney Int 2004;65:1975-1986.

  1791. Persuad TVN: Foetal abnormalities caused by the active principle of the fruit of Blighia sapida (Akee) . West Indian Medical Journal 1967; 16: 193-97.

  1792. Pertosa G, Grandaliano G, Gesualdo L et al. Interleukin-6, interleukin-8 and monocyte chemotactic peptide-1 gene expression and protein synthesis are independently modulated by hemodialysis membranes. Kidney Int 1998; 54: 570–579 (B)

  1793. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989; 9: 235–239 (C)

  1794. Petersdorf RG, Matrin JB, Fauci AS et al: Harrison's principals of internal medicine . 1991; 12th ed., volume 2: 2182-2187.

  1795. Petitclerc T, Bene B, Jacobs C, Jaudon MC, Goux N. Non-invasive monitoring of effective dialysis dose delivered to the haemodialysis patient. Nephrol Dial Transplant 1995; 10: 212–216 (B)

  1796. Petitclerc T, Goux N, Reynier AL, Bene B. A model for non-invasive estimation of in vivo dialyzer performances and patient’s conductivity during haemodialysis. Int J Artif Organs 1993; 16: 585–591 (B)

  1797. Petrie JJ, Fleming R, McKinnon P, Winney RJ, Cowie J. The use of ionxchange to remove aluminum from water used in haemodialysis. Am J Kidney Dis 1984; 4: 69–74 (B)

  1798. Petrosillo N, Gilli P, Serraino D et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Nephrol Dial Transplant 2001; 37: 1004–1010

  1799. Phakdeekitcharoen B, Leelasa-nguan P. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 2004;44:738-746.

  1800. Phelps KR, Oh MS, Carroll HJ. Heparin-induced hyperkalemia: report of a case. Nephron 1980; 25: 254 –258 (B)

  1801. Phillips G, Hudson S, Stewart WK. Persistence of microflora in biofilm within fluid pathways of contemporary haemodialysis monitors (Gambro AK-10). J Hosp Infect 1994; 27: 117–125 (B)

  1802. Piccoli GB, Quarello F, Salomone M et al. Are serum albumin and cholesterol reliable outcome markers in elderly dialysis patients? Nephrol Dial Transplant 1995; 10 [Suppl 6]: 72–77 (C)

  1803. Pieper A, Haffner D, Hoppe B, et al. A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. Am J Kidney Dis 2006;47:625-635.

  1804. Pierratos A, Ouwendyk M, Francoeur R et al. Nocturnal haemodialysis: three-year experience. J Am Soc Nephrol 1998; 9: 859–868 (B)

  1805. Pierratos A. Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 1999; 14: 2835–2840 (B)

  1806. Pinney R: Sea snakes . Reptile & Amphibian 1994; 26: 22-34.

  1807. Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Eng J Med 1983; 308: 258–261 (B)

  1808. Piraino B et al. Peritoneal Dialysis-Related Infections recommendations: 2005 Update. Peritoneal Dialysis International 2005;25:107-131

  1809. Piraino B, Bailie G, Bernardini J, et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25: 107-131.

  1810. Pisoni RL, Young EW, Dykstra DM et al. Vascular access use in Europe and the United States: results from the DOPPS. Kidney Int 2002; 61: 305–316

  1811. Pizzarelli F, Cerrai T, Dattolo P, Tetta C, Maggiore Q. Convective treatments with on-line production of replacement fluid: a clinical experience lasting 6 years. Nephrol Dial Transplant 1998; 13: 363–369 (B)

  1812. Planken RN, Tordoir JH, Dammers R et al. Stenosis detection in forearm hemodialysis arteriovenous fistulae by multiphase contrast-enhanced magnetic resonance angiography: preliminary experience. J Magn Reson Imaging 2003; 17: 54–64

  1813. Pol S, Romeo R, Zins B et al. Hepatitis C virus RNA in anti-HCV positive hemodialyzed patients: significance and therapeutic implications. Kidney Int 1993; 44: 1097–1100 (B)

  1814. Pol S, Thiers V, Carnot F et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412–1418 (B)

  1815. Polaschegg HD. Automatic, noninvasive intradialytic clearance measurement. Int J Artif Organs 1993; 16: 185–191 (B)

  1816. Polinsky M, Kaiser B, Stover J, et al. Neurologic development of children with severe chronic renal failure from infancy. Pediatr Nephrol 1987;1:157-165.

  1817. Pollock CA, Ibels LS, Allen BJ, Ayass W, Caterson RJ, Waugh DA, Macadam C, Pennock Y, Mahony JF: Total body nitrogen as a prognostic marker in maintenance dialysis. J Am Soc Nephrol 6:82-88, 1995

  1818. Pollock CA, Wyndham R, Collett PV et al. Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney Int 1994; 45: 897–902 (B)

  1819. Pond SM, Olson KR, Woo OF: Amatoxin poisoning in northern California, 1982-1983 . West J Med 1986; 145: 204-209.

  1820. Ponticelli C, Barbi G, Cantaluppi A et al. Lipid abnormalities in maintainance dialysis patients and renal transplant recipients. Kidney Int 1978; 13: 72–78 (B)

  1821. Poplack D. Acute lymphoblastic leukemia. In: Pizzo P, Poplack D, eds. Principles and practice of pediatric oncology. New York: JB Lippincott Co, 1989:323.

  1822. Popovich R, Moncrief J, Dechered J, et al. The definition of a novel wearable/portable equilibrium dialysis technique. Trans Am Soc Artif Intern Organs 1976;5:64.

  1823. Port FK, Orzol SM, Held PJ, Wolfe RA. Trends in treatment and survival for hemodialysis patients in the United States. Am J Kidney Dis 1998; 32 [Suppl 4]: S34–S38 (B)

  1824. Port FK, Wolfe RA, Hulbert-Shearon TE et al. Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: results from the USRDS Dialysis Morbidity and Mortality Study. Am J Kidney Dis 2001; 37: 276–286 (B)

  1825. Portale AA, Halloran BP, Morris Jr RC. Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D. J Clin Invest 1987; 80: 1147–1154.

  1826. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997

  1827. Potter D, McDaid T, Ramirez J, et al. Peritoneal dialysis in children. In: Atkins R, Thomson N, Farrell P, eds. Peritoneal dialysis. New York: Churchill Livingstone, 1981:356-361.

  1828. Pouria S, de Andrade A, Barbosa J et al. Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil. Lancet 1998; 352: 21–26 (B)

  1829. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999; 55: 1081–1090 (B)

  1830. Prabhakar SS, Zeballos GA, Montoya-Zavala M, Leonard C.Urea inhibits inducible nitric oxide synthase in macrophage cell line. Am J Physiol 1997; 273: C1882–C1888 (B)

  1831. Preuschof L, Keller F, Seemann J, Offermann G. Heparin-free hemodialysis with prophylactic change of dialyser and blood lines. Int J Artif Organs 1988; 11: 255–258 (B)

  1832. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1999; 48: 1–28 (B)

  1833. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 1997; 46: 1–24 (B)

  1834. Price C, Suki W. Newer modifications of peritoneal dialysis: options in the treatment of patients with renal failure. Am J Nephrol 1980; 1:97-104.

  1835. Prichard BN, Battersby LA, Cruickshank JM: Overdosage with beta-adrenergic blocking agents . Adverse Drug React Actue Poisoning Rev 1984; 3: 91-111.

  1836. Priester-Coary A, Daugirdas JT. A recommended technique for obtaining the post-dialysis BUN. Semin Dial 1997; 10: 23–25 (C)

  1837. Prince AM, Szmuness W, Mann MK et al. Hepatitis B immune globulin: final report of a controlled, multicenter trial of efficacy in prevention of dialysis-associated hepatitis. J Infect Dis 1978; 137: 131–144 (B)

  1838. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998; 32: 1041–1045 (A)

  1839. Proudfoot AT, et al. Paraquat poisoning: significance of plasma paraquat concen­trations. Lancet 1979;2:330-332.

  1840. Pugh LG: Muscular exercise on Mount Everest. J Physiol 141:233-261, 1958

  1841. Pumford N, Cassey J, Uttley W. Omentectomywith peritoneal catheter placement in acute renal failure. Nephron 1994;68:327-328.

  1842. Puolakka J, Janne O, Pakarinen A, Jarvinen PA, Vihko R: Serum ferritin as a measure of iron stores during and after normal pregnancy with and without iron supplements. Acta Obstet Gynecol Scand Suppl 95:S43-S51, 1980

  1843. Putiloff, PV. Materials for the study of the laws of growth of the human body in relation to the surface areas of different systems: the trial on Russian subjects of planigraphic anatomy as a means for exact anthropometry; one of the problems of anthropology. Report of Dr. P.V. Putiloff at the meeting of the Siberian Branch of the Russian Geographic Society, 1884.

  1844. Pyle, WK. Mass transfer in peritoneal dialysis. PhD dissertation. 1987. Austin, University of Texas.

  1845. Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300–1331 (C)

  1846. Pyorala K, Wood D. Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. Eur Heart J 1998; 19: 1413–1415 (C)

  1847. Quan A, Baum M. Protein losses in children on continuous cycler peritoneal dialysis. Pediatr Nephrol 1996;10:728-731.

  1848. Quarles LD, Rutsky EA, Rostand SG. Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 1985; 6: 412–419 (B)

  1849. Quaschning T, Schomig M, Keller M et al. Non-insulindependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 1999; 10: 332–341 (B)

  1850. Quintanilla AP, Weffer MI. Hyperkalemia in the patient on chronic dialysis. Int J Artif Organs 1987; 10: 17–19 (B)

  1851. Raad II, Hohn DC, Gilbreath BJ et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15: 231–238 (B)

  1852. Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM: Serum erythropoietin concentration in chronic renal failure: Relationship to degree of anemia and excretory renal function. Blood 54:877-884, 1979

  1853. Raff E, Halloran PF, Kjellstrand C: Renal Failure After Eating "Magic Mushrooms" . Can Med Assoc J 1992; 147: 1339-40.

  1854. Ragland G, in Tintinalli J, et al (eds): Hypoglycemia . Emergency Medicine: A Comprehensive Study Guide 1996; 939-946.

  1855. Raj DS, Ouwendyk M, Francoeur R, Pierratos A. Beta 2-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant 2000; 15: 58–64 (B)

  1856. Raj DS, Tobe S, Saiphoo C, Manuel MA. Quantitating dialysis using two dialysate samples: a simple, practical and accurate approach for evaluating urea kinetics. Int J Artif Organs 1997; 20: 422–427 (B)

  1857. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 1998; 13: 2281–2287 (B)

  1858. Raju S. PTFE grafts for hemodialysis access. Techniques for insertion and management of complications. Ann Surg 1987; 206: 666–673 (B)

  1859. Ramage I, Bailie A, Tyerman K, et al. Vascular access survival in children and young adults receiving long-term hemodialysis. Am J Kidney Dis 2005;45:708-714.

  1860. Ramoska EA, Spiller HA, Myers A: Calcium Channel Blocker Toxicity . Ann Emerg Med 1990; 19: 649-653.

  1861. Rao D, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171-175.

  1862. Rapoport J, Aviram M, Chaimovitz C, Brook JG. Defective high-density lipoprotein composition in patients on chronic hemodialysis. A possible mechanism for accelerated atherosclerosis. N Engl J Med 1978; 299: 1326–1329 (B)

  1863. Raptopoulou-Gigi M, Spaia S, Garifallos A et al. Interferonalpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1834–1837 (B)

  1864. Rautenberg P, Teifke I, Schlegelberger T, Ullmann U. Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination. Infection 1988; 16: 323–328 (B)

  1865. Ravanan R, Udayaraj U, Ansell D, Collett D, Johnson R, O’Neill J, Tomson CRV, Dudley CRK. Variation between centres in access to renal transplantation in the UK; longitudinal cohort study. BMJ 2010; 341: c3451

  1866. Ravani P, Brunori G, Mandolfo S et al. Cardiovascular comorbidity and late referral impact arteriovenous fistulasurvival: a prospective multicenter study. J Am Soc Nephrol 2004; 15: 204–209

  1867. Ravani P, Marcelli D, Malberti F. Vascular access surgery managed by renal physicians: the choice of native arteriovenous fistulas for hemodialysis. Am J Kidney Dis 2002; 40: 1264–1276

  1868. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101–2106 (A)

  1869. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44: 22–26

  1870. Rayner HC, Pisoni RL, Gillespie BW et al. Dialysis Outcomes and Practice Patterns Study. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63: 323–330

  1871. Reber G, Stoermann C, De Moerloose P, Ruedin P, Leski M. Hemostatic disturbances induced by two hollow-fiber hemodialysis membranes. Int J Artif Organs 1992; 15: 269–276 (B)

  1872. Recommendations of the advisory Committee on immunization Practices (ACIP) use of vaccins and immunoglobulins in persons with altered immunocompetence. Morb Mortal Wkly Rep 1993; 42 (RR-4): 1–18 (B)

  1873. Reddingus R, Schroder C, Monnens L. Intraperitoneal administration of recombinant human erythropoietin in children on continuous ambulatory peritoneal dialysis. Eur J Pediatr 1992;151:540-542.

  1874. Redmond HP, Shou J, Kelly CJ et al. Immunosuppressive mechanisms in protein-calorie malnutrition. Surgery 1991; 110: 311–317 (B)

  1875. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49:31–62 (C)

  1876. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193–2203.

  1877. Reichel H, Esser A, Roth H-J et al. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759–768.

  1878. Reid HA, Thean PC, Martin WJ: Epidemiology of snake bite in north Malaya . Brit Med J 1963; 1: 992-997.

  1879. Reid HA: Antivenom in sea-snake poisoning . Lancet 1975; 1(7907): 622-23.

  1880. Reid HA: Bites by foreign venomous snakes in Britain . Brit Med J 1978; 1: 1598-1600.

  1881. Reid HA: Cobra bites . Brit Med J 1964; 2: 540-545.

  1882. Reid HA: Epidemiology of sea-snake bites . J Trop Med Hyg 1975; 18: 106-13.

  1883. Reidenberg MM, Shear L, Cohen RV. Elimination of isoniazid in patients with impaired renal function. Am Rev Respir Dis 1973; 108: 1426–1428 (B)

  1884. Reissman P, Lyass S, Shiloni E, et al. Placement of a peritoneal dialysis catheter with routine omentectomy: does it prevent obstruction of the catheter? Eur J Surg 1998;164:703-707.

  1885. Reith DM, Dawson AH, Whyte IM: Relative toxicity of beta blockers in overdose . Clin Tox 1996; 34: 273-278.

  1886. Reynolds J, Morton M, Garralda M, et al. Psychosocial adjustment of adult survivors of a paediatric dialysis and transplant programme. Arch Dis Child 1993;68:104-110.

  1887. Ribeiro S, Ramos A, Brandao A et al. Cardiac valve calcification in haemodialysis patients: role of calciumphosphate metabolism. Nephrol Dial Transplant 1998; 13: 2037–2040 (B)

  1888. Rich SA, Libera JM, Locke RJ: Treatment of foxglove extract poisoning with digoxin-specific Fab fragments . Ann Emerg Med 1993; 22: 1904-1907.

  1889. Richalet JP, Souberbielle JC, Antezana AM, et al: Control of erythropoiesis in humans during prolonged exposure to the altitude of 6,542 m. Am J Physiol 266:R756-R764, 1994

  1890. Richmond M, Seger D: Central anticholinergic syndrome in a child: A case report . J Emerg Med 1985; 3: 453-6.

  1891. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979 (A)

  1892. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191–1193 (B)

  1893. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839–844 (B)

  1894. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–235 (B)

  1895. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 2001; 285: 2481–2485 (B)

  1896. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–1818 (B)

  1897. Riffer E, Curry SC, Gerkin R: Successful treatment with antivenin of marked thrombocytopenia without significant coagulopathy following rattlesnake bite . Ann Emerg Med 1987; 16: 1297-9.

  1898. Rimza ME, Zimmerman DR, Bergeson PS: Scorpion envenomation . Pediatrics 1980; 66: 298-302.

  1899. Rinaldi S, Sera F, Verrina E, et al. Chronic peritoneal dialysis catheters in children: a fifteen-year experience of the Italian Registry of Pediatric Chronic Peritoneal Dialysis. Perit Dial Int 2004;24:481-486.

  1900. Rippe B, Stelin G, Haraldsson B. Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 1991;40:315-325.

  1901. Rippe B, Stelin G. Simulations of peritoneal transport during CAPD. Kidney Int 1989;35:1234-1244.

  1902. Rippe B. A three-pore model of peritoneal transport. Perit Dial Int 1991;13:S35-S38.

  1903. Rissanen A, Heliovaara M, Knekt P, Aromaa A, Reunanen A, Maatela J: Weight and mortality in Finnish men. J Clin Epidemiol 42:781-789, 1989

  1904. Ritz E, Eisenhardt A: Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant 15:S40-S44, 2000 (suppl 3)

  1905. Ritz E. Why are lipids not predictive of cardiovascular death in the dialysis patient? Miner Electrolyte Metab 1996; 22: 9–12 (C)

  1906. Riva R, Contin M, Albani F: Free and Total Plasma Concentrations of Carbamazepine and Carbamazepine -10, 11-epoxide in Epileptic Patients: Diurnal Fluctuations and Relationship with Side Effects . Therapeutic Drug Monitoring 1984; 6: 408-412.

  1907. Ro¨ ckel A, Hertel J, Fiegel P et al. Permeability and secondary membrane formation of a high flux polysulfone hemofilter. Kidney Int 1986; 30: 429–432 (B)

  1908. Ro¨ ckel A, Klinke B, Hertel J et al. Allergy to dialysis materials. Nephrol Dial Transplant 1989; 4: 646–652 (B)

  1909. Robbin ML, Gallichio MH, Deierhoi MH, Young CJ, Weber TM, Allon M. US vascular mapping before hemodialysis access placement. Radiology 2000; 217: 83–88

  1910. Roberge R, McGuire S, Krenzelok E: Yohimbine as an antidote for clonidine overdose . American Journal of Emergency Medicine 1996; 14(7): 678-680.

  1911. Robinson DL, Fowler VG, Sexton DJ, Corey RG, Conlon PJ. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997; 30: 521–524 (B)

  1912. Robinson K, Gupta A, Dennis V et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743–2748 (B)

  1913. Robles NR, Murga L, Galvan S, Esparrago JF, Sanchez-Casado E. Hemodialysis with cuprophane or polysulfone: effects on uremic polyneuropathy. Am J Kidney Dis 1993; 21: 282–287 (A)

  1914. Robson MD, Charoenpanich R, Kant KS et al. Effect of first and subsequent use of hemodialyzers on patient well being. Analysis of the incidence of symptoms and events and description of a syndrome associated with new dialyzer use. Am J Nephrol 1986; 6: 101–106 (B)

  1915. Robson R, Collins J, Johnson R et al. Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol 1997; 10: 33–40 (A)

  1916. Roccatello D, Formica M, Cavalli G et al. Serum and intracellular detection of cytokines in patients undergoing chronic hemodialysis. Artif Organs 1992; 16: 131–140 (B)

  1917. Roccatello D, Mazzucco G, Coppo R et al. Functional changes of monocytes due to dialysis membranes. Kidney Int 1989; 35: 622–631 (B)

  1918. Rocco M, et al. Changes in peritoneal transport during the first month of peritoneal dialysis. Perit Dial Int 1995;15:12-17.

  1919. Rocco M. Body surface area limitations in achieving adequate therapy in peritoneal dialysis patients. Perit Dial Int 1996;16:617-622.

  1920. Rockel A, Hertel J, Fiegel P et al. Permeability and secondary membrane formation of a high flux polysulfone hemofilter. Kidney Int 1986; 30: 429–432 (B)

  1921. Rodriquez JH: Risk of upper gastrointestianl and perforation associated with individual NSAIDs . Lancel 1994; 343: 769-772.

  1922. Roger SD, McMahon LP, Clarkson A, et al: Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 15:148-156, 2004

  1923. Rolf N, Tenschert W, Lison AE. Results of a long-term administration of omega-3 fatty acids in haemodialysis patients with dyslipoproteinaemia. Nephrol Dial Transplant 1990; 5: 797–801 (B)

  1924. Romero A, Polo JR, Garcia ME, Garcia Sabrido JL, Quintans A, Ferreira JP. Salvage of angioaccess after late thrombosis of radiocephalic fistulas for hemodialysis. Int Surg 1986; 71: 122–124

  1925. Ronco C, Brendolan A, Crepaldi C, La Greca G. Ultrafiltrations—rates und dialyse hypotension. Dialyse J 1992; 40: 8–15 (C)

  1926. Ronco C, Heifetz A, Fox K et al. Beta 2-microglobulin removal by synthetic dialysis membranes. Mechanisms and kinetics of the molecule. Int J Artif Organs 1997; 20: 136–143 (B)

  1927. Rondeau ES, Everson GW, Savage W: Plant nurseries: a reliable resource for plant identification? . Vet Hum Toxicol 1992; 34: 544-546.

  1928. Ronnholm K, Holmberg C. Peritoneal dialysis in infants. Pediatr Nephrol 2006;21:751-756.

  1929. Roodhooft A, Van Hoeck K, Van Acker K. Hypophosphatemia in infants on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990;34:131-135.

  1930. Rooijens PPGM, Tordoir JHM, Stijnen T, Burgmans JPJ, Smet de AAEA, Yo TI. Radiocephalic wrist arteriovenous fistula for hemodialysis: meta-analysis indicates a high primary failure rate. Eur J Vasc Endovasc Surg 2004; 28: 571–680

  1931. Roselaar SE, Nazhat NB, Winyard PG et al. Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 1995; 48: 199–206 (B)

  1932. Rosen JF: Adverse health effects of lead at low exposure levels: trends in the management of childhood lead poisoning . Toxicology 1995; 97: 11-7.

  1933. Rosenkranz AR, Ko¨rmo¨ czi GF, Thalhammer F et al. Novel C5-dependent mechanism of neutrophil stimulation by bioincompatible dialyzer membranes. J Am Soc Nephrol 1999; 10: 128–135 (B)

  1934. Rosenkranz J, Bonzel K, Bulla M, et al. Psychosocial adaptation of children and adolescents with chronic renal failure. Pediatr Nephrol 1992;6:459-463.

  1935. Rosenkranz J, Reichwald-Klugger E, Oh J, et al. Psychosocial rehabilitation and satisfaction with life in adults with childhood-onset of end-stage renal disease. Pediatr Nephrol 2005;20:1288-1294.

  1936. Rosenzweig P, Gary NE, Gocke DJ et al. Heparin allergy accompanying acute renal failure. Artif Organs 1979; 3: 78–79 (B)

  1937. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–126 (C)

  1938. Ross RP, McCrea JB, Besarab A: Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J 40:M880-M885, 1994

  1939. Ross SD, Allen IE, Connelly JE et al. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999; 159: 1793–1802 (A)

  1940. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344–2348 (B)

  1941. Rostand SG, Kirk KA, Rutsky EA. Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 1982; 22: 304–308 (B)

  1942. Roth A, Kaluski E, Felner S: Clonidine for patients with rapid atrial fibrillation . Annals of Internal Medicine 1992; 116(5): 388-390.

  1943. Roth D, Smith RD, Schulman G, et al: Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994

  1944. Roth RI, Levin FC, Levin J. Optimization of detection of bacterial endotoxin in plasma with the Limulus test. J Lab Clin Med 1990; 116: 153–161 (C)

  1945. Roth VR, Jarvis WR. Outbreaks of infection anduor pyrogenic reactions in dialysis patients. Semin Dial 2000; 13: 92–96 (B)

  1946. Rousseau Y, Carreno MP, Poignet JL, Kazatchkine MD, Haeffner-Cavaillon N. Dissociation between complement activation, integrin expression and neutropenia during hemodialysis. Biomaterials 1999; 20: 1959–1967 (B)

  1947. Rowlings PA, Mansberg R, Rozenberg MC, Evans S, Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. Aust N Z J Med 1991; 21: 52–54 (B)

  1948. Roxborough HE, Mercer C, McMaster D, Maxwell AP, Young IS. Plasma glutathione peroxidase activity is reduced in haemodialysis patients. Nephron 1999; 81: 278–283 (B)

  1949. Rubies-Prat J, Espinel E, Joven J, Ras MR, Pira L. High-density lipoprotein cholesterol subfractions in chronic uremia. Am J Kidney Dis 1987; 9: 60–65 (B)

  1950. Rubies-Prat J, Reverter JL, Senti M et al. Calculated lowdensity lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care 1993; 16: 1081–1086 (B)

  1951. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410–418 (A)

  1952. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med 1990; 322: 717–722 (B)

  1953. Ruley E, et al. Feeding disorders and gastroesophageal reflux in infants with chronic renal failure. Pediatr Nephrol 1989;3:424-429.

  1954. Rumack BH (ed): Plants - cardiac glycosides . Poisondex 1997; 94:.

  1955. Rumack BH, Spoerke DG: Chapter . Handbook of Mushroom Poisoning Diagnosis and Treatment, 2nd ed. 1994;.

  1956. Rumpf KW, Seubert S, Seubert A et al. Association of ethylene-oxide-induced IgE antibodies with symptoms in dialysis patients. Lancet 1985; 2: 1385–1387 (B)

  1957. Ruprecht J: Scientific Monograph Dimaval (DMPS) . Investigators Brochure Heyltex Corporation Houston, Texas 1997;.

  1958. Rus RR, Ponikvar R, Kenda RB, Buturovic-Ponikvar J. Effect of local physical training on the forearm arteries and veins in patients with end-stage renal disease. Blood Purif 2003; 21(6): 389–394

  1959. Rusthoven E, van der Vlugt M, van Lingen-van Bueren L, et al. Evaluation of intraperitoneal pressure and the effect of different osmotic agents on intraperitoneal pressure in children. Perit Dial Int 2005;25:352-356.

  1960. Rutsky EA, Rostand SG. Mycobacteriosis in patients with chronic renal failure. Arch Intern Med 1980; 140: 57–61 (B)

  1961. Ryan KE, Lane DA, Flynn A et al. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991; 66: 277–282 (B)

  1962. Rylance PB, Gordge MP, Saynor R, Parsons V, Weston MJ. Fish oil modifies lipids and reduces platelet aggregability in haemodialysis patients. Nephron 1986; 43: 196–202 (B)

  1963. Rysz J, Luciak M, Kedziora J, Blaszczyk J, Sibinska E. Nitric oxide release in the peripheral blood during hemodialysis. Kidney Int 1997; 51: 294–300 (B)

  1964. Sabbioni E, Pietra R, Ubertalli L et al. Salts as a source of metals in dialysis fluids: an assessment study by means of neutron activation analysis. Sci Total Environ 1989; 84:13–23 (B)

  1965. Sabeel AI, et al.: Intensified dialysis treatment of ethylene glycol intoxication . Scand J Urol Nephrol 1995; 29(2): 125-129.

  1966. Sadowski R, Allred E, Jabs K. Sodium modeling ameliorates intradialytic and interdialytic symptoms in young hemodialysis patients. J Am Soc Nephrol 1993;4:1192-1198.

  1967. Sadowski R, et al. Acute hemodialysis of infants weighing less than five kilograms. Kidney Int 1994;45:903-906.

  1968. Sagedal S, Hartmann A, Sundstrom K et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant 1999; 14: 1943–1947 (B)

  1969. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001; 16: 987–993 (B)

  1970. Saha LK, Van Stone JC. Differences between KTV measured during dialysis and KTV predicted from manufacturer clearance data. Int J Artif Organs 1992; 15: 465–469 (B)

  1971. Saika Y, Kodama N, Kimura K et al. Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol. Nippon Jinzo Gakkai Shi 1999; 41: 430–435 (B)

  1972. Sakata N, Imanaga Y, Meng J et al. Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease. Atherosclerosis 1999; 142: 67–77 (B)

  1973. Sakurabayashi T, Fujimoto M, Takaesu Y et al. Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. Jpn Circ J 1999; 63: 692–696 (B)

  1974. Salkowski AA, Penney DG: Cyanide poisoning in animals and humans: A review . Vet Hum Toxicol 1994; 36: 455-466.

  1975. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation. Nephrol Dial Transplant 1999; 14: 2698–2703 (A)

  1976. Salusky IB, Kuizon BD, Belin TR et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intra-peritoneal administration. Kidney Int 1998; 54: 907–914.

  1977. Salusky I, Coburn J, Brill J, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988;33:975-982.

  1978. Salusky I, Coburn J, Foley J, et al. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986;108:767-770.

  1979. Salusky I, Fine R, Nelson P, et al. Nutritional status of children undergoing continuous peritoneal dialysis. Am J Clin Nutr 1983;38:599-611.

  1980. Salusky I, Goodman W, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005;16:2501-2508.

  1981. Salusky IB, Goodman WG, Sahney S et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005; 16: 2501–2508.

  1982. Salusky IB, Goodman WG. Managing phosphate retention: is a change necessary? Nephrol Dial Transplant 2000; 15: 1738–1742 (C)

  1983. Sampietro M, Badalamenti S, Salvadori S et al. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int 1995; 47: 911–917 (B)

  1984. Samtleben W, et al. Plasma therapy at Klinikum Grosshadern: a 15-year retrospec­tive. Artif Organs 1996;20:408-413.

  1985. Sanders PW, Taylor H, Curtis JJ. Hemodialysis without anticoagulation. Am J Kidney Dis 1985; 5: 32–35 (B)

  1986. Sands JJ, Jabyac PA, Miranda CL, Kapsick BJ. Intervention based on monthly monitoring decreases hemodialysis access thrombosis. ASAIO J 1999; 45: 147–150

  1987. Sanklecha M, Jog A, Raghavan K: Clonidine casualty . Indian Journal of Pediatrics 1993; 60: 611-612.

  1988. Santoro A, Ferrari G, Francioso A et al. Ethylene-oxide and steam-sterilised polysulfone membrane in dialysis patients with eosinophilia. Int J Artif Organs 1996; 19: 329–335 (B)

  1989. Saracho R, Martin-Malo A, Martinez I, Aljama P, Montenegro J. Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int 1998; 53 [Suppl 68]: S125–S129 (B)

  1990. Saran R, Dykstra DM, Pisoni RL et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19: 2334–2340

  1991. Sargent JA, Gotch FA. Mathematic modeling of dialysis therapy. Kidney Int 1980; 18 [Suppl 10]: S2–S10 (B)

  1992. Sargent JA, Gotch FA. Principles and biophysics of dialysis. In: Maher J, ed. Replacement of Renal Function by Dialysis. Kluwer Academic, Boston: 1989; 87–143 (C)

  1993. Sargent JA, Gotch FA. The analysis of concentration dependence of uraemic lesions in clinical studies. Kidney Int 1975;7 [Suppl 2]: S35–S44 (B)

  1994. Sarnak MJ, Coronado BE, Greene T, Wang S-R, Kusek JW, Beck GJ, Levey AS: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002 (in press)

  1995. Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000; 58: 1758–1764 (B)

  1996. Sasaki S, Akiba T, Suenaga M et al. Ten years’ survey of dialysis-associated tuberculosis. Nephron 1979; 24: 141–145 (B)

  1997. Sato T, Koga N. Centralized on-line haemodiafiltration system utilizing purified dialysate as substitution fluid. Artif Organs 1998; 22: 285–290 (B)

  1998. Satoh M, Yamasaki Y, Nagake Y et al. Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 2001; 59: 1943–1950 (B)

  1999. Sawai Y, Tseng CS: Snakebites on Taiwan . Snake 1969; 1: 9-18.

  2000. Schaefer F, Feneberg R, Aksu N, et al. Worldwide variation of dialysis-associated peritonitis in children. Kidney Int 2007;72:1374-1379.

  2001. Schaefer F, Fischbach M, Heckert K. Hydrostatic intraperitoneal pressure in children on peritoneal dialysis. Perit Dial Int 1996;16:S79.

  2002. Schaefer F, Haraldsson B, Haas S, et al. Estimation of peritoneal mass transport by three-pore model in children. Kidney Int 1998;54:1372-1379.

  2003. Schaefer F, Klaus G, Mehls O. Peritoneal transport properties and dialysis dose affect growth and nutritional status in children on chronic peritoneal dilaysis. Mid-European Pediatric Peritoneal Dialysis Study Group. J Am Soc Nephrol 1999;10:1786-1792.

  2004. Schaefer F, Langenbeck D, Heckert K, et al. Evaluation of peritoneal solute transfer by the peritoneal equilibration test in children. Adv Perit Dial 1992;8:410-415.

  2005. Schaefer F, Wuhl E, Haffner D, et al. Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Adv Perit Dial 1994;10:321-326.

  2006. Schaefer RM, Rauterberg EW, Deppisch R, Vienken J.Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction. Miner Electrolyte Metab 1990; 16: 73–76 (B)

  2007. Schaefer RM, Schaefer L, Horl WH. Anaphylactoid reactions during hemodialysis. Clin Nephrol 1994; 42 [Suppl 1]: S44–S47 (C)

  2008. Schambelam M: Licorice ingestion and blood pressure regulating hormones . Steroids 1994; 59: 127-130.

  2009. Scheiermann N, Gesemann M, Maurer C, Just M, Berger R. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine 1990; 8 [Suppl]: S44–S46 (B)

  2010. Schettler V, Wieland E, Methe H, Schuff-Werner P, Muller GA. Oxidative stress during dialysis: effect on free radical scavenging enzyme (FRSE) activities and glutathione (GSH) concentration in granulocytes. Nephrol Dial Transplant 1998; 13: 2588–2593 (B)

  2011. Schettler V, Wieland E, Verwiebe R et al. Plasma lipids are not oxidized during hemodialysis. Nephron 1994; 67: 42–47 (B)

  2012. Schiffl H, Fischer R, Lang SM, Mangel E. Clinical manifestations of AB-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000; 15: 840–845 (B)

  2013. Schild AF, Raines J. Preliminary prospective randomized experience with vascular clips in the creation of arteriovenous fistulae for hemodialysis. Am J Surg 1999; 178: 33–37

  2014. Schiller B, Ziegler-Heitbrock HWL, Meyer N, Schmidt B, Blumenstein M. Monocyte phenotype and interleukin-1 production in patients undergoing haemodialysis. Nephron 1991; 59: 573–579 (B)

  2015. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452–459 (A)

  2016. Schindler R, Boenisch O, Fischer C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452–459 (B)

  2017. Schindler R, Krautzig S, Lufft V et al. Induction of interleukin-1 and interleukin-1 receptor antagonist during contaminated in-vitro dialysis with whole blood. Nephrol Dial Transplant 1996; 11: 101–108 (B)

  2018. Schindler R, Linnenweber S, Schulze M et al. Gene expression of interleukin-1 during hemodialysis. Kidney Int 1993; 43: 712–721 (B)

  2019. Schindler R, Lonnemann G, Schaffer J, Shaldon S, Koch KM, Krautzig S. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic haemodialysis. Nephron 1994; 68: 229–233 (B)

  2020. Schindler R, Lonnemann G, Shaldon S, Koch KM, Dinarello CA. Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. Kidney Int 1990; 37: 85–93 (B)

  2021. Schindler R, Marra MN, MacKelligon BM et al. Plasma levels of bactericidalupermeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP) during hemodialysis. Clin Nephrol 1993; 40: 346–351 (B)

  2022. Schmidt RJ, Domico J, Samsell LS et al. Indices of activity of the nitric oxide system in haemodialysis patients. Am J Kidney Dis 1999; 34: 228–234 (A)

  2023. Schmidt RJ, Domico J, Samsell LS et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999; 34: 228–234 (B) SECTION VII. Vascular disease and risk factors 107

  2024. Schmitt C, von Heyl D, Rieger S, et al. Reduced systemic advanced glycation endproducts in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 2007;22:2038-2044.

  2025. Schmitt CP, Huber D, Mehls O et al. Altered instantaneous and calciummodulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 1998; 9: 1832–1844.

  2026. Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438–442 (B)

  2027. Schneditz D, Fariyike B, Osheroff R, Levin NW. Is intercompartmental urea clearance during haemodialysis a perfusion term? A comparison of two pool urea kinetic models. J Am Soc Nephrol 1995; 6: 1360–1370 (B)

  2028. Schneditz D, Van Stone JC, Daugirdas JT. A regional blood circulation alternative to in-series two compartment urea kinetic modeling. ASAIO J 1993; 39: M573–M577 (B)

  2029. Schneeweiss B, Graninger W, Stockenhuber F, Druml W, Ferenci P, Eichinger S, Grimm G, Laggner AN, Lenz K: Energy metabolism in acute and chronic renal failure. Am J Clin Nutr 52:596-601, 1990

  2030. Schoebel FC, Gradaus F, Ivens K et al. Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case-control study using quantitative coronary angiography. Heart 1997; 78: 337–342 (B)

  2031. Schoumacher R, Chevalier R, Gomez R, et al. Enhanced clearance of vancomycin by hemodialysis in a child. Pediatr Nephrol 1989; 3:83-85.

  2032. Schouten WE, Grooteman MP, van Houte AJ et al. Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 2000; 15: 379–384 (B)

  2033. Schrader J, Andersson LO, Armstrong VW et al. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Semin Thromb Hemost 1990; 16 [Suppl]: 41–45 (B)

  2034. Schrader J, Stibbe W, Armstrong VW et al. Comparison of low molecular weight heparin to standard heparin in hemodialysisuhemofiltration. Kidney Int 1988; 33: 890–896 (A)

  2035. Schröder C, Reddingius R, van Dreumel J, et al. Transcapillary ultrafiltration and lymphatic absorption during childhood continuous ambulatory peritoneal dialysis (CAPD). Nephrol Dial Transplant 1991;6:571-573.

  2036. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W. Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.Kidney Int 2001; 59: 19–24 (B)

  2037. Schrooten I, Elseviers MM, Lamberts LV, De Broe ME,D’Haese PC. Increased serum strontium levels in dialysis patients: an epidemiological survey. Kidney Int 1999;56: 1886–1892 (B)

  2038. Schulman G, Hakim R, Arias R et al. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J Am Soc Nephrol 1993; 3: 1563–1569 (B)

  2039. Schulz T, Schiffl H, Scheithe R, Hrboticky N, Lorenz R. Preserved antioxidative defense of lipoproteins in renal failure and during hemodialysis. Am J Kidney Dis 1995; 25: 564–571 (B)

  2040. Schuman E, Standage BA, Ragsdale JW, Hein P. Achieving vascular access success in the quality outcomes era. Am J Surg 2004; 187: 585–589

  2041. Schwab SJ, Weiss MA, Rushton F et al. Multicenter clinical trial results with the LifeSite hemodialysis access system. Kidney Int 2002; 62: 1026–1033

  2042. Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch KM, Floege J. Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term haemodialysis? Kidney Int 1997; 52: 1077–1083 (B)

  2043. Schwartz AB, Prior JE, Mintz GS, Kim KE, Kahn SB: Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin. Transplant Proc 23:1827-1830, 1991

  2044. Schwarz U, Amann K, Ritz E. Why are coronary plaques more malignant in the uraemic patient? Nephrol Dial Transplant 1999; 14: 224–225 (C)

  2045. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218–223 (B)

  2046. Schwedler S, Metzger T, Zimmermann J, Schinzel R, Wanner C. Why does carboxymethyllysine (CML), a marker of advanced glycation end products (AGEs) not predict cardiovascular and overall mortality in hemodialysis patients. J Am Soc Nephrol 2000; 11: 297 (Abstract) (B)

  2047. Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and growth of children with end-stage renal disease. In: Gurland H, Moran J, Samtleben W, Scigalla P, Wieczorek L, eds. Erythropoietin in renal and non-renal anemias. Contributions to nephrology. Basel: Karger, 1991:201-211.

  2048. Scolnik D, Balfe J. Initial hypoalbuminemia and hyperlipidemia persist during chronic peritoneal dialysis in children. Perit Dial Int 1993;13:136-139.

  2049. Scott MK, Mueller BA, Clark WR. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol Dial Transplant 1997; 12: 2647–2653 (B)

  2050. Seaworth B, Drucker J, Starling J et al. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 1988; 157: 332–337 (B)

  2051. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–27 (A)

  2052. Sedman A, Wilkening G, Warady B, et al. Encephalopathy in childhood secondary to aluminum toxicity. J Pediatr 1984;105:836-838.

  2053. Seeherunvong W, Nwobi O, Abitbol C, et al. Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patients. Pediatr Nephrol 2006;21:1434-1439.

  2054. Segal JH, Kayler LK, Henke P, Merion RM, Leavey S, Campbell Jr, DA, Vascular access outcomes using the transposed basilic vein arteriovenous fistula. Am J Kidney Dis 2003; 42: 151–157

  2055. Seger D: Endocrine Principles . Goldfrank's Toxicologic Emergencies 1994; 5: 338-390.

  2056. Sehgal AR, Snow RJ, Singer ME et al. Barriers to adequate delivery of haemodialysis. Am J Kidney Dis 1998; 31: 593–601 (B)

  2057. Seifert A, von Herrath D, Schaefer K. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. Q J Med 1987; 65: 1015–1024 (B)

  2058. Seifert R, Borchert W, Letendre P, Knutson R, Cipolle R. Heparin kinetics during hemodialysis: variation in sensitivity, distribution volume, and dosage. Ther Drug Monit 1986; 8: 32–36 (B)

  2059. Seme K, Poljak M, Zuzec-Resek S et al. Molecular evidence for nosocomial spread of two different hepatitis C virus strains in one hemodialysis unit. Nephron 1997; 77: 273–278 (B)

  2060. Sennesael JJ, Van der NP, Verbeelen DL. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121–128 (B)

  2061. Senti M, Romero R, Pedro BJ et al. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394–1399 (B)

  2062. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409–1415 (B)

  2063. Sesso R, Barbosa D, Leme IL et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol 1998; 9: 1085–1092 (A)

  2064. Seyfert UT, Helmling E, Hauck W, Skroch D, Albert W.Comparison of blood biocompatibility during haemodialysis with cuprophane and polyacrylonitrile membranes. Nephrol Dial Transplant 1991; 6: 428–434 (B)

  2065. Shackleton CA, Taylor OC, Buckley AR, Rowley VA, Cooperberg PL, Fry PD. Predicting failure in polytetrafluoroethylene vascular access grafts for hemodialysis: a pilot study. Can J Surg 1987; 30: 442–444

  2066. Shaldon S, Koch KM. Biocompatibility in haemodialysis clinical relevance in 1995. Artif Organs 1995; 19: 395–397 (C)

  2067. Sharma A, Espinosa P, Bell L, et al. Multicompartment urea kinetics in well-dialyzed children. Kidney Int 2000;58:2138-2146.

  2068. Sharma A, Zilleruelo G, Abitbol C, et al. Survival and complications of cuffed catheters in children on chronic hemodialysis. Pediatr Nephrol 1999;13:245-248.

  2069. Sharma P, Chaturvedi SK: Coversion disorder revisited. Acta Psychiatrica Scandinavica 1995; 92: 301-304.

  2070. Shemin D, Lapane KL, Bausserman L et al. Plasma total homocysteine and hemodialysis access thrombosis: a prospective study. J Am Soc Nephrol 1999; 10: 1095–1099 (B)

  2071. Sherman RA, Cody RP, Rogers ME, Solanchick JC. Accuracy of the urea reduction ratio in predicting dialysis delivery. Kidney Int 1995; 47: 319–321 (B)

  2072. Sheth R, Brandt M, Brewer E, et al. Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. Kidney Int 2002;62:1864-1869.

  2073. Sheth R, Kale A, Brewer E, et al. Successful use of Tesio catheters in pediatric patients receiving chronic hemodialysis. Am J Kidney Dis 2001;38:553-559.

  2074. Shiffman RN, Shekelle P, Overhage JM et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med 2003; 139: 493–498.

  2075. Shinzato T, Nakai S, Akiba T et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997; 12: 884–888 (B)

  2076. Shinzato T, Nakai S. Do shorter hemodialyses increase the risk of death? Int J Artif Organs 1999; 22: 199–201 (C)

  2077. Shohaib SA, Scrimgeour EM, Shaerya F. Tuberculosis in active dialysis patients in Jeddah. Am J Nephrol 1999; 19: 34–37 (B)

  2078. Shoji T, Kawagishi T, Emoto M et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2000; 153: 257–258 (B) 104 SECTION VII. Vascular disease and risk factors

  2079. Shoji T, Nishizawa Y, Kawagishi T et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998; 9: 1277–1284 (B)

  2080. Shoji T, Nishizawa Y, Kawasaki K et al. Effects of the nicotinic acid analogue niceritrol on lipoprotein Lp(a) and coagulationfibrinolysis status in patients with chronic renal failure on hemodialysis. Nephron 1997; 77: 112–113 (B)

  2081. Shorter E: Borderland between neurology and history. Neurologic Clinics 1995; 13(2): 229-239.

  2082. Shumaik GM, Wu AW, Ping AC: Oleander poisoning: Treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med 1988; 17: 732-735.

  2083. Siebels M, Andrassy K, Vecsei P et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res 1992; 66: 467–473 (B)

  2084. Sieniawska M, Roszkowska-Blaim M, Warchol S. Preliminary results with the swan neck presternal catheter for CAPD in children. Adv Perit Dial 1993;9:321-324.

  2085. Silva Jr, MB, Hobson RW, Pappas PJ et al. A strategy for increasing use of autogenous hemodialysis access procedures: impact of preoperative noninvasive evaluation. J Vasc Surg 1998; 27: 302–307

  2086. Silverberg DS, Iaina A, Peer G, et al: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996

  2087. Simard JM, Watt DD: Venoms and Toxins . In Polis GA (Ed): The Biology of Scorpions. Stanford University Press. 1990; 1: 414-444.

  2088. Simmons J, Wilson C, Potter D, et al. Relation of calorie deficiency to growth failure in children on hemodialysis and the growth response to calorie supplementation. N Engl J Med 1971;285:653-656.

  2089. Simon JA. Review: vitamin D supplementation decreases all-cause mortality in adults and older people. Evid Based Med 2008; 13: 47.

  2090. Simpson HK, Baird J, Allison M et al. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996; 26: 90–97 (B)

  2091. Sims JK, Ostman DC: Pufferfish poisoning: Emergency diagnosis and management of mild human tetrodotoxication. Ann Emerg Med 1986; 15: 1094-1098.

  2092. Singh A, Szczech L, Tang K, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.

  2093. Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysispatients: report of three cases and a review of the literature. Nephron 1993; 64: 303–306 (B)

  2094. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207–1211 (B)

  2095. Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron 1998; 79: 245–246 (B).

  2096. Skroeder NR, Kjellstrand P, Holmquist B, Nilsson U, Jacobson SH. Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: the relation with dialysis efficacy. Nephron 1996; 72: 523–529 (B)

  2097. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753–761.

  2098. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-161.

  2099. Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed cal. Kidney Int 1999; 55: 299–307 (B)

  2100. Slifman NR, Obermeyer WR, Aloi BK, et al: Contamination of botanical dietary supplements by Digitalis lantana . N Eng J Med 1998; 339: 806-811.

  2101. Sliman G, Klee K, Gall-Holden B, et al. Peritoneal equilibration test curves and adequacy of dialysis in children on automated peritoneal dialysis. Am J Kidney Dis 1994;24:813-818.

  2102. Smart D: Clinical toxicology of shellfish poisoning . Handbook of Clinical Toxicology of Animal Venoms and Poisons 1995; CRC Press: 33.

  2103. Smirnoff M, Patt C, Seckler B, Adler JJ. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998; 113: 25–27 (B)

  2104. Smith BP, Ward RA, Brier ME. Prediction of anticoagulation during hemodialysis by population kinetics and an artificial neural network. Artif Organs 1998; 22: 731–739 (B)

  2105. Smith MC, Danviriyasup K, Crow JW et al. Prostacyclin substitution for heparin in long-term hemodialysis. Am J Med 1982; 73: 669–678 (B)

  2106. Smolinske SC, Hall AH: Toxic effects of NSAID oversode . Drug Safety 1990; 5(4): 252-274.

  2107. Smye S, Evans J, Will E, et al. Paediatric haemodialysis: estimation of treatment efficiency in the presence of urea rebound. Clin Phys Physiol Meas 1992;13:51-62.

  2108. Smye SW, Dunderdale E, Brownridge G, Will E. Estimation of treatment dose in high-efficiency haemodialysis. Nephron 1994; 67: 24–29 (B)

  2109. Smye SW, Evans JH, Will E, Brocklebank JT. Paediatric haemodialysis: estimation of treatment efficiency in the presence of urea rebound. Clin Phys Physiol Meas 1992; 13: 51–62 (B)

  2110. Smye SW, Tattersall JE, Will EJ. Modeling the postdialysis rebound: the reconciliation of current formulas. ASAIO J 1999; 45: 562–567 (B)

  2111. Societa` Italiana di Nefrologia. Linee Guida sulla quantificazione della dose dialitica. Giornale Ital Nefrol 1999; 16: 22–26 (C)

  2112. Sodemann K, Polaschegg HD, Feldmer B. Two years’ experience with Dialock and CLS (a new antimicrobial lock solution). Blood Purif 2001; 19: 251–254

  2113. Sofer S: Scorpion envenomation . Intensive Care Medicine 1995; 21: 626-8.

  2114. Sombolos K, Berkelhammer C, Baker J: Nutritional assessment and skeletal muscle function in patients on continuous ambulatory peritoneal dialysis. Peritoneal Dial Bull 6:53-58, 1986

  2115. Sonikian M, Gogusev J, Zingraff J, Loric S, Quednau B, Bessou G, Siffert W, Drueke TB, Reusch HP, Luft FC: Potential effect of metabolic acidosis on beta 2-microglobulin generation: In vivo and in vitro studies. J Am Soc Nephrol 7:350-356, 1996

  2116. Souberbielle JC, Friedlander G, Cormier C. Practical considerations in PTH testing. Clin Chim Acta 2006; 366: 81–89.

  2117. Spaite D, Dart RC, Sullivan JB: Skin testing in cases of possible crotalid envenomation (letter) . Ann Emerg Med 1988; 17: 105-6.

  2118. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 1999; 19: 405–410 (B)

  2119. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G. Impact of membrane choice and blood flow pattern on coagulation and heparin requirement—potential consequences on lipid concentrations. Nephrol Dial Transplant 1997; 12: 2638–2646 (A)

  2120. Spiegel DM, Baker PL, Babcock S, Contiguglia R, Klein M. Haemodialysis urea rebound: the effect of increasing dialysis efficiency. Am J Kidney Dis 1995; 25: 26–29 (B)

  2121. Spies C, Dubisz N, Neumann T: Therapy of alcohol withdrawal syndrome in ICU patients following trauma . Critical Care Medicine 1996; 24(3): 414-422.

  2122. Spiller HA, Meyers A, Ziemba T: Delayed Onset of Cardiac Arrhythmias From Sustained-Release Verapamil . Ann Emerg Med 1991; 20: 201-203.

  2123. Spinowitz BS, Arslanian J, Charytan C et al. Impact of epoetin beta on dialyzer clearance and heparin requirements. Am J Kidney Dis 1991; 18: 668–673 (B)

  2124. Sprague S, Lerma E, McCormmick D, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:S51-S56.

  2125. Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.

  2126. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 1996; 27: 355–364 (B)

  2127. St. Peter W, Obrador G, Roberts T, et al. Trends in intravenous iron use amoung dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005;46:650-660.

  2128. Stahel F: Epidemiological aspects of snakebite on a Liberian rubber plantation . Acta Trop 1980; 37: 367-374.

  2129. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. J Am Med Assoc 1996; 276: 882–888 (A)

  2130. Stampfer MJ, Malinow MR, Willett WC et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992; 268: 877–881 (B)

  2131. Steiger D, Cantieni R, Frutiger A: Acute colonic pseudoobstruction (Ogilvie's syndrome) in two patients receiving high dose clonidine for delerium tremens . Intensive Care Medicine 1997; 23: 780-782.

  2132. Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, Troughton J, Bircher G, Walls J: Role of an improvement in acid-base status and nutrition in CAPD patients. Kidney Int 52:1089-1095, 1997

  2133. Stein M, Marraccini J, Rothschild: Fatal Portuguese Man-O-War (Physalia physalis) envenomation . Ann Emerg Med 1989; 18: 312-315.

  2134. Steingrimsdottir L, Gunnarsson O, Indridason OS et al. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 2005; 294: 2336–2341.

  2135. Stenver DI, Gotfredsen A, Hilsted J, Nielsen B: Body composition in hemodialysis patients measured by dual-energy X-ray absorptiometry. Am J Nephrol 15:105-110, 1995

  2136. Sterrett JR, Strom J, Stummvoll HK et al. Cinacalcet HCI (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 2007; 68: 10–17.

  2137. Steuer R, Leypoldt J, Cheung A, et al. Hematocrit as an indicator of blood volume and a predictor of intradialytic morbid events. ASAIO J 1994;40:M691-M696.

  2138. Steuer R, Leypoldt J, Cheung A, et al. Reducing symptoms during hemodialysis by continuously monitoring the hematocrit. Am J Kidney Dis 1996;27:525-532.

  2139. Stevens CE, Alter HJ, Taylor PE et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311: 496–501 (B)

  2140. Stevens J, Winearls C. Serum from continuous ambulatory peritoneal dialysis patients with acute bacterial peritonitis inhibits in vitro erythroid colony formation. Am J Kidney Dis 1994;24:569-574.

  2141. Stevenson KB, Adcox MJ, Mallea MC, Narasimhan N, Wagnild JP. Standardized surveillance of hemodialysis vascular access infections: 18-month experience at an outpatient, multifacility hemodialysis center. Infect Control Hosp Epidemiol 2000; 21: 200–203 (B)

  2142. Stitt AW, He C, Friedman S et al. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol Med 1997; 3: 617–627 (B)

  2143. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am 1994; 78: 117–141 (C)

  2144. Stoudt HW, Damon A, McFarland R: Weight, height, and selected body dimensions of adults. Rockville, MD, US Government Publications Office, DHEW Publications PHS, Vital and Health Statistics, Series 11, Nr 8, 1969

  2145. Strasser T, Schiffl H. Generation of leukotriene B4 by hemodialyzer membranes: a novel index of biocompatibility. Klin Wochenschr 1991; 69: 808–812 (B)

  2146. Strazdins V, Watson A, Harvey B. European Pediatric Peritoneal Dialysis Working Group. Renal replacement therapy for acute renal failurein children: European guidelines. Pediatr Nephrol 2004;19: 199-207.

  2147. Stremski ES, Brady WB, Prasad K: Pediatric carbamazepine intoxication . Ann Emer Med 1995; 25: 624-30.

  2148. Striker GE. Therapeutic uses of heparinoids in renal disease patients. Nephrol Dial Transplant 1999; 14: 540–543 (B)

  2149. Strippoli GF, Palmer S, Tong A et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis 2006; 47: 715–726.

  2150. Strippoli G, Tong A, Johnson D, et al. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients [review]. Cochrane Database Syst Rev 2007:2.

  2151. Strippoli G, Tong A, Johnson D, et al. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2005:2.

  2152. Strippoli G, Tong A, Palmer S, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2006;18:CD006254.

  2153. Sugimoto K, Higashino T, Kuwata Y, Imanaka K, Hirota S, Sugimura K. Percutaneous transluminal angioplasty of malfunctioning Brescia-Cimino arteriovenous fistula: analysis of factors adversely affecting long-term patency. Eur Radiol 2003; 13: 1615–1619

  2154. Suliman ME, Qureshi AR, Barany P et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727–1735 (B)

  2155. Sullivan JB, Wingert WA, Norris Jr RL: North American Venomous Reptile Bites, in Aurbach PS (ed)Wilderness Medicine: Management of Wilderness and Environmental Emergencies . Mosby-Year Book, Inc: St. Louis. 1995; 3: 680-709.

  2156. Sullivan JB, Wingert WA, Norris Jr. RL: North American Venomous Reptile Bites . Wilderness Medicine: Management of Wilderness and Environmental Emergencies: M 1995; 3: 680-709.

  2157. Sullivan JB, Wingert WA, Norris RL: North American venomous reptile bites . Wilderness Medicine: Management of Wilderness and Environmental Emergencies 1995; 680-709.

  2158. Sultan Y, London GM, Goldfarb B, Toulon P, Marchais SJ. Activation of platelets, coagulation and fibrinolysis in patients on long-term haemodialysis: influence of cuprophan and polyacrylonitrile membranes. Nephrol Dial Transplant 1990; 5: 362–368 (B)

  2159. Sun JB, Wang JP: Recommended diagnostic criteria for occupational chronic lead poisoning . Biomed Environ Sci 1995; 8: 318-29.

  2160. Sun KO: Management of pufferfish poisoning. Br J Anaesthesia 1995; 75: 500.

  2161. Sundaram S, Auriemma M, Howard G, Brandwein H, Leo F. Application of membrane filtration for removal of diminutive bioburden organisms in pharmaceutical products and processes.PDA J Pharm Sci Technol 1999; 53: 186–201 (B)

  2162. Sunder-Plassmann G, Fodinger M, Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11: 1106–1116 (B)

  2163. Surian M, Bonforte G, Scanziani R et al. Trace elements and micropollutant anions in the dialysis and reinfusion fluid prepared on-line for haemodiafiltration. Nephrol Dial Transplant 1998; 13 [Suppl 5]: 24–28 (B)

  2164. Suzuki H, Kanno Y, Sugahara S, et al. Effects of an angiotensin II receptor blocker, calsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004;43:1056-1064.

  2165. Suzuki M, Hirasawa Y, Hirashima K, et al: Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. Research Group for Clinical Assessment of rhEPO. Contrib Nephrol 76:179-192; discussion 212-178, 1989

  2166. Svanberg B, Arvidsson B, Norrby A, Rybo G, Solvell L: Absorption of supplemental iron during pregnancy—A longitudinal study with repeated bone-marrow studies and absorption measurements. Acta Obstet Gynecol Scand Suppl 48:S87-S108, 1975

  2167. Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow JW, Cato A. Epoprostenol (PGI2, prostacyclin) during highrisk hemodialysis: preventing further further bleeding complications. J Clin Pharmacol 1988; 28: 818–825 (B)

  2168. Swartz RD, Port FK. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int 1979; 16: 513–518 (A)

  2169. Szabo A, Merke J, Beier E, et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-1056.

  2170. Szepietowski T, Krajewska M. C-reactive protein (CRP) as a marker of of hemodialysis biocompatibility. Polim Med 1997; 27: 47–59 (B)

  2171. Szmuness W, Prince AM, Grady GF et al. Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. J Am Med Assoc 1974; 227: 901–906 (B)

  2172. Taboulet P, Cariou A, Berdeaux A: Pathophysiology and management of self-poisoning with beta-blockers . Clinical Toxicology 1993; 31: 531-551.

  2173. Taghizadeh A, Dasgupta P, Khan MS, Taylor J, Koffman G. Long-term outcomes of brachiobasilic transposition fistula for haemodialysis. Eur J Vasc Endovasc 2003; 26: 670–672

  2174. Takahashi M, Hoshino H, Kushida K et al. The advanced glycation endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: comparison with idiopathic carpal tunnel syndrome. Nephron 19989; 80: 444–449 (B)

  2175. Takenaka T, Itaya Y, Tsuchiya Y, Kobayashi K, Suzuki H. Fitness of biocompatible high-flux hemodiafiltration for dialysis-related amyloidosis. Blood Purif 2001; 19: 10–14 (B)

  2176. Tamura T, Vaughn W, Waldo F, et al. Zinc and copper balance in children on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 1989;3:309-313.

  2177. Tan SY, Irish A, Winearls CG et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50: 282–289 (B)

  2178. Tanaka K, et al: Jamaican Vomiting Sickness . NEJM 1976; 295: 461-67.

  2179. Taralov Z, Koumtchev E, Lyutakova Z: Erythrocyte ferritin levels in chronic renal failure patients. Folia Med (Plovdiv) 40:65-70, 1998

  2180. Tarng DC, Huang TP, Liu TY et al. Effect of vitamin E-bonded membrane on the 8-hydroxy 29-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int 2000; 58: 790–799 (B)

  2181. Tarng DC, Huang TP, Wei YH et al. 8-Hydroxy-29-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 2000; 36: 934–944 (B)

  2182. Tattersall JE, Chamney P, Aldridge C, Greenwood RN. Recirculation and the post-dialysis rebound. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 75–80 (B)

  2183. Tattersall JE, DeTakats D, Chamney P, Greenwood RN, Farrington K. The post-haemodialysis rebound: predicting and quantifying its effect on KtV. Kidney Int 1996; 50: 2094–2102 (B)

  2184. Tayeb JS, Provenzano R, El Ghoroury M et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 2000; 35: 606–610 (B)

  2185. Taylor DJ, Mallen C, McDougall N, Lind T: Effect of iron supplementation on serum ferritin levels during and after pregnancy. Br J Obstet Gynaecol 89:1011-1017, 1982

  2186. Taylor G, Patel V, Spencer S, et al. Long-term use of 1.1% amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol 2002;58:445-450.

  2187. Taylor GD, McKenzie M, Buchanan-Chell M et al. Central venous catheters as a source of hemodialysis-related bacteremia. Infect Control Hosp Epidemiol 1998; 19: 643–646 (B) 84 SECTION VI. Haemodialysis-associated infection

  2188. Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int 1993; 44: 182–190 (B)

  2189. Tenckhoff H, Meston B, Shilipetar G. A simplified automatic peritoneal dialysis system. Trans Am Soc Artif Intern Organs 1972; 18:436-440.

  2190. Tenckhoff H, Schechter H. A bacteriologically safe peritoneal access device. Trans Am Soc Artif Intern Organs 1966;14:181-186.

  2191. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519–530.

  2192. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: effect of hemodialysis. Kidney Int 2000; 58: 867–872 (B)

  2193. Teruel JL, Lasuncion MA, Rivera M et al. Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients. Am J Kidney Dis 1997; 29: 569–575

  2194. Thalhammer F, Kletzmayr J, El M I et al. Ofloxacin clearance during haemodialysis: a comparison of polysulfone and cellulose acetate hemodialyzers. Am J Kidney Dis 1998; 32: 642–645 (B)

  2195. The Canadian Society of Nephrology. Clinical practice guidelines the delivery of haemodialysis. J Am Soc Nephrol 1999; 10: S306–S310 (C)

  2196. The National Service Framework for Renal Services (Part One: Dialysis and Transplantation), Department of Health, January 2005

  2197. The Patient Registree Committee. Report of the Japanese Society of Nephrology. An overview of regular dialysis treatment in Japan (as of Dec. 31, 1997). 1998; 372–412 (C)

  2198. The Renal Association. Recommended standards for haemodialysis. Royal College of Physicians of London. Treatment of adult patients with renal failure. Recommended standards and audit measure. 1997; 17–29 (C)

  2199. The Textbook of Peritoneal Dialysis. Ed Gokal R, Nolph KD. 1994

  2200. The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System. Am J Kidney Dis 1997; 30: S67–S85 (C)

  2201. Thomas MC, MacIsaac RJ, Tsalamandris C, et al: The burden of anaemia in type 2 diabetes and the role of nephropathy: A cross-sectional audit. Nephrol Dial Transplant 19:1792-1797, 2004

  2202. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G: Unrecognized anemia in patients with diabetes: A cross-sectional survey.

  2203. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635–641 (A)

  2204. Thomsen MB, Bengtsson M, Lassvik C, Alm A, Elfstrom J. Adjuvant intravenous sympathetic block with guanethidine in construction of arteriovenous fistulas for blood access. Acta Chir Scand 1983; 149: 141–145

  2205. Thorlacius H, Fernvik E, Gautam N et al. Impaired leucocyte rolling, adhesion and transendothelial migration following cuprophane hemodialysis. Acta Physiol Scand 1997; 159: 277–283 (B)

  2206. Thunberg BJ, Swamy AP, Cestero RV: Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. Am J Clin Nutr 34:2005-2012, 1981

  2207. Thylen P, Fernvik E, Haegerstrand A, Lundahl J, Jacobson SH. Dialysis-induced serum factors inhibit adherence of monocytes and granulocytes to adult human endothelial cells. Am J Kidney Dis 1997; 29: 78–85 (B)

  2208. Thylen P, Lundahl J, Fernvik E et al. Mobilization of an intracellular glycoprotein (Mac-1) on monocytes during hemodialysis. Am J Nephrol 1992; 12: 393–400 (B)

  2209. Tielemans C, Delville JPC, Husson CP et al. Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993; 39: 158–165 (B)

  2210. Tielemans C, Husson C, Schurmans T et al. Effects of ultrapure and non-sterile dialysate on the inflammatory response during in vitro haemodialysis. Kidney Int 1996; 49: 236–243 (B)

  2211. Tielemans C, Lenclud C. Respective role of haemosiderosis and desferrioxamine therapy in the risk from infection of haemodialysed patients. Q J Med 1988; 68: 573–574 (B)

  2212. Tielemans C, Madhoun P, Lenaers M et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990; 38: 982–984 (B)

  2213. Tin-myint R, Maung-chit T, Warrell DA: Bites by the king cobra (Ophiophagus hannah) in Myanmar: successful treatment of severe neurotoxic envenoming . Q J Med 1991; 293: 751-762.

  2214. Tintinalli JE, Ruiz E, Krome RL: Chapter . Emergency Medicine, A Comprehensive Study Guide4th ed:.

  2215. Tintinalli JE, Ruiz E, Krome RL: Emergency medicine a comprehensive study guide . 1996; 4th ed.: 833-841.

  2216. Tirlapur VG, Gicheru K, Charalambous BM, Evans PJ, Mir MA: Packed cell volume, haemoglobin, and oxygen saturation changes in healthy smokers and non-smokers. Thorax 38:785-787, 1983

  2217. Tobin JR, Doyle TP, Ackerman AD: Astemizole-induced cardiac conduction disturbances in a child . JAMA 1991; 266: 2737-40.

  2218. Toborek M, Wasik T, Drozdz M et al. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 1992; 41: 1229–1232 (B)

  2219. Tokars JI, Alter MJ, Favero MS, Moyer LA, Bland LA. National surveillance of haemodialysis associated diseases in the United States, 1990. ASAIO J 1993; 39: 71–80 (B)

  2220. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J 1998; 44: 98–107 (B)

  2221. Tokars JI, Miller ER, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 1997. Semin Dial 2000; 13: 75–85 (B)

  2222. Tom A, McCauley L, Bell L, et al. Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. J Pediatr 1999;134:464-471.

  2223. Tonshoff B, et al. Growth-stimulating effects of recombinant human growth hormone in children with end-stage renal disease. J Pediatr 1990;116:561-566.

  2224. Tonshoff B, Mehls O. Growth retardation in children with chronic renal insufficiency: current aspects of pathophysiology and treatment. J Nephrol 1995;8:133-142.

  2225. Tordoir JH, Dammers R, de Brauw M. Video-assisted basilica vein transposition for haemodialysis vascular access: preliminary experience with a new technique. Nephrol Dial Transpl 2001; 16: 391–394

  2226. Tordoir JH, de Bruin HG, Hoeneveld H, Eikelboom BC, Kitslaar PJ. Duplex ultrasound scanning in the assessment of arteriovenous fistulas created for hemodialysis access: comparison with digital subtraction angiography. J Vasc Surg 1989; 10: 122–128

  2227. Tordoir JH, Hoeneveld H, Eikelboom BC, Kitslaar PJ. The correlation between clinical and duplex ultrasound parameters and the development of complications in arteriovenous fistulae for haemodialysis. Eur J Vasc Surg 1990; 4: 179–184

  2228. Tordoir JH, Rooyens P, Dammers R, Van Der Sande FM, de Haan M, Yo TI. Prospective evaluation of failure modes in autogenous radiocephalic wrist access for haemodialysis. Nephrol Dial Transpl 2003; 18: 378–383

  2229. Tordoir JHM, Dammers R, van der Sande FM. Upper extremity ischemia and hemodialysis vascular access. Eur J Vasc Endovasc Surg 2004; 27: 1–5

  2230. Touam M, Zingraff J, Jungers P et al. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56:2292–2296 (B)

  2231. Toxicologic Managements of Carbamazepine . Healthcare Series, Micromedex 95:.

  2232. Trachtenbarg DE: Getting the lead out: when is treatment necessary . Postgrad Med 1996; 99: 201-2, 207-18.

  2233. Traeger J, Sibai-Galland R, Delawari E, Arkouche W. Daily versus standard haemodialysis: one year experience. Artif Organs 1998; 22: 558–563 (B)

  2234. Trenkwalder E, Gruber A, Konig P, Dieplinger H,Kronenberg F. Increased plasma concentrations of LDLunbound apo(a) in patients with end-stage renal disease.Kidney Int 1997; 52: 1685–1692 (B)

  2235. Trerotola SO, Ponce P, Stavropoulos SW et al. Physical examination versus normalized pressure ratio for predicting outcomes of hemodialysis access interventions. J Vasc Interv Radiol 2003 Nov; 14(11): 1387–1394

  2236. Trerotola SO, Shah H, JohnsonMet al. Randomized comparison of high-flow versus conventional hemodialysis catheters. J Vasc Interv Radiol 1999; 10: 1032–1038

  2237. Trestrail JH: Monomethylhdrazine-containing mushrooms . In, Spoerke's and Rumack's Handbook of Mushroom Poisoning Diagnosis and Treatmen 1994; 279-287.

  2238. Tribouilloy C, Peltier M, Colas L et al. Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol 1998; 81: 321–326 (B)

  2239. Trivedi H, Moore H, Atalla J. Lack of significant circadian and postprandial variation in phosphate levels in subjects receiving chronic hemodialysis therapy. J Nephrol 2005; 18: 417–422.

  2240. Tschesche H, Kopp C, Horl WH, Hempelmann U. Inhibition of degranulation of polymorphonuclear leukocytes by angiogenin and its tryptic fragment. J Biol Chem 1994; 269: 30274 –30280 (B)

  2241. Tschope W, Koch M, Thomas B, Ritz E. Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Results of a prospective study. The German Study Group Diabetes and Uremia. Nephron 1993; 64: 354–358 (B)

  2242. Tsuchida K, Takemoto Y, Yamagami S et al. Detection of peptidoglycan and endotoxin in dialysate, using silkworm larvae plasma and limulus amebocyte lysate methods. Nephron 1997; 75: 438–443 (B)

  2243. Tu AT, Fulde G: Sea snake bites . Clinics in Derm 1987; 5(3): 118-26.

  2244. Tu AT: Biotoxicology of sea snake venoms . Ann Emerg Med 1987; 16(9): 1023-28.

  2245. Tuncok Y, Kozan O, Cavdar C, et al: Urginea maritima (squill) toxicity . Clin Tox 1995; 33: 83-86.

  2246. Tunget CL, Clark RF, Turden SG: Raising the Decontamination Level for Thyroid Hormone Ingestion . American Journal of Emergency Medicine 13(9): 9-13.

  2247. Tuomisto L, Tacke U: Is histamine an anticonvulsive inhibitory transmitter? . Neuropharmacology 1986; 25: 955-8.

  2248. Turmel-Rodrigues L, Pengloan J, Bourquelot P. Interventional radiology in hemodialysis fistulae and grafts: a multidisciplinary approach. Cardiovasc Intervent Radiol 2002; 25: 3–16

  2249. Turmel-Rodrigues L, Pengloan J, Rodrigue H et al. Treatment of failed native arteriovenous fistulae for hemodialysis by interventional radiology. Kidney Int 2000; 57: 1124–1140

  2250. Turmel-Rodrigues L, Raynaud A, Bourquelot P. Percutaneous treatment of arteriovenous access dysfunction. In: Conlon PJ, Schwab SJ, Nicholson ML, eds. Hemodialysis Vascular Access: Practice and Problems. Oxford University Press, Oxford; New York 2000; 183–202

  2251. Twardowski Z, et al. Four-year experience with swan neck presternal peritoneal dialysis catheter. Am J Kidney Dis 1996;27:99-105.

  2252. Twardowski Z, Nolph K, Khanna R, et al. Peritoneal equilibration test. Perit Dial Bull 1986;7:138-147.

  2253. U.S. Renal Data System. USRDS 2006 annual data report: atlas of end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006.

  2254. U.S. Renal Data System. USRDS 2007 annual report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.

  2255. ubstrate method for assay of bacterial endotoxins using Limulus hemocyte lysate. Prog Clin Biol Res 1979; 29: 209–220 (B)

  2256. Udayaraj U, Ben-Shlomo Y, Roderick P, Casula A, Dudley C, Johnson R, Collett D, Ansell D, Tomson D, Caskey F. Social deprivation, ethnicity and access to the deceased donor kidney transplant waiting list in England and Wales. Transplantation 2010; 90: 279-85

  2257. Udayaraj U, Ben-Shlomo Y, Roderick P, et al. Social deprivation, ethnicity and access to the deceased donor kidney transplant waiting list in England and Wales. Transplantation 2010;90:279-85

  2258. Uhlig K, Macleod A, Craig J et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 70: 2058–2065.

  2259. Ujhelyi MR, et al. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 1993;54:388-394.

  2260. UKT KPAG Equity of Access Task Force. Overview Report 2006 RTSM (06)2

  2261. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. Morb Mortal Wkly Rep 1996; 45: 468–480 (C)

  2262. Urabe A, Saito T, Fukamachi H, Kubota M, Takaku F: Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states. Int J Cell Cloning 5:202-208, 1987

  2263. Urena P, Herbelin A, Zingraff J et al. Permeability of cellulosic and non-cellulosic membranes to endotoxin subunits and cytokine production during in-vitro haemodialysis. Nephrol Dial Transplant 1992; 7: 16–28 (B)

  2264. Uribarri J: Moderate metabolic acidosis and its effects on nutritional parameters in hemodialysis patients. Clin Nephrol 48:238-240, 1997

  2265. US National Institutes of Health: CHOIR Trial. 2005. Accessed March 31, 2006

  2266. Vachharajani T, Abreo K, Phadke A, Oza U, Kirpalani A. Diagnosis and treatment of tuberculosis in hemodialysis and renal transplant patients. Am J Nephrol 2000; 20: 273–277 (B)

  2267. Valderrabano F, Jones EH, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 1995; 10 [Suppl 5]: 1–25 (B)

  2268. Vale JA, Meredith TJ: Acute poisoning due to non-steroidal anti-inflammatory drugs: Clinical features and management . Med Toxicol 1986; 1: 12-31.

  2269. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575 (B)

  2270. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 [Suppl 12]: S60–S62 (B)

  2271. van der Bom JG, de Maat MP, Bots ML et al. Elevated plasma fibrinogen: cause or consequence of cardiovascular disease? Arterioscler Thromb Vasc Biol 1998; 18: 621–625 (B)

  2272. van der Linde K, Lim BT, Rondeel JM, Antonissen LP, de Jong GM. Improved bacteriological surveillance of haemodialysis fluids: a comparison between Tryptic soy agar and Reasoner’s 2A media. Nephrol Dial Transplant 1999; 14: Res 1979; 29: 485–499 (B)

  2273. Van der Meulen J, Janssen MJ, Langendijk PN, Bouman AA, Oe PL. Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis. Clin Nephrol 1992; 37: 36–41 (B)

  2274. Van der Meyden CH: Acute Oral Loading of Carbamazepine-CR and Phenytoin In a Double Blind Randomized Study of Patients at Risk of Seizures . Epilepsia 1994; 35: 189-94.

  2275. Van der Poel CL, Cuypers HT, Reesink HW et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337: 317–319 (B)

  2276. van der Sande FM, Mulder AW, Hoorntje SJ et al. The hemodynamic effect of different ultrafiltration rates in patients with cardiac failure and patients without cardiac failure: comparison between isolated ultrafiltration and ultrafiltration with dialysis. Clin Nephrol 1998; 50: 301–308 (B)

  2277. van der Voort J, et al. Can the DOQI guidelines be met by peritoneal dialysis alone in pediatric patients? Pediatr Nephrol 2000; 14:717-719.

  2278. Van DeVoorde R, Barletta G, Chand D, et al. Blood pressure control in pediatric hemodialysis: the Midwest Pediatric Nephrology Consortium Study. Pediatr Nephrol 2007;22:547-553.

  2279. van Duijnhoven HL, Treskes M: Marked interference of hyperglycemia in measurements of mean (red) cell volume by Technicon H analyzers. Clin Chem 42:76-80, 1996

  2280. Van Egmond HP: Paralytic and diarrhetic shellfish poisons: Occurrence in Europe, toxicity, analysis and regulations . J Nat Toxins 1992; 2(1): 41.

  2281. Van Gool S, Van Damme-Lombaerts R, Cobbaert C, et al. Lipid and lipoprotein abnormalities in children on hemodialysis and after renal transplantation. Transplant Proc 1991;23:1375-1377.

  2282. van Guldener C, Janssen MJ, Lambert J et al. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 106–112 (B)

  2283. van Guldener C, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Carotid artery stiffness in patients with endstage renal disease: no effect of long-term homocysteinelowering therapy. Clin Nephrol 2000; 53: 33–41 (B)

  2284. van Hoek F, Scheltinga MR, Kouwenberg I, Moret KE, Beerenhout CH, Tordoir JH. Steal in hemodialysis patients depends on type of vascular access. Eur J Vasc Endovasc Surg 2006; 32: 710–717

  2285. Van Hoof A, Schurgers M, Boelaert J, Criel A. Low-molecularweight heparin dosage in haemodialysis. Nephrol Dial Transplant 1987; 2: 193–194 (B)

  2286. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758–2767 (B)

  2287. Van Stone JC. The effect of dialyzer membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO J 1995; 41: M713–M716 (B)

  2288. Van Teijlingen ME, Borgdorff P, Van Wijhe MH et al. In vivo visualization of hemodialysis-induced alterations in leukocyteendothelial interactions. Kidney Int 2000; 57: 2608–2617 (B)

  2289. Van Tellingen A, Grooteman MP, Bartels PC et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in haemodialysis patients. Kidney Int 2001; 59: 342–347 (B)

  2290. van Wijk V, Badenhorst PN, Luus HG, Kotze HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338–1343 (B)

  2291. van Ypersele de Strihou C, Jadoul M, Malghem J et al. Effect of dialysis membrane and patient’s age on signs of dialysisrelated amyloidosis. Kidney Int 1991; 39: 1012–1019 (B)

  2292. Van Ypersele DS, Jadoul M, Malghem J, Maldague B, Jamart J. Effect of dialysis membrane and patient’s age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991; 39: 1012–1019 (B)

  2293. Van Ypersele DS. Beta 2-microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 147–149 (C)

  2294. Vanherweghem JL, Dhaene M, Goldman M et al. nfections associated with subclavian dialysis catheters: the key role of nurse training. Nephron 1986; 42: 116–119 (B) 159: 310–319 (A) 116. Nielsen J, Ladefoged SD, Kolmos HJ. Dialysis catheter-related septicaemia—focus on Staphylococcus aureus septicaemia. Nephrol Dial Transplant 1998; 13: 2847–2852 223 (B)

  2295. Vanherweghem JL, Goldman M, Tielemans C. Eosinophilia in chronic dialysis. Semin Dial 1990; 3: 171–177 (C)

  2296. Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S. Pharmakokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Thromb Haemost 1997; 77: 650–655 (B)

  2297. Vanholder R, De Smet R, Jacobs V et al. Uraemic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 1994; 9: 1271–1278 (B)

  2298. Vanholder R, De Smet R. Pathophysiological effects of uraemic retention solutes. J Am Soc Nephrol 1999; 10: 1815–1823 (C) 41. Daugirdas JT. Simplified equations for monitoring KtuV, PCRn, eKtV, and ePCRn. Adv Ren Replace Ther 1995; 2: 295–304 (B)

  2299. Vanholder R, Dell’Aquila R, Jacobs V et al. Depressed phagocytosis in hemodialyzed patients: in vivo and in vitro mechanisms. Nephron 1993; 63: 409–415 (B)

  2300. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39: 320–327 (A)

  2301. Vanholder R, Ringoir S, Dhondt A, Hakim R. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. Kidney Int 1991; 39: 320–327 (B)

  2302. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3: 1541–1554 (C)

  2303. Vanholder R, Van Loo A, Dhondt AM, De Smet R, Ringoir S. Influence of uraemia and haemodialysis on host defence and infection. Nephrol Dial Transplant 1996; 11: 593–598 (C)

  2304. Vanholder R, Vanhaecke E, Ringoir S. Waterborne Pseudomonas septicemia. ASAIO Trans 1990; 36:M215–M516 (B)

  2305. Vanholder RC, Camez AA, Veys NM et al. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 45: 1754–1759 (A)

  2306. Vanholder RC, Pauwels RA, Vandenbogaerde J et al. Cuprophan reuse and intradialytic changes of lung diffusion capacity and blood gasses. Kidney Int 1987; 32: 117–122 (B)

  2307. Vanholder RC, Ringoir SM. Intradialytic body weight changes and dialyzer pore size as main contributing factors to the evolution of beta-2-microglobulin in dialysis. Blood Purif 1990; 8: 32–44 (B)

  2308. Vanholder V, Hoenich N, Ringoir S. Morbidity and mortality of central venous catheter hemodialysis: a review of 10 years’ experience. Nephron 1987; 47: 274–279 (B)

  2309. Varkey G. Ultrapure water for semiconductor industry. Proposed Specification for Electronic-Grade Water (1986).ASTM D-19 Proposal P 172, 1986 (B)

  2310. Vaslaki L, Karatson A, Voros P et al. Can sterile and pyrogen-free on-line substitution fluid be routinely delivered? A multicentric study on the microbiological safety of on-line haemodiafiltration. Nephrol Dial Transplant 2000; 15 [Suppl 1]:74–78 (B)

  2311. Vassalotti JA, Falk A, Cohl ED, Uribarri J, Teodorescu V. Obese and non-obese hemodialysis patients have a similar prevalence of functioning arteriovenous fistula using preoperative vein mapping. Clin Nephrol 2002; 58: 211–214

  2312. Vassalotti JA, Uribarri J, Chen SC et al. Trends in mineral metabolism: Kidney Early Evaluation Program (KEEP) and the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 2008; 51: S56–68.

  2313. Velandia M, Fridkin SK, Cardenas V et al. Transmission of HIV in dialysis centre. Lancet 1995; 345: 1417–1422 (B)

  2314. Veltri JC, Litovitz TL: 1983 Annual Report of the American Association of Poison Control Centers National Data Collection System . American Journal of Emergency Medicine 1984; 2: 420-443.

  2315. Ventura MT, Di Corato R, Giuliano G, Matino MG, Antonaci S. Evaluation of monocyte chemotactic responsiveness in uraemic patients undergoing haemodialysis with different dialytic membranes. Cytobios 1998; 96: 171–178 (B)

  2316. Verbeelen D, Jochmans K, Herman AG et al. Evaluation of platelets and hemostasis during hemodialysis with six different membranes. Nephron 1991; 59: 567–572 (A)

  2317. Verresen L, Fink E, Lemke HD, Vanrenterghem Y. Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes. Kidney Int 1994; 45: 1497–1503 (B)

  2318. Verrina E, Amici G, Perfumo F, et al. The use of the PD Adequest mathematical model in pediatric patients on chronic peritoneal dialysis. Perit Dial Int 1998;18:322-328.

  2319. Verrina E, Edefonti A, Gianoglio B, et al. A multicenter experience on patient and technique survival in children on chronic dialysis. Pediatr Nephrol 2004;19:82-90.

  2320. Verrina E, et al. Prevention of peritonitis in children on peritoneal dialysis. Perit Dial Int 2000;20:625-630.

  2321. Veys N, Vanholder R, De Cuyper K, Ringoir S. Influence of erythropoietin on dialyzer reuse, heparin need, and urea kinetics in maintenance hemodialysis patients. Am J Kidney Dis 1994; 23: 52–59 (B)

  2322. Veys N, Vanholder R, Ringoir S. Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. Am J Kidney Dis 1992; 19: 358–363 (B)

  2323. Villa ML, Ferrario E, Bergamasco E et al. Reduced natural killer cell activity and IL-2 production in malnourished cancer patients. Br J Cancer 1991; 63: 1010– 1014 (B)

  2324. Villarino ME, Ridzon R, Weismuller PC et al. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155: 1735–1738 (B)

  2325. Villaroel F, Ciarkowski A. A survey of hypersensitivity reactions in hemodialysis. Artif Organs 1985; 9: 231–238 (B)

  2326. Vimalachandra D, Hodson EM, Willis NS et al. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev 2006; 3: CD003264.

  2327. Vimalachandra D, Craig J, Cowell C, et al. Growth hormone treatment in children with chronic renal failure: a meta-analysis of randomized controlled trials. J Pediatr 2001;139:560-567.

  2328. Vincent FC, Tibi AR, Darbord JC. A bacterial biofilm in ahaemodialysis system. Assessment of disinfection and crossing of endotoxin. ASAIO Trans 1989; 35: 310–313 (B)

  2329. Viravan C, Looareesuwan S, Kosakorn W, et al: A hospital-based survey of snakes responsible for bites in Thailand . Trans Roy Soc Trop Med Hyg 1992; 86: 100-106.

  2330. Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopeniau thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81–88 (B)

  2331. Vivier PM, Lewander WJ, et al: Isopropyl alcohol intoxication in a neonate through chronic dermal exposure: A complication of a culturally-based umbilical care practice . Pediatr Emerg Care 1994; 10(2): 91-3.

  2332. Vlassopoulos D, Noussias C, Hadjipetrou A et al. Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients. J Nephrol 1997; 10: 111–114 (B)

  2333. von Albertini B, Miller JH, Gardner PW, Shinaberger JH. High-flux haemodiafiltration: under six houruweek treatment. ASAIO Trans 1984; 30: 227–231 (B)

  2334. von Appen K, Ivanovich P, Mujais S, Klinkmann H. Endothelium: the next frontier in biocompatibility. Artif Organs 1993; 17: 985–995 (C)

  2335. Von Bonsdorf M, Stiekema J, Harjanne A, Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Organs 1990; 13: 103–108 (A)

  2336. von Brecht J, Flanigan MJ, Freeman RM, Lim VS. Regional anticoagulation: hemodialysis with hypertonic trisodium citrate. Am J Kidney Dis 1986; 8: 196–201 (B)

  2337. Von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001; 344: 11–16 (B)

  2338. Von Lilien T, et al. Five years' experience with continuous ambulatory or continuous cycling peritoneal dialysis in children. J Pediatr 1987;111:513-518.

  2339. Vorbeck-Meister I, Sommer R, Vorbeck F, Horl WH. Quality of water used for haemodialysis: bacteriological and chemical parameters. Nephrol Dial Transplant 1999; 14: 666–675 (C)

  2340. Wada JA, Troupin AS, Friel P: Pharmocokinetic Comparison of Tablet and Suspension Dosage Forms of Carbamazepine . Epilepsia 1978; 19: 251-254.

  2341. Wadgymar A, Wu GG. Treatment of acute methanol intoxication with Hemodia­lysis. Am J Kidney Dis 1998;31:897.

  2342. Waggoner TL, Nishimoto JH, Eng J: Eye injury from tarantula . J Am Optom Assoc 1997; 68(3): 188-190.

  2343. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis 86 SECTION VI. Haemodialysis-associated infection patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol 1995; 5: 1930–1934 (B)

  2344. Wakabayashi Y, Okubo M, Shimada H et al. Decreased VLDL apoprotein CIIuapoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment. Metabolism 1987; 36: 815–820 (B)

  2345. Wald NJ, Watt HC, Law MR et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862–867 (B)

  2346. Walker BR, Edwards CRW: Licorice-induced hypertension and syndromes of apparent mineralcorticoid excess . Endrocrinology and Metabolism Clinics of North America 1994; 23: 359-377.

  2347. Walter FG, Frye G, Mullen JT: Amelioration of Nifedipine Poisoning Associated with Glucagon Therapy . Ann Emerg Med 1993; 22: 1234-1237.

  2348. Wang SA, Levine RB, Carson LA et al. An outbreak ofGram-negative bacteremia in haemodialysis patients traced tohaemodialysis machine waste drain ports. Infect Control HospEpidemiol 1999; 20: 746–751 (B)

  2349. Wanner C, Horl WH, Luley CH, Wieland H. Effects of HMGCoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754–760 (B)

  2350. Warady B, Alexander S, Hossli S, et al. Peritoneal membrane transport function in children receiving long-term dialysis. J Am Soc Nephrol 1996;7:2385-2391.

  2351. Warady B, Alexander S, Watkins S, et al. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis 1999;33:567-583.

  2352. Warady B, Andrews W. Peritoneal dialysis access. In: Geary D, Schaefer F, eds. Comprehensive clinical nephrology. Philadelphia: Elsevier Science, 2008.

  2353. Warady B, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating dialysis in early infancy. Pediatr Nephrol 1997;13:759-765.

  2354. Warady B, Borum P, Stall C, et al. Carnitine status of pediatric patients on continuous ambulatory peritoneal dialysis. Am J Nephrol 1990;10:109-114.

  2355. Warady B, Bunchman T. Dialysis therapy for children with acute renal failure: survey results. Pediatr Nephrol 2000;15:11-13.

  2356. Warady B, Campoy S, Gross S, et al. Peritonitis with continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis. J Pediatr 1984;105:726-730.

  2357. Warady B, Feneberg R, Verrina E, et al. Peritonitis in children who receive long-term peritoneal dialysis: a prospective evaluation of therapeutic guidelines. J Am Soc Nephrol 2007;18:2172-2179.

  2358. Warady B, Fischbach M, Geary D, et al. Frequent hemodialysis in children. Adv Chronic Kidney Dis 2007;14:297-303.

  2359. Warady B, Hebert D, Sullivan E, et al. Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997;11:49-64.

  2360. Warady B, Ho M. Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 2003;18:1055-1062.

  2361. Warady B, Jennings J. The short PET in pediatrics. Perit Dial Int 2007;27:441-445.

  2362. Warady B, Kausz A, Lerner G, et al. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 2004;19:655-661.

  2363. Warady B, Kriley M, Alon U, et al. Vitamin status of infants receiving long-term peritoneal dialysis. Pediatr Nephrol 1994;8:354-356.

  2364. Warady B, Kriley M, Belden B, et al. Nutritional and behavioral aspects of nasogastric tube feedings in infants receiving chronic peritoneal dialysis. Adv Perit Dial 1990;6:265-268.

  2365. Warady B, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 2000;20:610-624.

  2366. Warady B, Schaefer F. Peritonitis. In: Warady B, Schaefer F, Fine R, et al., eds. Pediatric dialysis. Dordrecht: Kluwer Academic Publishers, 2004:393-413.

  2367. Warady B, Seligman P, Dahl N. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients. Clin J Am Soc Nephrol 2007;2:1140-1146.

  2368. Warady B, Sullivan E, Alexander S. Lessons from the peritoneal dialysis patient database: a report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int 1996;49:S68-S71.

  2369. Warady B, Watkins S, Fivush B, et al. Validation of PD Adequest 2.0 for pediatric dialysis patients. Pediatr Nephrol 2001;16:205-211.

  2370. Warady B, Weis L, Johnson L. Nasogastric tube feeding in infants on peritoneal dialysis. Perit Dial Int 1996;16:S521-S525.

  2371. Warady B, Zobrist R, Finan E. Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex maintenance therapy in children on hemodialysis. Pediatr Nephrol 2006; 21:553-560.

  2372. Warady B, Zobrist R, Wu J, et al. The Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 2005; 20:1320-1327.

  2373. Warady B. Growth retardation in children with chronic renal insufficiency. J Am Soc Nephrol 1998;9:S85-S89.

  2374. Warady B. Neurodevelopment of infants with end-stage renal disease: is it improving? Pediatr Transplant 2002;6:5-7.

  2375. Warady B. New hormones in the therapeutic arsenal of chronic renal failure: growth hormone and erythropoietin. Pediatr Clin North Am 1995;42:1551-1577.

  2376. Warady B. Sclerosing encapsulating peritonitis: what approach should be taken with children? Perit Dial Int 2000;20:390-391.

  2377. Warady B. The peritoneal equilibration test (PET) in pediatrics. Contemp Dial nephrol 1994:21-41.

  2378. Warchol S, Roszkowska-Blaim M, Sieniawska M. Swan neck presternal peritoneal dialysis catheter: five-year experience in children. Perit Dial Int 1998;18:187.

  2379. Warchol S, Ziolkowska H, Roszkowska-Blaim M. Exit-site infection in children on peritoneal dialysis: comparison of two types of peritoneal catheters. Perit Dial Int 2003;23:169-173.

  2380. Ward RA, Schmidt B, Blumenstein M, Gurland HJ. Evaluation of phagocytic cell function in an ex vivo model of hemodialysis. Kidney Int 1990; 37: 776–782 (B)

  2381. Ward RA, Schmidt B, Gurland HJ. Prevention of blood loss in dialysers with DEAE-cellulose membranes does not require increased doses of heparin. Nephrol Dial Transplant 1993; 8: 1140–1145 (A)

  2382. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W.A comparison of on-line haemodiafiltration and high-flux haemodialysis: a prospective clinical study. J Am Soc Nephrol 2000; 11: 2344–2350 (A)

  2383. Ward RA. Heparinization for routine hemodialysis. Adv Ren Replace Ther 1995; 2: 362–370 (B)

  2384. Ward RA. Ultrapure dialysate: a desirable and achievable goal for routine haemodialysis. Semin Dial 2000; 13: 378–380 (C)

  2385. Warden CR, Benjamin DR: Acute Renal Failure Associated with Suspected Amanita smithiana Mushroom Ingestions: A case series . Acad Emerg Med 1998; 5 (8): 808-812.

  2386. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 1998; 79: 1–7 (B)

  2387. Warrell DA, Ormerod LD: Snake venom ophthalmia and blindness caused by the spitting cobra (Naja nigricollis) in Nigeria . Am J Trop Med Hyg 1976; 25: 525-529.

  2388. Warrell DA: Clinical toxicology of snakebite in Africa and the Middle East and Asia . Clinical Toxicology of Animal Venoms and Poisons 1995; 433-594.

  2389. Wasserberger J, Ordog G: Naloxone-induced hypertension in patients on clonidine . Annals of Emergency Medicine 1988; 17(5): 557.

  2390. Wassner S, Abitbol C, Alexander S, et al. Nutritional requirements for infants with renal failure. Am J Kidney Dis 1986;7:300-305.

  2391. Waterlot Y, Cantinieaux B, Hariga-Muller C et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. Br Med J (Clin Res Ed) 1985; 291: 501–504 (B)

  2392. Wathen R, Keshaviah P, Hommeyer P, Cadwell K, Comty C. Role of dialysate glucose in preventing gluconeogenesis during haemodialysis. ASAIO Trans 1977; 23: 393–398 (B)

  2393. Wathen RL, Keshaviah P, Hommeyer P, Cadwell K, Comty CM. The metabolic effects of haemodialysis with and without glucose in the dialysate. Am J Clin Nutr 1978; 31: 1870–1875 (B)

  2394. Watkins S, et al. Impact of flush-before-fill methodology on peritonitis rates in patients receiving automated peritoneal dialysis. J Am Soc Nephrol 1998;9:716A.

  2395. Watson A, Vigneux A, Bannatyne R, et al. Peritonitis during continuous ambulatory peritoneal dialysis in children. CMAJ 1986;134:1019-1022.

  2396. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33: 27–39 (B)

  2397. Watt G, Padre L, Tuazon ML, et al: Bites by the Philippine cobra (Naja naja philippinensis): Prominent neurotoxicity with minimal local signs . Am J Trop Med Hyg 1988; 39: 306-311.

  2398. Watt G, Theakston RDG, Hayes CG, et al: Positive response to edrophonium in patients with neurotoxic envenoming by cobras (Naja naja philippinensis) . New Engl J Med 1986; 315: 1444-1448.

  2399. Wautier JL, Zoukourian C, Chappey O et al. Receptormediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 1996; 97: 238–243 (B)

  2400. Way JL: Cyanide intoxication and its mechanism of antagonism . Ann Rev Pharmacol Toxicol 1984; 24: 451-481.

  2401. Webb AT, Reaveley DA, O’Donnell M et al. Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 1995; 10:354–357 (B)

  2402. Webb AT, Reaveley DA, O’Donnell M et al. Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1993; 8: 609–613 (B)

  2403. Webster JD, Parker TF, Alfrey AC et al. Acute nickel intoxication by dialysis. Ann Intern Med 1980; 92: 631–633 (B)

  2404. Wegner G. Chirurgische Bemerkungen umlautuber die peritoneal Humlautohle, mit besonder Berucksichtigung der Ovariotomie. Arch Klin Chir 1887;20:51.

  2405. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant 2004; 19: 670–677

  2406. Weinstein RS: Recognition and managemnet of poisoning with beta-adrenergic blocking agents . Ann Emerg Med 1984; 13: 1123-1131.

  2407. Weintraub M, Burstein A, Rassin T et al. Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 1992; 42: 1247–1252 (B)

  2408. Weintraub MS, Zechner R, Brown A, Eisenberg S, Breslow JL. Dietary polyunsaturated fats of the W-6 and W-3 series reduce postprandial lipoprotein levels. Chronic and acute effects of fat saturation on postprandial lipoprotein metabolism. J Clin Invest 1988; 82: 1884–1893 (B)

  2409. Weisensee D, Low-Friedrich I, Riehle M, Bereiter-Hahn J, Schoeppe W. In vitro approach to ‘uraemic cardiomyopathy’. Nephron 1993; 65: 392–400 (B)

  2410. Weisman R: Marine Animals . Goldranks's Toxicologic Emergencies 1994; 5th ed.: 1327-1332.

  2411. Weisman RS, Goldfrank LR: Antihistamines . Goldrank's Toxicologic Emergencies 1994; 5th ed: 601-6.

  2412. Welbel SF, Schoendorf K, Bland LA et al. An outbreak of Gram-negative bloodstream infections in chronic hemodialysis patients. Am J Nephrol 1995; 15: 1–4 (B)

  2413. Welch PG, Fattom A, Moore J et al. Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J Am Soc Nephrol 1996; 7: 247–253 (B)

  2414. Wheeler DC. Cardiovascular disease in patients with chronic renal failure. Lancet 1996; 348: 1673–1674 (C)

  2415. Wheeler DC. Should hyperlipidaemia in dialysis patients be treated? Nephrol Dial Transplant 1997; 12: 19–21 (C)

  2416. White C, Gowrishankar M, Feber J, et al. Canadian Association of Pediatric Nephrologists (CAPN) and Peritoneal Dialysis Working Group. Clinical practice guidelines for pediatric peritoneal dialysis. Pediatr Nephrol 2006; 21:1059-1066.

  2417. Whitehead TP, Robinson D, Hale AC, Bailey AR: Clinical chemistry and haematology: Adult reference values. London, UK, BUPA Medical Research, 1994

  2418. Whitley RE: Conservative treatment of copperhead snakebites without antivenin . J Trauma 1996; 41: 219-21.

  2419. Wiegmann TB, MacDougall ML, Diederich DA. Long-term comparisons of citrate and heparin as anticoagulants for hemodialysis. Am J Kidney Dis 1987; 9: 430–435 (A)

  2420. Wiggelinkhuizen J. Peritoneal dialysis in children. S Afr Med J 1971;45:1047-1054.

  2421. Williams AJ, Dittmer ID, McArley A, Clarke J: High bicarbonate dialysate in haemodialysis patients: Effects on acidosis and nutritional status. Nephrol Dial Transplant 12:2633-2637, 1997

  2422. Williams P, Krafcik J, Potter B: Cardiac toxicity of clonidine . Chest 1977; 72(6): 784-785.

  2423. Wilson JD, Braunwald E, Isselbacher K: Harrison's principals of internal medicine . 1991; 2: 2182-2187.

  2424. Wingert WA, Chan L: Rattlesnake bites in southern California and rationale for recommended treatment . West J Med 1988; 148: 37-44.

  2425. Wingert WA, Pattabhiraman TR, et al: Distribution and pathology of copperhead (Agkistrodon contortrix) venom . Toxicon 1980; 18: 591-601.

  2426. Winneke G, Lilienthal H, Kramer U: The neurobehavioural toxicology and teratology of lead . Arch Toxicol Suupl 1996; 18: 57-70.

  2427. Witko-Sarsat V, Friedlander M, Capeille`re-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313 (B)

  2428. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uraemia. Kidney Int 1996; 49: 1304 –1313 (B)

  2429. Witko-Sarsat V, Friedlander M, Nguyen KT et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998; 161: 2524–2532 (B)

  2430. Wizemann V, Leibinger A, Mueller K, Nilson A: Influence of hydration state on plasma volume changes during ultrafiltration. Artif Organs 19:416-419, 1995

  2431. Woeltje KF, Mathew A, Rothstein M, Seiler S, Fraser VJ. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998; 31: 848–852 (B)

  2432. Wolf LR, Spadafora MP, Otten EJ: Use of Amrinone and Glucagon in a Case of Calcium Channel Blocker Overdose . Ann Emerg Med 1993; 22: 1225-1228.

  2433. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004–1013.

  2434. Wolfe RA, Ashby VB, Daugirdas JT et al. Body size, dose of haemodialysis, and mortality. Am J Kidney Dis 2000; 35: 80–88 (B)

  2435. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation and recipients of a first cadaveric transplant. New Eng J Med 1999;341:1725-30

  2436. Wolfson M, Jones MR, Kopple JD: Amino acid losses during hemodialysis with infusion of amino acids and glucose. Kidney Int 21:500-506, 1982

  2437. Wolfson M, Strong CJ, Minturn D, Gray DK, Kopple JD: Nutritional status and lymphocyte function in maintenance hemodialysis patients. Am J Clin Nutr 39:547-555, 1984

  2438. Wong V, Ward R, Taylor J, Selvakumar S, How TV, Bakran A. Factors associated with early failure of arteriovenous fistulae for haemodialysis access. Eur J Vasc Endovasc Surg 1996; 12: 207–213

  2439. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19 [Suppl A]: A12–A19 (C)

  2440. Wood E, Bunchman T, Khurana R, et al. Complications of nasogastric and gastrostomy tube feeding in infants receiving chronic peritoneal dialysis. Adv Perit Dial 1990;6:162-164.

  2441. Woods HF, Nandakumar M. Improved outcome for haemodialysis patients treated with high-flux membranes. Nephrol Dial Transplant 2000; 15 [Suppl 1]: 36–42 (B)

  2442. Woods JD, Port FK, Orzol S et al. Clinical and biochemical correlates of starting ‘daily’ haemodialysis. Kidney Int 1999; 55: 2467–2476 (B)

  2443. Worcester EM, Gillen DL, Evan AP et al. Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol 2007; 292: F66–75.

  2444. World Health Organization: Iron Deficiency Anaemia: Assessment, Prevention and Control. A Guide for Programme Managers. Geneva, Switzerland, World Health Organization, 2001

  2445. Wratten ML, Navino C, Tetta C, Verzetti G. Haemolipodialysis. Blood Purif 1999; 17: 127–133 (B)

  2446. Wright MJ, Woodrow G, Umpleby S et al. Low thrombogenicity of polyethylene glycol-grafted cellulose membranes does not influence heparin requirements in hemodialysis. Am J Kidney Dis 1999; 34: 36–42 (A)

  2447. Wright R, et al: Poison antidotes: Guidelines for rational use in the emergency department . Emergency Medicine Reports 1995; 16(21):.

  2448. Wu MS, Yu CC, Yang CW et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2105–2110 (B)

  2449. Wuhl E, Fusch C, Schärer K, et al. Assessment of total body water in paediatric patients on dialysis. Nephrol Dial Transplant 1996;11:75-80.

  2450. Wuhl E, Haffner D, Nissel R, et al. Short dialyzed children repond less to growth hormone than patients prior to dialysis. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Pediatr Nephrol 1996;10:294-298.

  2451. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ: Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 40:1153-1161, 2002

  2452. Yakubovich M, Vienken J. Is there a need for plasticizer-free biomaterials in dialysis therapy? Med Device Technol 2000; 11: 12–21 (C)

  2453. Yamada K, Miyahara Y, Hamaguchi K et al. Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994; 42: 354–361 (B)

  2454. Yamagami S, Adachi T, Sugimura T et al. Detection of bacteria in dialysate and its antibody in long-term haemodialysis patients. ASAIO Trans 1989; 35: 331–333 (B)

  2455. Yamamoto S, Koide M, Matsuo M et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 1996; 28: 82–85 (B)

  2456. Yanagita T, Satoh M, Nomura H, Enomoto N, Sugano M. Alteration of hepatic phospholipids in rats and mice by feeding di-(2-ethylhexyl)adipate and di-(2-ethylhexyl)phthalate. Lipids 1987; 22: 572–577 (B)

  2457. Yang C, Wu T, Huang C. Low molecular weight heparin reduces triglyceride, VLDL and cholesteroluHDL levels in hyperlipidemic diabetic patients on hemodialysis. Am J Nephrol 1998; 18: 384–390 (B)

  2458. Yang WS, Kim SB, Min WK et al. Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol Dial Transplant 1995; 10: 1668–1671 (B)

  2459. Yango A, Shemin D, Hsu N et al. Rapid communication: Lfolinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001; 59: 324–327 (B)

  2460. Yasuhiro I, Eiichi N, Mineo O et al. Removal of serum beta-2 microglobulin using high-performance membranes and analysis of changes in serum BMG levels after dialysis. Am J Nephrol 1998; 18: 228–232 (B)

  2461. Yerram P, Gill A, Prowant B, et al. A 9-year survival analysis of the presternal Missouri swan-neck catheter. Adv Perit Dial 2007; 23:90-93.

  2462. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469–476 (B)

  2463. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469–476 (B)

  2464. Yip L, et al. Concepts and controversies in salicylate toxicity. Emerg Med Clin North Am 1994;12:351-364.

  2465. Yoshida S, Yamada K, Hamaguchi K et al. Immunohistochemical study of human advanced glycation end-products (AGE) and growth factors in cardiac tissues of patients on maintenance dialysis and with kidney transplantation. Clin Nephrol 1998; 49: 273–280 (B)

  2466. Young EW, Dykstra DM, Goodkin DA, Mapes DL, Wolfe RA, Held PJ. Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2002; 61: 2266–2271

  2467. Young GA, Woodrow G, Kendall S et al. Increased plasma leptinufat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997; 12: 2318–2323 (B)

  2468. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315: 91–96 (B)

  2469. Yukawa S, Hibino A, Maeda T et al. Effect of alpha-tocopherol on in vitro and in vivo metabolism of low-density lipoproteins in haemodialysis patients. Nephrol Dial Transplant 1995; 10 [Suppl 3]: 1–3 (B)

  2470. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 154 –160 (A)

  2471. Zachwieja J, Duran M, Joles J, et al. Amino acid and carnitine supplementation in haemodialysed children. Pediatr Nephrol 1994;8:739-743.

  2472. Zaoui P, Green W, Hakim RM. Hemodialysis with cuprophane membrane modulates interleukin-2 receptor expression. Kidney Int 1991; 39: 1020–1026 (B)

  2473. Zaoui P, Hakim R. Natural killer-cell function in hemodialysis patients: effect of the dialysis membrane. Kidney Int 1993; 43: 1298–1305 (B)

  2474. Zaoui P, Hakim RM. The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 1994; 4: 1711–1718 (B)

  2475. Zaoui P, Stone W, Hakim R. Effects of dialysis membranes on β-2-microglobulin production and cellular expression. Kidney Int 1990;38:962-968.

  2476. Zaoui P, Stone WJ, Hakim RM. Effect of dialysis membranes on beta2-microglobulin production and cellular expansion. Kidney Int 1990; 38: 962–968 (B)

  2477. Zaritsky AL, Horowitz M, Chernow B: Glucagon Antagonism of Calcium Channel Blocker Induced Myocardial Dysfunction . Crit Care Med 1988; 16: 246-251.

  2478. Zdunek M, et al. Plasma exchange for the removal of digoxin-specific antibody frag­ments in renal failure: timing is important for maximizing clearance. Am J Kidney Dis 2000-36:177-183.

  2479. Zeebregts CJ, van den Dungen JJ, van Det RJ, Verhoeven EL, Geelkerken RH, van Schilfgaarde R. Randomized clinical trial of continuous sutures or non-penetrating clips for radiocephalic arteriovenous fistula. Br J Surg 2004; 91: 1438–1442

  2480. Zehnder C, Blumberg A. Influence of dialyser clearance measurement accuracy on haemodialysis prescription based on KtV. Nephrol Dial Transplant 1994; 9: 753–757 (B)

  2481. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration—a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 1999; 52: 152–159 (B) SECTION VII. Vascular disease and risk factors 105

  2482. Zima T, Haragsim L, Stipek S, Bartova V, Nemecek K. Lipid peroxidation on dialysis membranes. Biochem Mol Biol Int 1993; 29: 531–537 (B)

  2483. Zima T, Tesar V, Mestek O, Nemecek K. Trace elements in end-stage renal disease. 1. Methodological aspects and the influence of water treatment and dialysis equipment. Blood Purif 1999; 17: 182–186 (B)

  2484. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658 (B)

  2485. Zingraff J, Beyne P, Urena P et al. Influence of haemodialysis membranes on b2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284–290 (B)

  2486. Zingraff J, Beyne P, Urena P et al. Influence of haemodialysis membranes on beta 2-microglobulin kinetics: in vivo and in vitro studies. Nephrol Dial Transplant 1988; 3: 284 –290 (B)

  2487. Zingraff J, Dru¨eke T. b2-microglobulin amyloidosis: past and future. Artif Organs 1998; 22: 581–584 (C)

  2488. Zlotkin S, Rundle M, Hanning R, et al. Zinc absorption from the glucose and amino acid dialysates in children on continuous ambulatory peritoneal dialysis (CAPD). J Am Coll Nutr 1987;6:345-350.

  2489. Zoccali C, Mallamaci F, Bode-Boger SM et al. Asymetric dimethylarginine (ADMA): and endogenous inhibitor of NO synthase is elated to the severity of atherosclerosis and predicts mortality in end-stage renal disease (ESRD). J Am Soc Nephrol 2000; 11: 308 (Abstract) (B)

  2490. Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 1988;8:163-168.

  2491. Zucchelli P, Zuccala A. Control of blood pressure in patients on haemodialysis. In: Cameron S, Davison A, Grunfeld J, et al., eds. Oxford textbook of clinical nephrology. Oxford: Oxford University Press, 1992:1458-1467.

  2492. Г Groleau: Электрокардиографические манифестации циклической терапии антидепрессанта и передозировки: Обзор . Журнал Чрезвычайной Медицины 1990; 8: 597-605.

  2493. Гудвин DA: Происходящая вне организма поддержка мембранного кислородонасыщения сердечной дисфункции от трициклической передозировки антидепрессанта . Критическая Медицина Заботы 1993; 21(4): 625-627.

  2494. МП Boenhert, пожарный ГИДРАНТ Lovejoy: Значение продолжительности QRS против serum наркотического уровня в предсказании захватов и желудочковых аритмий после острого overdosage трициклического antidepresssants. Новый английский Журнал Медицины 1985; 313: 474-479.

  2495. Франциск EL, ФУНТ Woolf: Руководство КАРДИОГРАММЫ aVR против интервала QRS в предсказании захватов и аритмий в острой трициклической токсичности антидепрессанта. Анналы Чрезвычайной Медицины 1995; 26(2): 195-201.

188

Тут вы можете оставить комментарий к выбранному абзацу или сообщить об ошибке.

Оставленные комментарии видны всем.